



Ensifentrine for the Treatment of Chronic Obstructive Pulmonary Disease: Effectiveness and Value

Evidence Report

May 30, 2024

Prepared for



ICER Staff and Consultants	Center for the Evaluation of Value and Risk in Health (CEVR), Tufts Medical Center
<p>Grace A. Lin, MD Medical Director for Health Technology Assessment Institute for Clinical and Economic Review</p> <p>Abigail Wright, PhD, MSc Research Scientist Institute for Clinical and Economic Review</p> <p>Avery McKenna, BS Associate Research Lead Institute for Clinical and Economic Review</p> <p>Marina Richardson, PhD, MSc Associate Director, HTA Methods and Health Economics Institute for Clinical and Economic Review</p> <p>David M. Rind, MD, MSc Chief Medical Officer Institute for Clinical and Economic Review</p>	<p>Melanie D. Whittington, PhD, MS Senior Fellow Center for the Evaluation of Value and Risk in Health, (CEVR) Tufts Medical Center</p>

DATE OF

PUBLICATION: May 30, 2024

How to cite this document: Lin G, Whittington MD, Wright A, McKenna A, Richardson M, Rind DM. Ensifentrine for the Treatment of Chronic Obstructive Pulmonary Disease: Effectiveness and Value. Institute for Clinical and Economic Review, May 30, 2024. <https://icer.org/assessment/copd-2024/>

Grace A. Lin served as the lead author for the report. Abigail Wright and Avery McKenna led the systematic review and authorship of the comparative clinical effectiveness section of the report with assistance from Finn Raymond. Melanie D. Whittington developed the cost-effectiveness model and authored the corresponding sections of the report. Marina Richardson conducted analyses for the budget impact model. David M. Rind provided methodologic guidance on the clinical and economic evaluations. We would also like to thank Kelsey Gosselin, Liis Shea, Grace Ham, Anna Geiger, and Yasmine Kayali for their contributions to this report.

About ICER

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at <https://icer.org/>.

The funding for this report comes from non-profit foundations, with the largest single funder being Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers (PBMs), or life science companies. ICER receives approximately 22% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. For a complete list of funders and for more information on ICER's support, please visit <https://icer.org/who-we-are/independent-funding/>.

For drug topics, in addition to receiving recommendations [from the public](#), ICER scans publicly available information and also benefits from a collaboration with [IPD Analytics](#), an independent organization that performs analyses of the emerging drug pipeline for a diverse group of industry stakeholders, including payers, pharmaceutical manufacturers, providers, and wholesalers. IPD provides a tailored report on the drug pipeline on a courtesy basis to ICER but does not prioritize topics for specific ICER assessments.

About the Midwest CEPAC

The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) – a core program of ICER – provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. The Midwest CEPAC seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care.

The Midwest CEPAC Panel is an independent committee of medical evidence experts from across Midwest, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy. All Panel members meet strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions. More information about the Midwest CEPAC is available at <https://icer.org/who-we-are/people/independent-appraisal-committees/midwest-comparative-effectiveness-public-advisory-council-m-cepac/>.

The findings contained within this report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future.

The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost-effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical or cost outcomes for any specific patient. In addition, data inputs to ICER models often come from clinical trials; patients in these trials may differ in real-world practice settings.

In the development of this report, ICER's researchers consulted with clinical experts, patients, manufacturers, and other stakeholders. The following individuals served as external reviewers of the draft evidence report:

Expert Reviewers

Igor Barjaktarevic, MD, PhD

Associate Professor; Medical Director COPD Program, UCLA Division of Pulmonary and Critical Care Medicine

David Geffen School of Medicine at UCLA

Dr. Barjaktarevic has served as site PI for Enhance 1. He has received financial support in excess of \$5,000 dollars from health care companies. He also serves on the advisory board for Verona Pharma.

David Mannino, MD

Chief Medical Officer

COPD Foundation

Dr. Mannino has served as a consultant for AstraZeneca, GlaxoSmithKline, Regeneron, Genentech. The COPD Foundation has received financial support from the manufacturer of ensifentrine (Verona Pharma).

Martine Hoogendoorn-Lips, PhD

Assistant Director

Institute for Medical Technology Assessment, Erasmus University Rotterdam

Dr. Hoogendoorn-Lips has not received any funding from Verona Pharma. iMTA receives funding for projects from pharmaceutical companies (e.g., AstraZeneca, Astellas, Boehringer Ingelheim, Sanofi)

None of the external reviewers or other experts we spoke to are responsible for the final contents of this report, nor should it be assumed that they support any part of it. Furthermore, it is possible that external reviewers may not have had the opportunity to review all portions of this draft report. The report should be viewed as attributable solely to the ICER team and its affiliated researchers.

To protect patient confidentiality, ICER does not routinely name individual patients or care partners who provided us with input and feedback.

For a list of stakeholders from who we requested input from, or who have submitted public comments so far, please visit:

https://icer.org/wp-content/uploads/2023/12/COPD-Key-Stakeholder-List_For-Publication_12212023.pdf

Table of Contents

Executive Summary	1
1. Background	3
2. Patient and Caregiver Perspectives	6
3. Comparative Clinical Effectiveness	9
3.1. Methods Overview	9
Scope of Review	9
Evidence Base.....	9
3.2. Results	11
Clinical Benefits	11
Harms.....	19
Subgroup Analyses and Heterogeneity.....	20
Uncertainty and Controversies.....	20
3.3. Summary and Comment.....	22
4. Long-Term Cost Effectiveness	24
4.1. Methods Overview	24
4.2. Key Model Assumptions and Inputs	25
4.3. Results.....	27
Base-Case Results.....	27
Sensitivity Analyses	28
Scenario Analyses.....	30
Threshold Analyses.....	30
Uncertainty and Controversies.....	31
4.4 Summary and Comment.....	32
5. Benefits Beyond Health and Special Ethical Priorities	33
6. Health Benefit Price Benchmarks	35
7. Potential Budget Impact.....	36
7.1. Overview of Key Assumptions	36
7.2. Results.....	36
References	39

A. Background: Supplemental Information	A1
A1. Definitions	A1
A2. Potential Cost-Saving Measures in COPD	A5
A3. Patient Input on Clinical Trial Design	A6
B. Patient Perspectives: Supplemental Information	B1
B1. Methods	B1
C. Clinical Guidelines	C1
American Thoracic Society (ATS) 2020 Clinical Practice Guideline for the Pharmacologic Management of COPD ⁷⁶	C1
The National Institute for Health and Care Excellence (NICE) 2019 ⁷⁷	C1
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 ⁵	C2
D. Comparative Clinical Effectiveness: Supplemental Information	D1
D1. Detailed Methods	D1
PICOTS	D1
Data Sources and Searches	D6
Study Selection	D9
Data Extraction	D9
Assessment of Bias	D16
D2. Additional Clinical Evidence	D18
Additional Methods	D18
D3. Evidence Tables	D28
D4. Ongoing Studies	D61
D5. Previous Systematic Reviews and Technology Assessments	D62
Axson EL, Lewis A, Potts J, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. <i>BMJ Open</i> . 2020. ⁹⁸	D62
Koarai A, Sugiura H, Yamada M, et al. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. <i>BMC Pulm Med</i> . 2020. ⁹⁹	D62
E. Long-Term Cost-Effectiveness: Supplemental Information	E1
E1. Detailed Methods	E1
Description of evLY Calculations	E2
Target Population	E2

Treatment Strategies.....	E3
E2. Model Inputs and Assumptions	E3
Model Inputs	E3
E3. Results	E11
E4. Sensitivity Analyses	E12
E5. Scenario Analyses	E12
Scenario Analysis 1: Modified Societal Perspective	E12
Scenario Analysis 2: Unrelated Health Care Costs Excluded	E13
Scenario Analysis 3: Ensifentrine Effect on Quality of Life	E14
E6. Model Validation	E14
Prior Economic Models	E15
F.Potential Budget Impact: Supplemental Information	F1
Methods.....	F1

List of Acronyms and Abbreviations Used in this Report

%	Percent
AE	Adverse event
AHRQ	Agency for Healthcare Research and Quality
BID	Twice daily
CAT	COPD Assessment Test
CDR	Clinical trial Diversity Rating tool
CI	Confidence interval
COPD	Chronic obstructive pulmonary disease
COVID-19	Coronavirus disease 2019
EQ-5D-5L	EuroQol-5-Domain Questionnaire
E-RS	Evaluating-Respiratory Symptoms Tool
evLY	Equal Value of Life Year
evLYG	Equal Value of Life Years Gained
FDA	Food and Drug Administration
FEV	Forced expiratory volume
FVC	Forced vital capacity
GOLD	Global Initiative for Obstructive Lung Disease
HIDI	Health Improvement Distribution Index
HR	Hazard ratio
ICS	Inhaled corticosteroids
LABA	Long-acting β 2 agonist
LAMA	Long-acting antimuscarinic antagonist
MCID	Minimal clinically important difference
MD	Mean difference
mg	Milligrams
ml	Milliliters
mMRC	modified Medical Research Council scale
N	Total number
NE	Not estimated
NR	Not reported
PDE	Phosphodiesterase
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
QALY	Quality-adjusted life year
RCT	Randomized controlled trial
RR	Relative risk
SD	Standard deviation
SE	Standard error
SGRQ	St. George's Respiratory Questionnaire
TDI	Transition Dyspnea Index
TEAE	Treatment-emergent adverse event
US	United States
WAC	Wholesale acquisition cost

Executive Summary

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases characterized by progressive and persistent airflow obstruction in the lungs. The most common forms of COPD are emphysema and chronic bronchitis; cigarette smoking, including secondhand smoke, is the leading cause of COPD in the United States (US)¹. COPD affects nearly 16 million people in the US, is the 6th leading cause of death², results in more than one million emergency department visits and 500,000 hospitalizations, and results in costs of almost \$50 billion per year³.

Symptoms of COPD include persistent shortness of breath, fatigue, wheezing, chest tightness, sputum production, and cough. Symptom burden is high, with more than 50% of people living with COPD reporting having daily symptoms⁴, particularly shortness of breath and fatigue, which can limit activities. In people with more severe disease, reliance on caregivers for many routine independent activities of daily living (e.g., dishwashing, laundry) is common. Although inhaled therapy can be effective, currently available medications do not necessarily address all COPD symptoms, and side effects can be burdensome for some. Oxygen therapy may be required for people with severe COPD and may limit mobility outside of the home due to the weight of the oxygen tanks or the limited battery life of a portable oxygen concentrator.

Treatment of COPD includes non-pharmacologic measures such as smoking cessation, vaccinations, and pulmonary rehabilitation, as well as pharmacologic therapy.⁵ The goals of pharmacologic therapy are to improve symptoms and reduce exacerbations. The mainstay of therapy is inhaled bronchodilators, including long-acting beta-2-agonists (LABA) and antimuscarinics (LAMA) to relieve symptoms, improve lung function, and reduce exacerbations.⁵ Combination therapy with LAMA + LABA therapy, when indicated, is more effective than monotherapy.⁶ The addition of inhaled corticosteroids (ICS) can be considered for patients with frequent exacerbations and a blood eosinophil count of ≥ 300 cells/ μl .⁷ For patients with frequent exacerbations, additional treatment options such as roflumilast, azithromycin, or N-acetylcysteine may be added. For patients with severe or very severe disease, long-term, continuous supplemental oxygen may be needed; lung volume reduction surgery may be considered in certain cases.

Despite therapy, nearly two-thirds of patients report continuing to have symptoms of COPD.⁸ Ensifentrine (Verona Pharma) is a novel inhaled dual inhibitor of PDE3 and PDE4 enzymes that relaxes airway smooth muscle and decreases inflammation. It is under review by the US Food and Drug Administration (FDA) as an add-on maintenance treatment of moderate to severe COPD. It is delivered twice daily via standard jet nebulizer. Ensifentrine was evaluated in two 24-week multicenter, randomized, placebo-controlled trials.⁹ Participants had moderate to severe COPD and were on stable background therapy, including no therapy or LAMA or LABA, with or without ICS. Patients on dual LAMA+LABA therapy or triple LAMA+LABA+ICS were excluded from the trials. Participants in the trials had a mean age of around 65 years and were mainly white; 50-60% had

moderate disease, 20-25% had an exacerbation within the last 15 months, and 30-45% were on no background therapy at baseline.

Treatment with ensifentrine met the primary endpoint of the trials of improving measures of lung function, including average FEV₁, at 12 weeks. It also decreased the annualized rate of moderate to severe exacerbations by 40%, with a pooled rate ratio of 0.60 (95% confidence interval (CI) 0.41, 0.79) at week 24. Time to first exacerbation was also delayed by 40% at week 24, a benefit that was maintained to week 48 in an extension trial. Ensifentrine had mixed impact on quality of life measures with statistically significant improvements in some measures but not in others or in only one of the two trials. Ensifentrine was well-tolerated with similar rates of adverse events and discontinuation in the ensifentrine and placebo arms.

The trials were conducted during the COVID-19 pandemic, leading to multiple trial withdrawals either from COVID infection or, presumably, because of patient concerns about trial participation during the pandemic. These withdrawals increase uncertainty and could potentially bias results. The exclusion of patients on LAMA/LABA therapy or on triple inhaler therapy raises questions about the benefits of ensifentrine when added on to some of the most recommended regimens.

While the results of ENHANCE-1 and -2 are promising, there remains some uncertainty about the magnitude of overall benefit in patients receiving the most optimized modern inhaler therapies for COPD, although there was no effect modification by background therapy type in the trials. We do not have significant concerns about harms with ensifentrine. For these reasons, we have high certainty that ensifentrine added to maintenance therapy, compared with maintenance therapy alone, results in at least a small net health benefit, and may result in substantial net health benefit (“B+”). We have somewhat greater certainty in the benefits when ensifentrine is added to the regimens studied than to regimens that combine LABA and LAMA therapy.

Table ES1. Evidence Ratings

Treatment	Comparator	Evidence Rating
Adults with moderate to severe COPD		
Ensifentrine + Maintenance therapy	Maintenance therapy alone	B+

COPD: Chronic obstructive pulmonary disease

In cost-effectiveness analyses, ensifentrine results in fewer exacerbations and in greater QALYs, evLYs, and life years. At a placeholder price of \$18,000 per year, the incremental cost-effectiveness ratios for ensifentrine are \$248,000 per QALY gained and \$214,000 per evLY gained. The actual cost-effectiveness of ensifentrine will depend on its price. Ensifentrine would meet commonly used cost-effectiveness thresholds at an annual price between \$7,500 and \$12,700. If ensifentrine is shown to increase the quality of life of patients living with COPD, beyond quality of life improvements associated with fewer exacerbations, the cost-effectiveness would improve.

1. Background

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases characterized by progressive and persistent airflow obstruction in the lungs. COPD affects approximately 15.7 million people in the United States (US), with higher rates among non-Hispanic White individuals, American Indian/Alaska Native individuals, women, and adults older than 65.¹⁰ There is also significant geographic variation in rates of COPD in the US -- states in the midwestern and southern United States having the highest rates of disease, with up to 12% of the population affected in some states.¹¹ COPD is the 6th leading cause of death among Americans² and is the cause of over 500,000 hospitalizations, one million emergency department visits per year, and 16.4 million lost working days per year.^{3,12} The total economic burden of COPD is estimated to be almost \$50 billion per year, with \$29.5 billion attributable to direct medical costs³; having COPD may also lead to lost time from work and premature retirement, costing persons with COPD more than \$300,000 in estimated lifetime income.¹³

The two most common forms of COPD are chronic bronchitis and emphysema. Chronic bronchitis is characterized by airway inflammation that causes mucus production; the hallmark of emphysema is destruction of alveoli causing difficulty with oxygen exchange. Both forms of the disease cause persistent shortness of breath, fatigue, wheezing, chest tightness, sputum production, and cough, and they often coexist. Symptom burden is high, with about half of COPD patients reporting near daily symptoms, and the majority reporting that symptoms have a moderate-to-great impact on everyday life.⁴ In very severe COPD, patients may lose weight, have anorexia, or develop right-sided heart failure. Cigarette smoking, including secondhand smoke, is the leading cause of COPD in the US.¹ Workplace exposures such as dust, fumes, gases, chemicals are the most common causes of COPD among non-smokers.¹⁴ Other causes include pre-existing lung injury (e.g., prematurity, prior infections) and alpha-1-antitrypsin deficiency.¹ Women with COPD have been observed to be younger, smoke less, and have more dyspnea than men;¹⁵ women also account for a higher proportion of hospitalizations.¹⁶ Lower socioeconomic status has been linked with greater disease progression.¹⁷ The presence of chronic bronchitis symptoms such as cough and phlegm has also been associated with worse quality of life, poorer lung function, and more frequent exacerbations.¹⁸ Multimorbidity is often present in patients with COPD, with chronic diseases such as cardiovascular disease, osteoporosis, depression, anxiety, and lung cancer coexisting with COPD, and may also influence exacerbation risk and mortality independent of COPD.⁵

Diagnosis of COPD is based on symptoms and evidence of airflow obstruction, defined as a post-bronchodilator forced expiratory volume/forced vital capacity ratio (FEV₁/FVC) of <0.7.⁵ Initial classification of COPD is based on airflow limitation measured by FEV₁ (Table 1.1). Additionally, exacerbations are an important marker of disease, as they are associated with substantial decrements in health, including association with an increased risk of cardiovascular events (particularly heart failure decompensation) in the peri-exacerbation period¹⁹, predict a greater risk

of future severe exacerbations and death²⁰, and potentially accelerate disease progression²¹. Exacerbations also impact health-related quality of life and account for a large portion of COPD spending.²¹ Symptoms and exacerbations may not necessarily correlate only with the degree of airflow obstruction. Thus, treatment of COPD is based on a combined assessment of the severity of airflow limitation, exacerbation history, and symptom status (Supplement Figure A1).

Table 1.1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Classification of COPD

Classification of airflow limitation		
	COPD Classification	Definition
Mild	GOLD Stage 1	FEV ₁ ≥ 80% predicted
Moderate	GOLD Stage 2	FEV ₁ ≥ 50% predicted but < 80% predicted
Severe	GOLD Stage 3	FEV ₁ ≥ 30% predicted but < 50% predicted
Very severe	GOLD Stage 4	FEV ₁ < 30% predicted
Classification of symptoms and risk of exacerbation		
GOLD Category A		mMRC 0-1 or CAT < 10 AND 0-1 moderate exacerbations per year
GOLD Category B		mMRC ≥ 2 or CAT ≥ 10 AND 0-1 moderate exacerbations per year
GOLD Category E		≥ 2 moderate exacerbations or ≥ 1 exacerbation leading to hospitalization per year

COPD: Chronic obstructive pulmonary disease, FEV₁: Forced expiratory volume in 1 second, GOLD: Global Initiative for Chronic Obstructive Lung Disease, mMRC: modified Medical Research Council questionnaire, CAT: COPD Assessment Test

Treatment of COPD includes both non-pharmacologist and pharmacologic approaches. In patients who currently smoke, smoking cessation is a key component of treatment. Other non-pharmacologic therapies such as pulmonary rehabilitation can also improve exercise capacity, symptoms and quality of life, and impact mortality.²² Vaccinations against respiratory diseases such as influenza, pneumonia, pertussis, respiratory syncytial virus and COVID can decrease the incidence of lower respiratory infections and are recommended for all COPD patients.

The goals of pharmacologic therapy in COPD are to improve symptoms and reduce exacerbations. The mainstays of pharmacologic therapy are inhaled bronchodilators, including long-acting beta-2-agonists (LABA) and antimuscarinic (LAMA) drugs, which improve airflow by relaxing airway smooth muscle tone.⁵ These therapies are helpful for relieving symptoms, improving lung function, dyspnea, health status, and reducing exacerbations. Furthermore, dual therapy with LAMA and LABA (LAMA+LABA), when indicated, is more effective than monotherapy.⁶

Initial therapy choice is driven by symptoms and exacerbation risk. For patients with less severe symptoms and infrequent exacerbations, monotherapy with a long-acting bronchodilator monotherapy is recommended. For patients with more severe symptoms and more frequent exacerbations, dual therapy with LAMA+LABA is recommended. For certain patients with frequent exacerbations, particularly those with a blood eosinophil count ≥300 cells/μL, triple therapy with LAMA, LABA, and inhaled corticosteroids (LAMA+LABA+ICS) is recommended, as it is more effective

than bronchodilators alone in improving lung function and reducing exacerbations, and may reduce mortality.⁷ However, long-term use of ICS may increase risk of pneumonia.²³ For patients who continue to have exacerbations and/or symptoms on maximal inhaled therapy, there may be a role for the oral phosphodiesterase-4 (PDE4) inhibitor roflumilast, azithromycin, or N-acetylcysteine. Dupilumab has also been shown to reduce exacerbations and is currently under FDA review for a label expansion for the treatment of COPD.²⁴ In patients with hypoxemia, long-term continuous oxygen therapy has been shown to decrease mortality.²⁵ Lung volume reduction surgery or endobronchial valve placement may be considered in selected patients with emphysema.⁵ Despite therapy, nearly two-thirds of patients report continuing to have symptoms of COPD.⁸

Ensifentrine (Verona Pharma) is a novel inhaled dual inhibitor of PDE3 and PDE4. Inhibition of PDE3 and PDE4 enzymes can relax airway smooth muscle, decrease inflammatory cells, improve ciliary function, and activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which can reduce mucous viscosity and improve mucociliary clearance.²⁶ The drug is delivered twice-daily via nebulizer. The manufacturer has submitted a new drug application with the US Food and Drug Administration (FDA) for ensifentrine for maintenance treatment of COPD, with a decision expected by June 26, 2024.²⁷

Table 1.2. Interventions of Interest

Intervention	Mechanism of Action	Delivery Route	Prescribing Information
Ensifentrine	PDE3/PDE4 inhibitor	Standard jet nebulizer	3 mg nebulized twice daily

PDE: Phosphodiesterase, mg: milligrams

2. Patient and Caregiver Perspectives

This report was developed with input from diverse stakeholders, including patients, clinicians, researchers, payers, and manufacturer of the agent of focus in this review. We interviewed 6 people living with COPD and talked with two patient advocacy groups. We also spoke with 9 clinicians, all specialists in pulmonary medicine, and two payers, as well the manufacturer of ensifentrine. Additional details about the interviews can be found in the [Supplement](#).

Patient groups pointed out that the demographics of COPD are changing, and that there are now more women living with COPD than men. We heard concerns that women are less likely to be diagnosed, potentially because doctors are less likely to recognize COPD symptoms in women, often leading to delays in diagnosis and treatment. Additionally, there is concern that a diagnosis of COPD carries a stigma because of its link with cigarette smoking and thus leads people to underreport their smoking habits and blame themselves for their symptoms.

Individuals living with COPD described limitations in their daily activities, often due to shortness of breath and fatigue. For example, many tasks take more energy and time than usual to complete. Some chores that require bending and lifting, such as making the bed, filling the dishwasher, or doing laundry, are very difficult or impossible. Since symptoms can vary from day to day, there is a need to plan ahead and for patients to pace themselves – e.g., learning to sit and rest between activities, not going out when it's too hot or humid, and learning proper breathing techniques to help with shortness of breath. With more severe disease, equipment such as shower chairs and wheelchairs may become necessary to help them complete activities of daily living. Additionally, traveling outside of the house can pose significant logistical challenges if wheelchairs and oxygen tanks are required.

Treatment for COPD can be complex. Inhaled medications are a mainstay of therapy; however, patients, patient groups, clinicians, and payers all brought up the concern that patients often have difficulty with proper inhaler technique, which may decrease the effectiveness of the treatments. Side effects of inhaled therapies include dry mouth, thrush, dental cavities, and pneumonia. There may be less variability in drug delivery using nebulized devices; however, nebulized treatments can be time-consuming and are less portable than inhalers. Patients who require systemic steroids, such as prednisone, can have significant side effects such as diabetes, weight gain, and osteoporosis, which then require separate management, adding to the complexity of care. Furthermore, treatments for COPD can be expensive, and 1 in 6 US adults with COPD have reported cost-related non-adherence, including missing doses, taking lower than prescribed doses, and delaying filling prescriptions²⁸, which could affect disease control. Finally, pulmonary rehabilitation and regular exercise play important roles in helping individuals with COPD maintain quality of life. However, pulmonary rehabilitation programs may be difficult to access, particularly in more rural areas, and maintenance of improvement after the program ends is challenging.

In people with severe COPD, oxygen therapy may become necessary, and eventually some people need around-the-clock oxygen supplementation. Individuals who use oxygen regularly described numerous challenges to being oxygen-dependent. For example, the tubing delivering the oxygen often gets tangled when doing activities, and the oxygen itself can cause secondary nasal and sinus issues. The weight of oxygen tanks may limit mobility; patients may also need to limit their activities so that they do not run out of oxygen before returning home. Portable oxygen concentrators help mobility but patients may still be limited by battery life or having oxygen requirements that are too high for concentrators. Finally, access to liquid oxygen is extremely limited but people who used liquid oxygen described how it improved their mobility and quality of life, as it is lighter, lasts longer, and is less drying than other types of oxygen supplementation.

Prevention and management of exacerbations is an important part of disease management. Exacerbations are particularly common after respiratory infections, so patients described strategies to try to avoid respiratory infections whenever possible. They also expressed that it can take a long time to recover from a more severe exacerbation and that one may not completely recover to one's prior baseline. Some people with COPD formed a written plan with their doctor to understand what their respiratory status is and potential interventions when they are having increased symptoms (e.g., [American Lung Association COPD Action Plan](#)).

The caregiving burden for COPD falls mainly to unpaid caregivers. For patients with less severe disease, caregiving for COPD involves helping patients primarily with symptom and medication management. This is particularly relevant for older patients and those with comorbidities, as they may have additional challenges with medication adherence. Such patients may require careful monitoring or adaptations to treatment due to the possibility that the effects of COPD medications may exacerbate other conditions.^{29,30} As the disease progresses, caregivers may need to take on more physical chores such as shopping, cooking, housekeeping, and hygiene needs. Anxiety and depression are more common in individuals with COPD, and caregivers may need to help patients with emotional and psychological support.

When asked about considerations for future treatments, persons with COPD we interviewed cited the need for treatments with new mechanisms of action, particularly those which are disease-modifying and could decrease the need for supplemental oxygen, and those that could decrease mucus production, as current treatments do not adequately address this symptom. We also heard that treatments with fewer side effects could improve quality of life for people with COPD.

Patient groups raised the concern that existing COPD quality of life measures focus only on physical symptoms and limitations caused by COPD. However, they do not adequately address the psychosocial burden of disease that may affect a patient's ability to engage in meaningful life activities (e.g., work, travel, playing with grandchildren, participation in community events) and thus may underestimate the impact of COPD symptoms on a person's quality of life.

Health Equity Considerations

Patients and patient groups reported that access to care could be extremely difficult in rural areas, particularly for patients who were dependent on oxygen that limited their mobility. Additionally, the high price of inhalers and coverage of nebulizers under the medical benefit may affect access and affordability of these treatments. Thus, patient groups advocated for flexibility in treatment choice to accommodate individual patient needs.

3. Comparative Clinical Effectiveness

3.1. Methods Overview

Scope of Review

We evaluated the clinical effectiveness of ensifentrine as an add-on therapy to current maintenance therapy versus no additional treatment for adults with moderate to severe COPD. We sought and reviewed evidence on patient-important outcomes (e.g., changes in COPD exacerbations, respiratory symptoms, quality of life, etc.), changes in lung function (i.e., changes in forced expiratory volume in 1 second [FEV₁]), and harms. Data permitting, we reviewed evidence on treatment effect modification by subpopulations reported to be important in COPD research. The full protocol of the review is available in [Section D1 of the Supplement](#).

Evidence Base

Evidence informing our review of ensifentrine for the treatment of moderate to severe COPD was derived from two Phase III RCTs: ENHANCE-1 and ENHANCE-2.⁹ Data on harms was supplemented by two Phase II RCTs^{31,32}; trial characteristics, including baseline characteristics and efficacy data from these trials are reported in [Supplement Tables D3.1, 3.3, 3.9-12, 3.18-20](#).

ENHANCE-1 and -2 were Phase III multicenter, randomized trials that evaluated nebulized ensifentrine 3 mg twice daily versus placebo for 24 weeks, with an additional 24-week safety extension in ENHANCE-1 only.³³ The trials ran concurrently between September 2020 and December 2022. Participants were randomized in a 5:3 ratio to ensifentrine:placebo over 24 weeks (3:1 ratio in the safety extension in ENHANCE-1). The primary outcome of the trials was a change in lung function as measured by FEV₁ at week 12. Participants were between 40 and 80 years of age, current or former smokers (i.e., ≥10 pack years), and had symptomatic moderate to severe COPD with an established diagnosis (i.e., score of ≥2 on the modified Medical Research Council [mMRC] Dyspnea Scale and post-bronchodilator FEV₁/FVC <0.70 [to confirm COPD] and FEV₁ ≥30% and ≤70% [to confirm moderate-severe COPD]). Exclusion criteria included: history of life-threatening COPD, recent COPD-related hospitalization, pneumonia, or COVID-19, history of another respiratory disorder, lung resection or reduction surgery in the last year, or long-term use of oxygen or pulmonary rehabilitation (unless stable for the last four weeks). Participants were allowed to continue with LAMA or LABA therapy (with or without ICS) if stable for 28 days prior to randomization; however, patients on dual LAMA+LABA therapy or triple LAMA+LABA+ICS therapy were excluded. Prohibited medications are reported in [Supplement Table D3.1](#).

Baseline characteristics and key outcome measures are reported in Table 3.1. Participants were around 65 years of age, mostly White and non-Hispanic, and a substantial proportion of participants

were not on background medication (31% in ENHANCE-1 and 45% in ENHANCE-2). See [Supplement Table D3.2](#) for all baseline characteristics. Compared to real-world observational studies in COPD, participants in the ENHANCE-1 and -2 trials were younger, had more hypertension (60%³⁴ vs. ~34%³⁵), and were less likely to have experienced a recent exacerbation.³⁶

Trial withdrawal was high (ENHANCE-1 at week 48: 14.8%; ENHANCE-2 at week 24: 23.1%). See [Supplement Table D3.17](#). Both trials were conducted during the COVID-19 pandemic; as such, many withdrew consent during the trial (of those who withdrew, 37-45% withdrew consent) and participants were required to withdraw from the trial if they tested positive for COVID-19 any time after enrollment (of those who withdrew, 13-15% had COVID-19). As a result, there were missing outcome data. The investigators noted that they used multiple imputation for missing values. However, it is unclear the percentage of missing data in each analysis.

Evaluation of Clinical Trial Diversity

We rated the demographic diversity (race/ethnicity, sex, age) of the participants in the trials using the ICER-developed Clinical trial Diversity Rating (CDR) Tool.³⁷ In general, ENHANCE-1 and -2 trials achieved “fair” diversity on most demographic categories evaluated. See [Supplement D1](#) for full details of CDR methods and results.

Table 3.1. Baseline Characteristics and Key Measures in ENHANCE-1 and -2.

Baseline Characteristics and Key Measures	ENHANCE-1 N=477 ensifentrine* N=283 placebo	ENHANCE-2 N=498 ensifentrine N=291 placebo
Age in Years, Mean (SD)	65 (7.4)	65.2 (7.4)
Sex, Female %	41.8	51.8
Race/Ethnicity, %		
White	89.8	94.7
Black or African American	3.3	4.3
Asian	3.3	0.3
Hispanic or Latino	2.6	5
Severity of Airflow Obstruction, %		
GOLD (moderate)	59.8	51.2
GOLD (severe)	39.8	48.7
Background Therapy, %		
Any	68.9	55.1
LAMA	29.3	32.3
LAMA+ICS	1.3	0.1
LABA	17.3	7.4
LABA+ICS	20.8	15.4
Exacerbation in the Last 15 Months, %	25.9	20.9
E-RS, mean (SD)	13.7 (6.5)	13.3 (6.5)
TDI, mean (SD)	5.9 (1.1)	5.9 (1.3)
SGRQ, mean (SD)	47.5 (17.7)	50.9 (16.9)
Rescue Medication Puffs per Day [†] , mean (SD)	1.53 (2.3)	1.9 (2.4)
Mean Baseline FEV ₁ , ml (SD)	1412 (478)	1282 (462)

E-RS: Evaluating Respiratory Symptoms, FEV₁: forced expiratory volume in 1 second, GOLD: Global Initiative for Chronic Obstructive Lung Disease, ICS: inhaled corticosteroid, LABA: long-acting β_2 -agonist, LAMA: long-acting muscarinic antagonist, ml: milliliters, SD: standard deviation, SGRQ: St. George's Respiratory Questionnaire, TDI: Transition Dyspnea Index, %: percent.

*48-week extension safety study included 228 participants in ensifentrine and 70 participants in placebo.

[†]Rescue medication included albuterol/salbutamol

3.2. Results

Clinical Benefits

In this main report, we describe changes in patient-important outcomes at week 24 (and week 48 where available for ENHANCE-1) and changes in lung function at week 12. As ENHANCE-1 and -2 were sufficiently similar in study design, baseline characteristics, and key outcome measures, we pooled data from ENHANCE-1 and -2 using pairwise fixed-effects meta-analyses. Our meta-analysis methods and model fit data are described in Section D1 of the Supplement. When there were discrepancies between the trial results, we also qualitatively report individual trial results. In [Section A1](#) of the Supplement, we provide definitions of each outcome. To interpret changes in respiratory symptoms and quality of life measures, we examined whether the changes observed met criteria for minimal clinically importance differences (MCID) based on published thresholds.

Table 3.2. provides MCID thresholds in COPD. Finally, harms and discontinuation rates are summarized. Data from other outcomes and from two Phase II trials are available in [Section D3. of the Supplement](#).

Table 3.2. Minimal Clinically Importance Differences for Patient-Reported Outcomes

Outcome*	Score Range	Minimal Clinically Important Difference (MCID) in COPD
Respiratory Symptoms		
Evaluating-Respiratory Symptoms (E-RS)	0 to 40, higher score indicates more severe symptoms	≥2.0-point reduction in total score ³⁸
Transitional Dyspnea Index (TDI)	-9 to +9, negative score indicates more severe dyspnea	1-unit change ³⁹
Quality of Life		
St. George's Respiratory Questionnaire (SGRQ)	0 to 100, higher score indicates poorer health	≥4-point reduction, based upon data from patients with asthma and COPD. ^{40,41} Recent data suggest MCID for COPD should be at least 7 points. ⁴²
EuroQoL-5-Domain Questionnaire (EQ-5D-5L) utility index	-0.59 to 1, with 1 being the best possible health state	0.037 to 0.063 ⁴³

COPD: Chronic Obstructive Pulmonary Disease, MCID: Minimal Clinically Important Difference.


*There are no established MCID for rescue medication use and lung function.

Rate of Moderate to Severe Exacerbations

Moderate exacerbation was defined as worsening of COPD symptoms for >2 days requiring a minimum of 3 days of therapy with oral or systemic corticosteroids and/or antibiotics. Severe exacerbation was defined as worsening of symptoms and inpatient hospitalization.⁹ Our meta-analysis that pooled data from ENHANCE-1 and -2 showed a statistically significant 40% decrease in the annualized event rate (based on 24 week data) of moderate or severe COPD exacerbations compared with placebo (rate ratio [RR]: 0.60; 95% CI: 0.41, 0.79; P<0.0001; I²=0%) (Figure 3.1). Data presented at the American Thoracic Society 2024 conference reported that patients who received ensifentrine had a numerically, but not significantly, lower risk of transitioning from GOLD Category B ([See Table 1.1.](#)) to GOLD Category E (HR: 0.64; 95% CI: 0.41-1.01; P=0.058) and, in order to prevent one exacerbation on an annual basis, 6.25 patients needed to be treated.⁴⁴ Of note, although the RR estimates seen in ENHANCE-1 and -2 were numerically similar at week 24 (RR for ENHANCE-1: 0.64; 95% CI: 0.40, 1.00; P=0.05 and ENHANCE-2: 0.57; 95% CI: 0.38, 0.87; P=0.009), the ENHANCE-1 results were not statistically significant either at week 24 or week 48 (RR at week 48: 0.56; 95% CI: 0.32, 1.00; P=0.052).⁹

Figure 3.1. Forest Plot of Annualized Event Rate of Moderate or Severe COPD Exacerbations versus Placebo

**Exacerbation Rate
Versus Placebo**




Legend: RR represents the rate ratio. Summary estimates with 95% confidence intervals that do not cross 1.0 are statistically significant.

Time to First Exacerbation

In both ENHANCE-1 and -2, there was a statistically significant longer time to first COPD exacerbation in those randomized to receive ensifentrine versus those randomized to placebo at week 24 (Figure 3.2). Our pooled estimate also showed an overall 40% delay in time to first exacerbation (HR: 0.60; 95% CI: 0.41, 0.78; $P < 0.0001$; $I^2 = 0\%$). This benefit was maintained at week 48 for participants in ENHANCE-1 (HR: 0.48; 95% CI: 0.28, 0.82; $P = 0.007$).⁹

Figure 3.2. Forest Plot of Time to First COPD Exacerbation versus Placebo

**Time to First Exacerbation
Versus Placebo**



Legend: HR represents the hazard ratio. Estimates with 95% confidence intervals that do not cross 1.0 are statistically significant.

Respiratory Symptoms

Evaluating Respiratory Symptoms (E-RS)


In ENHANCE-1, there was a statistically significant reduction in E-RS score in the ensifentrine group versus placebo at week 24, signifying improvement in respiratory symptoms in the ensifentrine group (mean difference [MD] versus placebo: -1.0; 95% CI: -1.7, -0.2; $P=0.011$).⁹ Those in the ensifentrine group were also significantly more likely to achieve a ≥ 2.0 -point reduction (MCID for E-RS³⁸) at week 24 compared to the placebo group (48% vs. 39.4%, $P\leq 0.05$).⁴⁵ However, in ENHANCE-2, there was no statistically significant difference in E-RS scores at week 24 between the ensifentrine and placebo groups (MD versus placebo: -0.6; 95% CI: -1.4, 0.2; $P=0.134$).

Our pooled estimate showed a statistically significant reduction in E-RS score in the ensifentrine group (MD versus placebo: -0.69; 95% CI: -1.38, -0.01; $P=0.047$; $I^2=0\%$) (Figure 3.3). However, the change from baseline in E-RS versus placebo did not exceed MCID. In both trials, there was symptom improvement from baseline to 6-week follow-up, and then the scores appear to plateau through 24 weeks. (Supplement Figure D2.1) Line charts representing the change in raw scores for patient-important outcomes from baseline to weeks 6, 12, and 24 are reported in Figures D2.1.-4.

The individual mean difference and 95% CIs estimated by our meta-analyses of E-RS (and other outcomes) may be slightly different to the estimates reported in the main trial publication.⁹ See Supplement Tables D3.5-8 for all efficacy estimates. In our meta-analyses, we included the total number of participants reported to have been included in the trial. However, the published manuscript did not report the number of participants who contributed E-RS scores to the analysis. Thus, it is possible that the analyses in the manuscript are based upon a smaller pool of participants, and hence the difference in estimates.

Figure 3.3. Forest Plot of Change in E-RS versus Placebo.

**E-RS
Versus Placebo**




Legend: MD represents the mean difference versus placebo. Estimates with 95% confidence intervals that do not cross 0 are statistically significant.

Transition Dyspnea Index (TDI)

Both ENHANCE-1 and -2 trials reported a statistically significant improvement in TDI scores in the ensifentrine compared to the placebo groups at week 24 (MD versus placebo for ENHANCE-1: 1.0; 95% CI: 0.6, 1.5; $P < 0.001$, and ENHANCE-2: 0.9; 95% CI: 0.4, 1.4; $P < 0.001$).^{9,46} Our pooled estimate was statistically significant (MD versus placebo: 1.00; 95% CI: 0.58, 1.41; $P < 0.001$; $I^2 = 0\%$). (Figure 3.4). This change from baseline in TDI versus placebo just meets the published MCID of a 1-unit change in the scale.³⁹ Again, the improvement seen in ENHANCE-1 was larger than in ENHANCE-2, though both were statistically significant.

Figure 3.4. Forest Plot of Change in TDI versus Placebo.

**TDI
Versus Placebo**



Legend: MD represents the mean difference versus placebo. Estimates with 95% confidence intervals that do not cross 0 are statistically significant.

Quality of Life


St. George's Respiratory Questionnaire (SGRQ)

The results from ENHANCE-1 reported a statistically significant improvement in quality of life in the ensifentrine group versus placebo at week 24 (MD versus placebo: -2.3; 95% CI: -4.3, -0.3; $P=0.025$)⁹. Those who were in the ensifentrine group were significantly more likely to achieve MCID (≥ 4 -point reduction)^{40,41} at week 24 compared to those in the placebo group (58.2% vs. 45.9%, $P\leq 0.05$).⁴⁵ See [Supplement Table D3.6](#). On the other hand, ENHANCE-2 did not report a statistically significant improvement in quality of life in the ensifentrine group versus the placebo group at week 24 (MD versus placebo: -0.5; 95% CI: -2.7, 1.7; $P=0.669$) and, in fact, a greater proportion of participants in the placebo group were considered responders compared to the ensifentrine group (50% in the placebo group vs 45% in the ensifentrine group).⁴⁷ Our pooled estimate was not statistically significant and did not exceed MCID (MD versus placebo: -1.51; 95% CI: -3.13, 0.12; $P=0.069$; $I^2=22\%$) (Figure 3.5).

Figure 3.5. Forest Plot of Change in SGRQ versus Placebo

SGRQ

Versus Placebo



Legend: MD represents the mean difference versus placebo. Estimates with 95% confidence intervals that do not cross 0 are statistically significant.

EuroQol-5-Domain Questionnaire (EQ-5D-5L)

Measurements from the EQ-5D-5L were available only from ENHANCE-2. In this trial, those in the ensifentrine group reported a statistically significant increase in EQ-5D-5L at week 24 compared to placebo (MD versus placebo: 0.027; 95% CI: 0.004, 0.050; P=0.019).


Use of Rescue Medication

The investigators evaluated the use of rescue medication (albuterol/salbutamol) by calculating an average daily use across a seven-day period. ENHANCE-1 reported a statistically significant reduction in use of rescue medication in the ensifentrine group at week 24 compared to the placebo group (MD versus placebo: -0.45; 95% CI: -0.70, -0.20; P<0.001). However, in the ENHANCE-2 trial, there was no statistically significant difference between the groups at week 24 (MD versus placebo: -0.14; 95% CI: -0.41, 0.14; P=0.32).

Our pooled estimate was statistically significant (MD versus placebo: -0.28; 95% CI: -0.52, -0.04; P=0.02; I²=39%). (Figure 3.6). Moderate heterogeneity was detected in the fixed-effects meta-analysis. We conducted a random-effects meta-analysis and the estimate remained stable, though the P value was no longer statistically significant ([Supplement Table D2.1](#)).

Figure 3.6. Forest Plot of Change in Daily Use of Rescue Medication versus Placebo

**Daily Average Rescue Medication Use
Versus Placebo**




Legend: MD represents the mean difference versus placebo. Estimates with 95% confidence intervals that do not cross 0 are statistically significant.

Lung Function

Both ENHANCE-1 and -2 trials reported a statistically significant improvement in lung function in the ensifentrine versus placebo groups at week 12 (average FEV₁). See [Supplement Table D3.4](#). Our pooled estimate was statistically significant (MD versus placebo: 92.29 ml; 95% CI: 66.22, 118.36; P<0.0001; I²=0%). (Figure 3.7).

Figure 3.7. Forest Plot of Change in Average FEV₁ versus Placebo

**Average FEV₁
Versus Placebo**



Legend: MD represents the mean difference versus placebo. Estimates with 95% confidence intervals that do not cross 0 are statistically significant.

Additional lung function measures, as well as other outcome data, can be found in [Section D2 of the Supplement and Supplement Tables D3.4.-8](#). No data for oxygen use nor functional capacity was reported in the trials.

Harms

The safety profile for ensifentrine was evaluated at week 24 for ENHANCE-1 and -2, and at week 48 for ENHANCE-1 only.⁹ Across both trials, the risk of any treatment-emergent adverse events (TEAEs) was similar between ensifentrine and placebo groups (36.8% v 35.9%) at week 24. Events that occurred greater than 1% in the ensifentrine group at week 24 are reported in Table 3.4. TEAEs reported at 48 weeks in ENHANCE-1 were similar to those reported at 24 weeks.

Discontinuation overall was high in the trials, and higher in ENHANCE-2 compared to ENHANCE-1 (ENHANCE-1: 19.4% vs. ENHANCE-2: 28.5%). In our meta-analysis that removed COVID-19 cases, discontinuation rates due to TEAEs were similar between the ensifentrine and placebo groups (RR: 0.92; 95% CI: 0.6, 1.41; P=0.7) ([Supplement Figure D2.5](#)).

Adverse events of interest to our review (e.g., pneumonia, hypertension, cardiac disorder, gastrointestinal adverse events) were reported at a low frequency and similar in both ensifentrine and placebo groups. See Table 3.4 for rates of specific adverse events. In a Phase II trial, a higher proportion of those who received ensifentrine reported headache compared to placebo (9% vs.

4%).³² However, this was not observed in the Phase III trials. Additional data on harms from Phase III and II can be found in Supplement Section D2 and Supplement Tables D3.13-20.

Table 3.4. Treatment-emergent Adverse Events Occurring in >1% in Ensifentrine Group at Week 24⁹

TEAEs, n (%)	ENHANCE-1		ENHANCE-2	
	Ensifentrine (N=477)	Placebo (N=283)	Ensifentrine (N=498)	Placebo (N=291)
Nasopharyngitis	13 (2.7)	16 (5.7)	9 (1.8)	3 (1.0)
Hypertension	12 (2.5)	4 (1.4)	5 (1.0)	1 (0.3)
Back Pain	10 (2.1)	1 (0.4)	8 (1.6)	5 (1.7)
COPD	7 (1.5)	6 (2.1)	11 (2.2)	5 (1.7)
Toothache	6 (1.3)	2 (0.7)	0 (0)	1 (0.3)
Pneumonia	6 (1.3)	2 (0.7)	4 (0.8)	5 (1.7)
Urinary Tract Infection	5 (1.0)	1 (0.4)	8 (1.6)	5 (1.7)
Diarrhea	2 (0.4)	2 (0.7)	8 (1.6)	2 (0.7)
Sinusitis	1 (0.2)	1 (0.4)	6 (1.2)	0 (0)

COPD: chronic obstructive pulmonary disease, N: total number, TEAE: treatment-emergent adverse event

Subgroup Analyses and Heterogeneity

In ENHANCE-1 and -2, subgroup analyses were conducted for some of the outcomes of interest. There was no evidence of effect modification by: age, sex, eosinophil count (e.g., <100 or ≤150 cells/uL versus ≥100 or >150 cells/uL), COPD exacerbation in the past 15 months, chronic bronchitis, background medication (e.g., any, LABA or LABA+ICS, LAMA or LAMA+ICS, LAMA only), smoking status, or whether the participant had moderate or severe COPD.^{9,48-56} However, we note that the trials were not powered to detect subgroup differences. See [Supplement Tables D3.20-25](#). Evidence for effect modification was not explored for: medical comorbidities (e.g., hypertension, osteoporosis, obesity, cardiovascular disease, diabetes, frailty), emphysema, nor people with frequent exacerbations.

Uncertainty and Controversies

The trials were largely conducted during the COVID-19 pandemic. This led to withdrawals both because of COVID infection (required by trial protocol) and, presumably, because patients did not wish to participate in a trial during the pandemic, which caused a significant number of both related to participants testing positive for COVID and non-COVID withdrawals. Loss to follow-up of a large number of trial participants can threaten the validity of results. While this is unlikely to be a problem with withdrawals due to COVID infection, other withdrawals increase the risk of bias. We note, of course, that this is an expected, unfortunate outcome of a trial of a respiratory treatment being conducted during the pandemic and not a reflection on the overall quality of the ENHANCE trials.

The population recruited into the trials compared were generally younger and had fewer exacerbations than participants in real world observational studies. Additionally, the background therapy used in the trials does not reflect the most recent standards of care for treatment for moderate to severe COPD. Approximately 30% of participants in ENHANCE-1 and 45% of participants in ENHANCE-2 were on no background therapy at baseline. While participants taking dual LAMA+LABA therapy or triple LAMA+LABA+ICS background therapy, which has become standard of care in symptomatic patients and/or those with frequent exacerbations, were excluded from the Phase III trials, short-term data from a Phase IIb study suggests that ensifentrine (dosed at 1.5 mg or 6 mg) added on to LAMA + LABA therapy can improve FEV₁.⁹ Additionally, there was no effect modification by background therapy in the trial results. Longer term and larger studies are needed to characterize the magnitude of the benefit of ensifentrine added on to dual and triple therapy, the patient population for whom the drug is most likely to be prescribed for in clinical practice.


Our meta-analyses showed that, overall, ensifentrine improved lung function and decreased exacerbations. However, there were some inconsistencies in results on quality of life measures. For example, the overall differences in E-RS and SGRQ did not meet the MCID values defined in the literature, though analyses by responder status show that participants treated with ensifentrine in ENHANCE-1 were more likely to have clinically important improvements in quality of life compared with placebo. Additionally, changes in the E-RS and SGRQ in ENHANCE-2 were smaller than in ENHANCE-1. Study investigators pointed out that in ENHANCE-2, a higher proportion of COPD patients in the placebo group withdrew from treatment (41.9% vs 23.4% in the ensifentrine group), leading to a less severe placebo group at week 24, as an explanation for why changes in ENHANCE-2 may have been smaller than in ENHANCE-1.⁹ Finally, we did not have access to individual participant data, so we are unable to assess which patients may have had greater benefit from treatment. Given that a substantial portion of trial participants were on no maintenance therapy at baseline, understanding whether quality of life improvements differed between background therapy groups is important in understanding the magnitude of benefit that may be seen in real-world practice, where the vast majority of patients would be on some background therapy.

Both Phase III trials were relatively short, with the primary outcomes measured at 12 and 24 weeks. Although the differences in most outcomes appeared to be stable up to 24 weeks, longer-term data are needed to confirm the durability of ensifentrine's effects. For example, trials for roflumilast and dupilumab, which would similarly be add-on therapies for patients with symptomatic moderate-to-severe COPD, have some outcomes up to 52 weeks. Furthermore, the short duration of the trial may obscure seasonal effects, as exacerbations may be more prevalent in winter months when there are more respiratory viruses circulating. Long-term, real-world data are needed to confirm the magnitude of ensifentrine's benefits.

3.3. Summary and Comment

An explanation of the ICER Evidence Rating Matrix (Figure 3.8) is provided [here](#).

Figure 3.8. ICER Evidence Rating Matrix



Comparative Net Health Benefit

- A = "Superior" - High certainty of a substantial (moderate-large) net health benefit
- B = "Incremental" - High certainty of a small net health benefit
- C = "Comparable" - High certainty of a comparable net health benefit
- D = "Negative" - High certainty of an inferior net health benefit
- B+ = "Incremental or Better" - Moderate certainty of a small or substantial net health benefit, with high certainty of at least a small net health benefit
- C+ = "Comparable or Incremental" - Moderate certainty of a comparable or small net health benefit, with high certainty of at least a comparable net health benefit
- C- = "Comparable or Inferior" - Moderate certainty that the net health benefit is either comparable or inferior with high certainty of at best a comparable net health benefit
- C++ = "Comparable or Better" - Moderate certainty of a comparable, small, or substantial net health benefit, with high certainty of at least a comparable net health benefit
- P/I = "Promising but Inconclusive" - Moderate certainty of a small or substantial net health benefit, small (but nonzero) likelihood of a negative net health benefit
- I = "Insufficient" - Any situation in which the level of certainty in the evidence is low

ENHANCE-1 and ENHANCE-2 were parallel Phase III trials testing ensifentrine as an add-on therapy for patients with moderate to severe COPD. Results from these trials show overall benefit of ensifentrine in terms of lung function, exacerbation rate, and some parameters of quality of life; there were relatively few side effects. However, interpretation of the results must be done with caution, as there were some differences between trial participants and background therapy from real-world practice. In particular, more data are needed to assess the effect of ensifentrine in patients who are on dual LAMA+LABA therapy or triple LAMA+LABA+ICS therapy. Although such

patients were not included in the trial, there are some data to suggest that ensifentrine could add benefit in such populations without the potential side effects that limit use of roflumilast. There were also a large number of withdrawals from the trial. This may have biased the results for some outcomes. Finally, longer-term data are needed to assess the durability of effect.

While the results of ENHANCE-1 and -2 are promising, there remains some uncertainty about the magnitude of overall benefit in patients receiving the most optimized modern inhaler therapies for COPD, although there was no effect modification by background therapy type in the trials. We do not have significant concerns about harms with ensifentrine. For these reasons, we have high certainty that ensifentrine added to maintenance therapy, compared with maintenance therapy alone, results in at least a small net health benefit, and may result in substantial net health benefit (“B+”). We have somewhat greater certainty in the benefits when ensifentrine is added to the regimens studied than to regimens that combine LABA and LAMA therapy.

Table 3.5. Evidence Ratings

Treatment	Comparator	Evidence Rating
Adults with Moderate to Severe COPD		
Ensifentrine + Maintenance therapy	Maintenance therapy alone	B+

COPD: Chronic Obstructive Pulmonary Disease

4. Long-Term Cost Effectiveness

4.1. Methods Overview

The primary aim of this analysis is to estimate the cost-effectiveness of ensifentrine added on to current maintenance therapy for the treatment of COPD relative to current maintenance therapy alone over a lifetime time horizon. The base-case took a health care sector perspective (i.e., focused on health care costs only). Patient and caregiver productivity impacts were considered in a modified societal perspective scenario analysis.

We developed a *de novo* decision analytic model in Microsoft Excel for this evaluation, informed by key clinical trials and prior relevant economic models.^{57 58-61} Costs and outcomes were discounted at 3% per year.


The Markov model focused on an intention-to-treat analysis, with a hypothetical cohort of patients with moderate to severe COPD being treated with either ensifentrine added on to current maintenance therapy or current maintenance therapy alone entering the model. The model cycle length was one year, and a lifetime time horizon was used.

The model had four primary health states (Figure 4.1), including three health states defined by COPD severity based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification and a fourth health state defined by death.⁵⁹ Members of the modeled cohort could only transition to more severe health states, and within each severity health state, exacerbations were tracked as events. Exacerbations were defined using an event-based definition based on the health care utilization required.⁵⁹ A moderate exacerbation was defined as an exacerbation that led to a prescription of a corticosteroid and/or an antibiotic but did not result in a hospitalization, and a severe exacerbation was defined as an exacerbation that led to a hospitalization for COPD.⁵⁹ Exacerbations could have downstream implications on mortality, quality of life, and costs.

Patients remained in the model until they died. All patients could transition to the death health state due to all-cause or COPD-specific mortality from any of the alive health states.

The findings within this report are the same as those reported in the Draft Report, but additional detail has been added around model inputs and assumptions based on feedback received in the public comment period.

Figure 4.1. Model Structure



4.2. Key Model Assumptions and Inputs

Table 4.1 summarizes key model assumptions along with a rationale for each.

Table 4.1. Key Model Assumptions

Assumption	Rationale
Members of the modeled cohort could only transition to more severe health states.	COPD is a progressive disease with irreversible effects on lung function. ⁶¹ Some economic models have allowed for transitions to a less severe health state in the first model cycle. We do not include this in our model due to the lack of evidence as well as concerns for double counting when assigning an effect for fewer exacerbations and an effect on moving to a less severe health state with fewer exacerbations.
Ensifentrine’s effect on pulmonary function testing did not result in different health state transition probabilities between the intervention and the comparator.	Ensifentrine is not expected to be disease modifying, and thus it was not modeled to impact disease progression.

Assumption	Rationale
<p>Ensifentrine’s effect on improved quality of life was downstream of its effect on exacerbations. Ensifentrine’s effect on pulmonary function testing did not result in daily improved quality of life in patients not experiencing exacerbations.</p>	<p>Data on the impact of ensifentrine on quality of life while patients were not experiencing an exacerbation was requested from the manufacturer to assess whether the differences in quality of life between the intervention and comparator arm of the trial was the result of ensifentrine’s effect on exacerbations, pulmonary function, or both. However, these data were not provided and thus we assumed the improved quality of life associated with ensifentrine was the result of fewer exacerbations in alignment with other economic models. In a scenario analysis, we tested this assumption by assuming that ensifentrine results in higher health state utility estimates as compared to current maintenance therapy alone.</p>
<p>Individuals who discontinued ensifentrine due to adverse events discontinued at week 12. No subsequent discontinuation or treatment stopping was modeled.</p>	<p>Individuals who discontinued ensifentrine due to adverse events should be captured over the trial follow-up period. The ensifentrine effect size was not adjusted for discontinuation due to the intent to treat nature of the evidence source for the ensifentrine effect.</p>
<p>Adverse events associated with ensifentrine only impacted discontinuation. No costs or consequences were assigned to any specific adverse event.</p>	<p>Adverse events were comparable between the ensifentrine arm and the placebo arm of the trials.</p>
<p>Transition probabilities between COPD severity states do not differ by age, but they do depend on smoking status.</p>	<p>In past economic models that have incorporated age and smoking cessation into disease progression estimations, age and age² have not been statistically significant, but smoking cessation has been.⁵⁹</p>

COPD: Chronic obstructive pulmonary disease

Table 4.2 presents key model inputs, but greater detail on these inputs, along with a more comprehensive description of model inputs, can be found in the Supplement.

Table 4.2. Key Model Inputs

Parameter	Input	Source
Cohort with Moderate COPD at Baseline, %	78.1%	Mannino et al., 2022 ⁶²
Cohort with Severe COPD at Baseline, %	21.9%	Mannino et al., 2022 ⁶²
Exacerbations per Year, Moderate COPD*, Current Maintenance Therapy	1.17	Hoogendoorn et al., 2011 ⁵⁹
Exacerbations per Year, Severe COPD†, Current Maintenance Therapy	1.61	Hoogendoorn et al., 2011 ⁵⁹
Exacerbations per Year, Very Severe COPD‡, Current Maintenance Therapy	2.10	Hoogendoorn et al., 2011 ⁵⁹
Percent of Exacerbations that are Severe	13.7%	Hoogendoorn et al., 2011 ⁵⁹
Percent of Exacerbations that are Moderate	86.3%	Hoogendoorn et al., 2011 ⁵⁹
Ensifentrine Exacerbation Rate Ratio	0.60	ICER's meta-analysis of week 24 data from ENHANCE-1 and ENHANCE-2
Case-Fatality Rate per Severe Exacerbation	15.6%	Hoogendoorn et al., 2011 ⁵⁹
Ensifentrine Adverse-Event Discontinuation	5.1%	ICER's combination of week 24 data from ENHANCE-1 and ENHANCE-2, excluding COVID cases
Ensifentrine Annual Cost	\$18,000	PLACEHOLDER ⁶³
Current Maintenance Therapy Annual Cost	\$3,453	Redbook, SSR Health
Health Care Cost per Moderate Exacerbation	\$2,415	Bogart et al., 2020 ⁶⁴
Health Care Cost per Severe Exacerbation	\$26,047	Bogart et al., 2020 ⁶⁴

COPD: Chronic obstructive pulmonary disease, %: percent

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

‡ Defined as an FEV₁ of less than 30%, GOLD 4

4.3. Results

Base-Case Results

Over a lifetime time horizon, treatment with ensifentrine is expected to result in fewer exacerbations, thus resulting in more QALYs, evLYs, and life years gained. Using a placeholder annual cost of \$18,000 per year, the intervention costs (i.e., the costs to acquire ensifentrine) are greater with ensifentrine, but there are slightly fewer non-intervention costs (e.g., costs associated with exacerbations) in those treated with ensifentrine. Table 4.3 reports the base-case model outcomes for each arm of the model with incremental cost-effectiveness ratios reported in Table 4.4.

Table 4.3. Results for the Base-Case for Ensifentrine Added on to Current Maintenance Therapy as Compared to Current Maintenance Therapy Alone

Treatment	Intervention Cost*	Total Cost*	Total Exacerbations	QALYs	evLYs	Life Years
Ensifentrine + Current Maintenance Therapy	\$144,300	\$424,900	8.03	6.25	6.34	8.43
Current Maintenance Therapy Alone	\$0	\$283,600	12.26	5.68	5.68	7.71

evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Table 4.4. Incremental Cost-Effectiveness Ratios for the Base Case

Treatment	Comparator	Cost per QALY Gained*	Cost per evLY Gained*	Cost per Life Year Gained*
Ensifentrine + Current Maintenance Therapy	Current Maintenance Therapy Alone	\$248,000	\$214,000	\$195,000


evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Sensitivity Analyses

Figure 4.2 reports the inputs with the most influence on the incremental cost-effectiveness ratio. The parameters with the greater influence on the cost-effectiveness of ensifentrine was the ensifentrine exacerbation rate ratio, severity distribution of exacerbations, and the mortality risk associated with a severe exacerbation.

Figure 4.2. Tornado Diagram



COPD: Chronic obstructive pulmonary disease

Tables 4.5 and 4.6 present the probability of ensifentrine being cost-effective at common thresholds of \$50,000, \$100,000, \$150,000, and \$200,000 per QALY and evLY gained, respectively. At the assumed placeholder price for ensifentrine, 12% of the 1,000 iterations within the probabilistic sensitivity analysis resulted in incremental cost-effectiveness ratios beneath \$150,000 per evLY gained.

Table 4.5. Probabilistic Sensitivity Analysis Cost per QALY Gained Results

	Cost Effective at \$50,000 per QALY Gained*	Cost Effective at \$100,000 per QALY Gained*	Cost Effective at \$150,000 per QALY Gained*	Cost Effective at \$200,000 per QALY Gained*
Enfisentrine	0%	0%	4%	24%

QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Table 4.6. Probabilistic Sensitivity Analysis Cost Per evLY Gained Results

	Cost Effective at \$50,000 per evLY Gained*	Cost Effective at \$100,000 per evLY Gained*	Cost Effective at \$150,000 per evLY Gained*	Cost Effective at \$200,000 per evLY Gained*
Enfisentrine	0%	0%	12%	38%

evLYs: equal value of life years gained

* Based on placeholder price of \$18,000 per year

Additional sensitivity analysis result tables can be found in the Supplement.

Scenario Analyses

Table 4.7 reports the incremental cost per evLY gained for the base-case and three scenario analyses assuming a placeholder price of \$18,000 per year for ensifentrine. Cost-effectiveness stayed nearly the same from the modified societal perspective. Cost-effectiveness improved in the scenario analysis that excluded future unrelated health care costs and in the scenario that assumed a positive effect of ensifentrine on quality of life.

Table 4.7. Scenario Analysis Results

Treatment	Base-Case* (\$/evLY)	Modified Societal Perspective* (\$/evLY)	Exclusion of Unrelated Costs* (\$/evLY)	Ensifentrine Effect on Quality of Life* (\$/evLY)
Ensifentrine	\$214,000	\$230,000	\$190,000	\$175,000

evLY: equal value of life year

* Based on placeholder price of \$18,000 per year

Additional scenario analysis findings can be found in Section E of the Supplement.

Threshold Analyses

Tables 4.8 and 4.9 report the threshold prices at \$50,000, \$100,000, \$150,000, and \$200,000 per QALY and evLY gained, respectively.

Table 4.8. QALY-Based Threshold Analysis Results

	WAC per Unit	Net Price per Unit	Annual Price to Achieve \$50,000 per QALY Gained	Annual Price to Achieve \$100,000 per QALY Gained	Annual Price to Achieve \$150,000 per QALY Gained	Annual Price to Achieve \$200,000 per QALY Gained
Ensifentrine	N/A	N/A	\$3,900	\$7,500	\$11,000	\$14,600

QALY: quality-adjusted life year, WAC: wholesale acquisition cost

Table 4.9. evLY-Based Threshold Analysis Results

	WAC per Unit	Net Price per Unit	Annual Price to Achieve \$50,000 per evLY Gained	Annual Price to Achieve \$100,000 per evLY Gained	Annual Price to Achieve \$150,000 per evLY Gained	Annual Price to Achieve \$200,000 per evLY Gained
Ensifentrine	N/A	N/A	\$4,500	\$8,600	\$12,700	\$16,800

evLYs: equal value of life years gained, WAC: wholesale acquisition cost

Uncertainty and Controversies

The health states in the model were defined by the GOLD classification which considers lung function to define disease severity and disease progression. There are newer classifications, such as the GOLD ABE classification, that factor in both symptoms and exacerbations to classify a patient's severity. These newer classifications are primarily used for guiding treatment recommendations, but the underlying severity progression largely remains the same. We chose the GOLD classification to define our health states due to the vast amount of data for transitions, costs, and consequences stratified by the GOLD classifications. We do not anticipate dramatically different findings if a different classification was used for disease severity/progression due to the differential impact of the treatment that is primarily on exacerbations and not disease severity/progression.

Additionally, we did not assume that exacerbations impact disease progression. This assumption was aligned with the majority of economic models in COPD; however, a few models have incorporated a reduction in FEV₁ following an exacerbation. Most of those models were modeling FEV₁ decline over time, rather than modeling defined health states. We engaged with economic experts who had previously incorporated a link between an exacerbation and lung function and heard that the evidence to support this assumption is limited and it was not a key driver of the cost-effectiveness.

We also assumed that ensifentrine's effect on pulmonary function testing did not result in improved quality of life. Ensifentrine's effect on improved quality of life observed in the model was downstream of ensifentrine's effect on exacerbations. Data on the impact of ensifentrine on quality of life while patients were not experiencing an exacerbation was requested from the manufacturer to assess whether the differences in quality of life between the intervention and comparator arm of the trial was the result of fewer exacerbations, slower decline in lung function, or both. However, these data were not provided and thus we assumed the improved quality of life associated with ensifentrine was the result of fewer exacerbations in alignment with other economic models. In a scenario analysis, we tested this assumption by assuming that ensifentrine results in higher health state utility estimates as compared to current maintenance therapy alone. If data become available to suggest that ensifentrine improves quality of life outside of fewer exacerbations, the cost-effectiveness would improve.

There is variability, both in the regimens that are used and in the specific treatments within each regimen that are used, in the current maintenance therapy that people living with COPD use. Regimen- and treatment-specific evidence for the current maintenance therapy was only used to inform the cost of current maintenance therapy. We used the best available source (i.e., source with a large representative sample and estimates stratified by GOLD classification) to inform the basket of regimens and treatments within current maintenance therapy; however, the dates included in this source largely predated LABA/LAMA combination products. To account for this potential limitation, we varied the cost of current maintenance therapy across a very wide range in

the sensitivity analyses. Variability in the cost of the current maintenance therapy had a very small impact on the overall findings given ensifentrine is added on to current maintenance therapy.

Finally, the findings from the modified societal perspective scenario analysis may not fully represent the impact of COPD on patients and caregivers. The current modified societal perspective includes patient productivity and caregiver time spent caregiving. Data on other indirect impacts such as caregiver quality of life were not available for inclusion.

4.4 Summary and Comment

These analyses suggest that treatment with ensifentrine results in fewer exacerbations and in greater QALYs, greater evLYs, and greater life years. At a placeholder price of \$18,000 per year, the incremental cost-effectiveness ratio for ensifentrine exceeds commonly used thresholds. If ensifentrine is shown to increase the quality of life of patients living with COPD, beyond quality of life improvements associated with fewer exacerbations, cost-effectiveness improves but still remains above commonly used thresholds at a placeholder price of \$18,000 per year.

5. Benefits Beyond Health and Special Ethical Priorities

Our reviews seek to provide information on benefits beyond health and special ethical priorities offered by the intervention to the individual patient, caregivers, the delivery system, other patients, or the public that was not available in the evidence base nor could be adequately estimated within the cost-effectiveness model. These elements are listed in the table below, with related information gathered from patients and other stakeholders. Following the public deliberation on this report the appraisal committee will vote on the degree to which each of these factors should affect overall judgments of long-term value for money of the intervention(s) in this review.

Table 5.1. Benefits Beyond Health and Special Ethical Priorities

Benefits Beyond Health and Special Ethical Priorities	Relevant Information
<p>There is substantial unmet need despite currently available treatments.</p>	<p>Almost half of persons with COPD report that symptoms affect their daily life at least 24 days out of the month and 54% of patients on triple therapy were dissatisfied with the current control of their COPD.^{4,8} Additionally, side effects from current therapies can limit their use. Therefore, there is substantial need for new therapies.</p> <p>To inform unmet need as a benefit beyond health, the results for the evLY and QALY absolute and proportional shortfalls have been reported below:</p> <p>evLY shortfalls:</p> <ul style="list-style-type: none"> • Absolute evLY shortfall: 8.1 • Proportional evLY shortfall: 54% <p>QALY shortfalls:</p> <ul style="list-style-type: none"> • Absolute QALY shortfall: 7.5 • Proportional QALY shortfall: 52% <p>The absolute and proportional shortfalls represent the total and proportional health units of remaining quality-adjusted life expectancy, respectively, that would be lost due to untreated illness. Please refer to the ICER Reference Case – Section 2. Quantifying Unmet Need (QALY and evLY Shortfalls) for the shortfalls of other conditions assessed in prior ICER reviews.</p>
<p>This condition is of substantial relevance for people from a racial/ethnic group that have not been equitably served by the health care system.</p>	<p>Rates of COPD are higher in the American Indian/Alaska Native populations compared with the general US population.⁶⁵</p> <p>The Health Improvement Distribution Index (HIDI) for the American Indian/Alaska Native population is 1.7.</p>
<p>The treatment is likely to produce substantial improvement in caregivers' quality of life and/or ability to pursue their own education, work, and family life.</p>	<p>Ensifentrine is not thought to be disease-modifying and is not likely to have a large effect on caregivers' quality of life and/or their ability to pursue their own goals in the long-term.</p>

Benefits Beyond Health and Special Ethical Priorities	Relevant Information
The treatment offers a substantial opportunity to improve access to effective treatment by means of its mechanism of action or method of delivery.	Although ensifentrine has a novel mechanism of action, its delivery is via standard nebulizer and thus it is not likely to have an effect on access.

evLY: equal value of life years, COPD: Chronic obstructive pulmonary disease, QALY: quality-adjusted life-year, HID: Health Improvement Distribution Index

6. Health Benefit Price Benchmarks

Health Benefit Price Benchmarks (HBPBs) for the annual cost of ensifentrine are presented in Table 6.1 below. The HBPB for a drug is defined as the price range that would achieve incremental cost-effectiveness ratios between \$100,000 and \$150,000 per QALY or per evLY gained. The HBPB for ensifentrine is \$7,500 to \$12,700 per year.

Table 6.1. Annual Cost-Effectiveness Threshold Prices for Ensifentrine

Annual Prices Using...	Annual Price at \$100,000 Threshold	Annual Price at \$150,000 Threshold
QALYs Gained	\$7,500	\$11,000
evLYs Gained	\$8,600	\$12,700

evLY: equal value life year, QALY: quality-adjusted life year, WAC: wholesale acquisition cost

7. Potential Budget Impact

7.1. Overview of Key Assumptions

Results from the cost-effectiveness model were used to estimate the potential total budgetary impact of ensifentrine as an add-on therapy to current maintenance therapy compared to current maintenance therapy alone for adults with moderate to severe COPD. In alignment with the cost-effectiveness analysis, current maintenance therapy was represented by a combination of treatments informed by retrospective administrative claims data.⁶⁶ We used an annual placeholder price (\$18,000) for ensifentrine, and the three threshold prices (at \$50,000, \$100,000, and \$150,000 per evLYG) in our estimates of budget impact.

This potential budget impact analysis includes the estimated number of individuals in the US who would be eligible for treatment. To estimate the size of the potential candidate populations for treatment, we used inputs for the size of the adult U.S. population 271,616,592 (average over 2024-2028), the prevalence of COPD in adults (5.6%),⁶⁷ and the percentage of adult patients with moderate-to-severe COPD (63.3%).⁶² Applying these sources results in estimates of 9,628,265 eligible patients in the US. For the purposes of this analysis, we will assume that 20% of these patients would initiate treatment in each of the five years, or 1,925,653 patients per year.

The aim of the potential budgetary impact analysis is to document the percentage of patients who could be treated at selected prices without crossing a potential budget impact threshold that is aligned with overall growth in the US economy. The five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to be approximately \$735 million per year for new drugs. ICER's methods for estimating potential budget impact are described in detail in [Section F of the Supplement](#).

7.2. Results

Figure 7.1 illustrates the cumulative annual per patient treated potential budget impact for ensifentrine as an add-on therapy to current maintenance therapy compared to current maintenance therapy alone. At ensifentrine's placeholder price of \$18,000 annually, the average annual budget impact per patient treated, per year, was \$14,119 in Year 1 with cumulative net annual costs increasing to \$67,799 in Year 5.

Figure 7.1. Cumulative Annual Per-Patient Treated Budget Impact of Ensifentrine (Using a Placeholder Price) as an Add-on Therapy to Current Maintenance Therapy Compared to Current Maintenance Therapy Alone for Adults with Moderate to Severe COPD





Figure 7.2 illustrates the potential budget impact of ensifentrine as an add-on therapy to current maintenance therapy at a placeholder price of \$18,000 annually. At the placeholder price, approximately 1% of adults living with moderate to severe COPD who are eligible for treatment could be treated with ensifentrine without crossing the ICER potential budget impact threshold of \$735 million per year. At prices to reach thresholds of \$150,000, \$100,000, and \$50,000 per evLYG (\$12,706, \$8,596, and \$4,486), approximately 1.4%, 2.4%, and 6.9% of adults living with moderate to severe COPD, respectively, could be treated over five years without reaching the ICER potential budget impact threshold of \$735 million per year.

Figure 7.2. Potential Budgetary Impact of Ensifentrine (at a Placeholder Price and three Threshold Prices) as an Add-on Therapy to Current Maintenance Therapy Compared to Current Maintenance Therapy Alone for Adults with Moderate to Severe COPD



evLYG : equal-value life year gained

References

1. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission. *Lancet*. Sep 17 2022;400(10356):921-972. doi:10.1016/S0140-6736(22)01273-9
2. Xu J, Murphy SL, Kochanek KD, Arias E. Mortality in the United States, 2021. *NCHS Data Brief*. Dec 2022;(456):1-8.
3. American Lung Association. COPD Trends Brief: Burden. American Lung Association. Accessed November 14, 2023. <https://www.lung.org/research/trends-in-lung-disease/copd-trends-brief/copd-burden>
4. Phreesia Life Sciences. *Patients in Focus: COPD treatment and perceptions*. 2021. Accessed December 17, 2023. https://engage.phreesia.com/rs/867-GML-252/images/Phreesia_Life_Sciences_COPD_Report.pdf
5. Agusti A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *Am J Respir Crit Care Med*. Apr 1 2023;207(7):819-837. doi:10.1164/rccm.202301-0106PP
6. Mammen MJ, Pai V, Aaron SD, Nici L, Alhazzani W, Alexander PE. Dual LABA/LAMA Therapy versus LABA or LAMA Monotherapy for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis in Support of the American Thoracic Society Clinical Practice Guideline. *Ann Am Thorac Soc*. Sep 2020;17(9):1133-1143. doi:10.1513/AnnalsATS.201912-915OC
7. Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H. Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. *Respir Res*. Jun 22 2021;22(1):183. doi:10.1186/s12931-021-01777-x
8. Chen S, Small M, Lindner L, Xu X. Symptomatic burden of COPD for patients receiving dual or triple therapy. *Int J Chron Obstruct Pulmon Dis*. 2018;13:1365-1376. doi:10.2147/COPD.S163717
9. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). *Am J Respir Crit Care Med*. Aug 15 2023;208(4):406-416. doi:10.1164/rccm.202306-0944OC
10. Wheaton AG, Cunningham TJ, Ford ES, Croft JB, Centers for Disease C, Prevention. Employment and activity limitations among adults with chronic obstructive pulmonary disease--United States, 2013. *MMWR Morb Mortal Wkly Rep*. Mar 27 2015;64(11):289-95.
11. Centers for Disease Control and Prevention. State-level Estimates of COPD. Accessed March 19, 2024. <https://www.cdc.gov/copd/data-and-statistics/state-estimates.html>
12. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. *Chest*. Jan 2015;147(1):31-45. doi:10.1378/chest.14-0972
13. Fletcher MJ, Upton J, Taylor-Fishwick J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. *BMC Public Health*. Aug 1 2011;11:612. doi:10.1186/1471-2458-11-612
14. Syamlal G, Doney B, Mazurek JM. Chronic Obstructive Pulmonary Disease Prevalence Among Adults Who Have Never Smoked, by Industry and Occupation - United States, 2013-2017. *MMWR Morb Mortal Wkly Rep*. Apr 5 2019;68(13):303-307. doi:10.15585/mmwr.mm6813a2
15. Jenkins CR, Chapman KR, Donohue JF, Roche N, Tsiligianni I, Han MK. Improving the Management of COPD in Women. *Chest*. Mar 2017;151(3):686-696. doi:10.1016/j.chest.2016.10.031

16. Goel K, Bailey M, Borgstrom M, et al. Trends in Chronic Obstructive Pulmonary Disease Hospitalization and In-Hospital Deaths in the United States by Sex: 2005 to 2014. *Ann Am Thorac Soc*. Mar 2019;16(3):391-393. doi:10.1513/AnnalsATS.201807-488RL
17. Lowe KE, Make BJ, Crapo JD, et al. Association of low income with pulmonary disease progression in smokers with and without chronic obstructive pulmonary disease. *ERJ Open Res*. Oct 2018;4(4)doi:10.1183/23120541.00069-2018
18. Mejza F, Gnatiuc L, Buist AS, et al. Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. *Eur Respir J*. Nov 2017;50(5)doi:10.1183/13993003.00621-2017
19. Hawkins NM, Nordon C, Rhodes K, et al. Heightened long-term cardiovascular risks after exacerbation of chronic obstructive pulmonary disease. *Heart*. Apr 25 2024;110(10):702-709. doi:10.1136/heartjnl-2023-323487
20. Whittaker H, Rubino A, Mullerova H, et al. Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. *Int J Chron Obstruct Pulmon Dis*. 2022;17:427-437. doi:10.2147/COPD.S346591
21. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. *Eur Respir J*. Jun 2007;29(6):1224-38. doi:10.1183/09031936.00109906
22. Lindenauer PK, Stefan MS, Pekow PS, et al. Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. *JAMA*. May 12 2020;323(18):1813-1823. doi:10.1001/jama.2020.4437
23. Mammen MJ, Lloyd DR, Kumar S, et al. Triple Therapy versus Dual or Monotherapy with Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease. A Systematic Review and Meta-analysis. *Ann Am Thorac Soc*. Oct 2020;17(10):1308-1318. doi:10.1513/AnnalsATS.202001-023OC
24. Dupixent sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation. February 22, 2024, 2024. <https://www.sanofi.com/en/media-room/press-releases/2024/2024-02-23-06-00-00-2834219>
25. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. *Ann Intern Med*. Sep 1980;93(3):391-8. doi:10.7326/0003-4819-93-3-391
26. Martin C, Burgel PR, Roche N. Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. *Int J Chron Obstruct Pulmon Dis*. 2021;16:2363-2373. doi:10.2147/COPD.S226688
27. Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD. September 11, 2023, 2023. Accessed November 14, 2023. <https://www.veronapharma.com/media/verona-pharma-announces-us-fda-has-accepted-new-drug-application>
28. Wen X, Qiu H, Yu B, et al. Cost-related medication nonadherence in adults with COPD in the United States 2013-2020. *BMC Public Health*. Mar 20 2024;24(1):864. doi:10.1186/s12889-024-18333-z
29. Taffet GE, Donohue JF, Altman PR. Considerations for managing chronic obstructive pulmonary disease in the elderly. *Clin Interv Aging*. 2014;9:23-30. doi:10.2147/CIA.S52999
30. Recio Iglesias J, Diez-Manglano J, Lopez Garcia F, Diaz Peromingo JA, Almagro P, Varela Aguilar JM. Management of the COPD Patient with Comorbidities: An Experts Recommendation Document. *Int J Chron Obstruct Pulmon Dis*. 2020;15:1015-1037. doi:10.2147/COPD.S242009
31. Ferguson GT, Kerwin EM, Rheault T, Bengtsson T, Rickard K. A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy. *International journal of chronic obstructive pulmonary disease*. 2021-01-01 2021;16doi:10.2147/copd.s307160

32. Singh D, Martinez FJ, Watz H, Bengtsson T, Maurer BT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. *Respiratory research*. 2020-01-01 2020;21(1)doi:10.1186/s12931-020-1307-4
33. Anzueto A, Barjaktarevic I, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function and Reduces Exacerbation Rate and Risk in Phase 3 Enhance-2 Trial. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c15
34. Siler TM, Fogarty CM, Rheault T, Bengtsson T, Ann Rickard K. POOLED SAFETY RESULTS OVER 24 WEEKS FROM THE ENHANCE PROGRAM WITH ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR. *Chest*. 2023-01-01 2023;164(4)doi:10.1016/j.chest.2023.07.3224
35. Samp JC JM, Schumock GT, Calip GS, Pickard AS, Lee TA. . Risk of cardiovascular and cerebrovascular events in COPD patients treated with long-acting β 2-agonist combined with a long-acting muscarinic or inhaled corticosteroid. *Annals of Pharmacotherapy*. 2017;51(11):945-53.
36. Palli SR FM, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J. . Differences in real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy. *Journal of Managed Care & Specialty Pharmacy*. 2020;26(10):1363-74.
37. Agboola FW, AC. A Framework for Evaluating the Diversity of Clinical Trials. *Journal of Clinical Epidemiology*. 2024:111299.
38. Leidy NK, Bushnell DM, Thach C, Hache C, Gutzwiller FS. Interpreting Evaluating Respiratory Symptoms(TM) in COPD Diary Scores in Clinical Trials: Terminology, Methods, and Recommendations. *Chronic Obstr Pulm Dis*. Oct 26 2022;9(4):576-590. doi:10.15326/jcopdf.2022.0307
39. Mahler DA, Witek TJ, Jr. The MCID of the transition dyspnea index is a total score of one unit. *Copd*. Mar 2005;2(1):99-103. doi:10.1081/copd-200050666
40. Jones PW. Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. *Eur Respir J*. Jan 1994;7(1):55-62. doi:10.1183/09031936.94.07010055
41. Jones PW. St. George's Respiratory Questionnaire: MCID. *Copd*. Mar 2005;2(1):75-9. doi:10.1081/copd-200050513
42. Mol-Alma H. *Discovering the Dynamics of the Minimal Clinically Important Difference of Health Status Instruments in Patients with Chronic Obstructive Pulmonary Disease*. University of Groningen; 2020.
43. Nolan CM, Longworth L, Lord J, et al. The EQ-5D-5L health status questionnaire in COPD: validity, responsiveness and minimum important difference. *Thorax*. Jun 2016;71(6):493-500. doi:10.1136/thoraxjnl-2015-207782
44. Scirba F, Rickard K, Bengtsson T, Rheault T. Ensifentrine Reduces Exacerbation Frequency and Delays Progression From Gold B to Gold E. 2024-01-01 2024;
45. Scirba FC, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c40
46. Mahler D, Bhatt S, Singh D, et al. Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Improved Dyspnea in Subjects With Symptomatic, Moderate-to-Severe COPD Over 24 Weeks. 2024-05-20 2024;
47. ClinicalTrials.gov. A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD. 2024. <https://clinicaltrials.gov/study/NCT04542057?term=NCT04542057&rank=1>
48. Barjaktarevic I, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First

Exacerbation in COPD: pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c40

49. Ferguson GT, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: a Sub-group Analysis of ENHANCE-2, a Phase 3 Trial. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c40

50. Sciruba FC, Rheault T, Bengtsson T, Ann Rickard K. ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR, REDUCES EXACERBATION RATE AND RISK REGARDLESS OF EXACERBATION HISTORY IN POOLED ENHANCE TRIAL ANALYSES. *Chest*. 2023-01-01 2023;164(4)doi:10.1016/j.chest.2023.07.3238

51. Siler TM, Fogarty CM, Rheault T, Bengtsson T, Ann Rickard K. NEBULIZED ENSIFENTRINE IMPROVES LUNG FUNCTION, SYMPTOMS, QUALITY OF LIFE AND REDUCES EXACERBATIONS IN SYMPTOMATIC COPD PATIENTS REGARDLESS OF BACKGROUND LAMA OR LABA THERAPY. *Chest*. 2023-01-01 2023;164(4)doi:10.1016/j.chest.2023.07.3210

52. Siler TM, Rheault T, Bengtsson T, Rickard K. Twice-daily, Nebulized Ensifentrine Significantly Improves Lung Function: sub-group Analysis in the Phase 3 Trial ENHANCE-1. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c40

53. Rickard K, Bengtsson T, Rheault T. Twice-daily, Nebulized Ensifentrine Produced Significant Improvement in Week 12 Lung Function: sub-group Analysis in the Phase 3 Trial Enhance-2. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.b22

54. Dransfield M, Kalhan R, Anzueto A, et al. Ensifentrine Added on to LAMA Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to- Severe COPD. 2024-05-20 2024;

55. Kalhan R, Marchetti N, Anzueto A, et al. Ensifentrine Added on to LAMA Therapy Improved COPD Symptoms and Quality of Life in Subjects With Symptomatic Moderate-to-Severe COPD. 2024-05-20 2024;

56. Anzueto A, T. Dransfield M, Marchetti N, et al. Ensifentrine Added on to LABA/ICS Therapy Reduced Dyspnea and Improved Quality of Life in Subjects With Symptomatic Moderate-to- Severe COPD. 2024-05-20 2024;

57. Menn P, Leidl R, Holle R. A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease. *Pharmacoeconomics*. Sep 1 2012;30(9):825-40. doi:10.2165/11591340-000000000-00000

58. Hoogendoorn M, Feenstra TL, Asukai Y, et al. Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. *Value Health*. Jul 2014;17(5):525-36. doi:10.1016/j.jval.2014.03.1721

59. Hoogendoorn M, Rutten-van Mólken MPMH, Hoogenveen RT, Al MJ, Feenstra TL. Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease. *Value in Health*. 2011/12/01/ 2011;14(8):1039-1047. doi:<https://doi.org/10.1016/j.jval.2011.06.008>

60. Hansen RN, Xu X, Sullivan SD. PRS18 A Dynamic Cohort Model of Chronic Obstructive Pulmonary Disease and Its Treatments. *Value in Health*. 2012/06/01/ 2012;15(4):A54. doi:<https://doi.org/10.1016/j.jval.2012.03.302>

61. Price D, Gray A, Gale R, et al. Cost-utility analysis of indacaterol in Germany: A once-daily maintenance bronchodilator for patients with COPD. *Respiratory Medicine*. 2011/11/01/ 2011;105(11):1635-1647. doi:<https://doi.org/10.1016/j.rmed.2011.06.005>

62. Mannino D, Siddall J, Small M, Haq A, Stiegler M, Bogart M. Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey. *Int J Chron Obstruct Pulmon Dis*. 2022;17:749-761. doi:10.2147/copd.S340794

63. IPD Analytics. New Drug Preview: Ensifentrine for the Treatment of COPD. 2023;
64. Bogart MR, Hopson SD, Shih HC, Stanford RH, Coutinho AD. COPD exacerbation costs in the IMPACT study: a within-trial analysis. *Am J Manag Care*. May 1 2020;26(5):e150-e154. doi:10.37765/ajmc.2020.43157
65. Liu Y, Carlson SA, Watson KB, Xu F, Greenlund KJ. Trends in the Prevalence of Chronic Obstructive Pulmonary Disease Among Adults Aged ≥ 18 Years - United States, 2011-2021. *MMWR Morb Mortal Wkly Rep*. Nov 17 2023;72(46):1250-1256. doi:10.15585/mmwr.mm7246a1
66. Wallace AE, Kaila S, Bayer V, et al. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population. *J Manag Care Spec Pharm*. Feb 2019;25(2):205-217. doi:10.18553/jmcp.2019.25.2.205
67. Centers for Disease Control and Prevention. Chronic Obstructive Pulmonary Disease. 2021;
68. Agustí A, Celli BR, Criner GJ, et al. Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary. *American Journal of Respiratory and Critical Care Medicine*. 2023;207(7):819-837. doi:10.1164/rccm.202301-0106PP
69. Malerba M, Foci V, Patrucco F, et al. Single Inhaler LABA/LAMA for COPD. *Front Pharmacol*. 2019;10:390. doi:10.3389/fphar.2019.00390
70. Mkorombindo T, Dransfield MT. Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Benefits and Risks. *Clin Chest Med*. Sep 2020;41(3):475-484. doi:10.1016/j.ccm.2020.05.006
71. Oh YM, Lee KS, Hong Y, et al. Blood eosinophil count as a prognostic biomarker in COPD. *Int J Chron Obstruct Pulmon Dis*. 2018;13:3589-3596. doi:10.2147/copd.S179734
72. Launois C, Barbe C, Bertin E, et al. The modified Medical Research Council scale for the assessment of dyspnea in daily living in obesity: a pilot study. *BMC Pulm Med*. Oct 1 2012;12:61. doi:10.1186/1471-2466-12-61
73. Ottersen T, Førde R, Kakad M, et al. A new proposal for priority setting in Norway: Open and fair. *Health Policy*. Mar 2016;120(3):246-51. doi:10.1016/j.healthpol.2016.01.012
74. van de Wetering EJ, Stolk EA, van Exel NJ, Brouwer WB. Balancing equity and efficiency in the Dutch basic benefits package using the principle of proportional shortfall. *Eur J Health Econ*. Feb 2013;14(1):107-15. doi:10.1007/s10198-011-0346-7
75. Stolk EA, van Donselaar G, Brouwer WB, Busschbach JJ. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall. *Pharmacoeconomics*. 2004;22(17):1097-107. doi:10.2165/00019053-200422170-00001
76. Nici L, Mammen MJ, Charbek E, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. *Am J Respir Crit Care Med*. May 1 2020;201(9):e56-e69. doi:10.1164/rccm.202003-0625ST
77. National Institute for Health and Care Excellence. *Chronic obstructive pulmonary disease in over 16s: diagnosis and management*. 2019. <https://www.nice.org.uk/guidance/ng115>
78. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med*. Mar 1 1997;126(5):376-80.
79. Higgins J, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, Welch, VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). <https://training.cochrane.org/handbook/current>
80. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. Mar 29 2021;372:n71. doi:10.1136/bmj.n71
81. Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019;366:l4898. doi:10.1136/bmj.l4898
82. Agboola F, Whittington MD, Pearson SD. Advancing Health Technology Assessment Methods that Support Health Equity. March 15, 2023 2023;

83. Health Equity Tracker. Satcher Health Leadership Institute. Morehouse School of Medicine. Accessed January 26, 2024, <https://healthequitytracker.org/exploredata?mls=1.copd-3.00>
84. Global Burden of Disease Collaborative Network. Global Health Data Exchange. Accessed March 14 2022, <https://vizhub.healthdata.org/gbd-results/>
85. Ollendorf D, Pearson, SD. ICER Evidence Rating Matrix: A User's Guide. Updated January 31, 2020. <https://icer.org/evidence-rating-matrix/>
86. Ollendorf DA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. *Medical care*. Jun 2010;48(6 Suppl):S145-52. doi:10.1097/MLR.0b013e3181d9913b
87. Valentine JC, Pigott, T. D., & Rothstein, H. R. How many studies do you need? A primer on statistical power for meta-analysis. *Journal of Educational and Behavioral Statistics*. 2010;35(2):215-247.
88. Singh D, P. Bhatt S, A. Mahler D, et al. Improvements in Breathlessness, COPD Symptoms and Quality of Life Reported With Ensifentrine in a Pooled Analysis of the ENHANCE Trials. 2024-05-20 2024;
89. Barjaktarevic I, Rheault T, Bengtsson T, Rickard K. Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.b22
90. ClinicalTrials.gov. A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD. ClinicalTrials.gov. 2024. <https://clinicaltrials.gov/study/NCT04535986?term=NCT04535986&rank=1>
91. Scirba FC, Wise RA, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c40
92. Rheault T, Bengtsson T, Rickard K. Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c40
93. Siler TM, Rickard K, Bengtsson T, Rheault T. Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2. *Am J Respir Crit Care Med*. 2023-01-01 2023;207(1)doi:10.1164/ajrccm-conference.2023.c40
94. Verona Pharma. Verona Pharma Data Submission. *Data on File*. 2024;
95. Barjaktarevic I, Rheault T, Bengtsson T, Rickard K. Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-group Analyses of ENHANCE-1 and ENHANCE-2 Phase 3 Trials. presented at: American Thoracic Society; 2023; Washington, DC, USA.
96. Marchetti N. Ensifentrine Added on to LABA/ICS Therapy Improved Lung Function and Reduced Exacerbations in Symptomatic Subjects With Moderate-to- Severe COPD. 2024-05-20 2024;
97. Scirba F, Christenson S, Rheault T, et al. Ensifentrine, A Novel, Selective Inhibitor of PDE3 and PDE4, Reduced Moderate/Severe Exacerbation Rate and Risk in Subjects With COPD Regardless of Baseline Blood Eosinophils. 2024-01-01 2024;
98. Axson EL, Lewis A, Potts J, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *BMJ Open*. Sep 29 2020;10(9):e036455. doi:10.1136/bmjopen-2019-036455
99. Koarai A, Sugiura H, Yamada M, et al. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. *BMC Pulm Med*. Apr 29 2020;20(1):111. doi:10.1186/s12890-020-1152-8

100. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. Sep 13 2016;316(10):1093-103. doi:10.1001/jama.2016.12195
101. Pickard AS, Law EH, Jiang R, et al. United States Valuation of EQ-5D-5L Health States Using an International Protocol. *Value Health*. Aug 2019;22(8):931-941. doi:10.1016/j.jval.2019.02.009
102. Pace WD, Brandt E, Carter VA, et al. COPD Population in US Primary Care: Data From the Optimum Patient Care DARTNet Research Database and the Advancing the Patient Experience in COPD Registry. *Ann Fam Med*. Jul-Aug 2022;20(4):319-327. doi:10.1370/afm.2829
103. Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. *PLoS One*. 2011;6(9):e24870. doi:10.1371/journal.pone.0024870
104. Social Security Administration. Actuarial Life Table. Accessed January 31, 2024. <https://www.ssa.gov/OACT/STATS/table4c6.html>
105. Liu Y, Greenlund KJ, VanFrank B, Xu F, Lu H, Croft JB. Smoking Cessation Among U.S. Adult Smokers With and Without Chronic Obstructive Pulmonary Disease, 2018. *Am J Prev Med*. Apr 2022;62(4):492-502. doi:10.1016/j.amepre.2021.12.001
106. Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: findings from the International Tobacco Control (ITC) Four Country Survey. *Addiction*. Dec 2009;104(12):2088-99. doi:10.1111/j.1360-0443.2009.02732.x
107. Fenwick E, Martin A, Schroeder M, et al. Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK. *ERJ Open Res*. Jan 2021;7(1)doi:10.1183/23120541.00480-2020
108. Masters M. Does Medicare Cover Nebulizer Machines? Accessed January 31, 2024. <https://www.ehealthinsurance.com/medicare/coverage/does-medicare-cover-nebulizer-machines/#:~:text=If%20you've%20already%20met,80%25%20of%20the%20remaining%20cost.>
109. Healthline. Does Medicare Cover Nebulizers? Accessed January 31, 2024. <https://www.healthline.com/health/medicare/does-medicare-cover-nebulizers>
110. Nebology. How Often Should You Replace Nebulizer Supplies? Accessed January 31, 2024. <https://nebology.com/blogs/education/when-to-replace-nebulizer-supplies#:~:text=Look%20for%20cracks%20or%20other,as%20directed%20by%20the%20manufacturer.>
111. Nebology. PARI LC Sprint Reusable Nebulizer Cup & Tubing. Accessed January 31, 2024. <https://nebology.com/products/pari-lc-sprint-reusable-nebulizer-cup-tubing>
112. Jiao B, Basu A. Catalog of Age- and Medical Condition-Specific Healthcare Costs in the United States to Inform Future Costs Calculations in Cost-Effectiveness Analysis. *Value Health*. Jul 2021;24(7):957-965. doi:10.1016/j.jval.2021.03.006
113. Patel JG, Coutinho AD, Lunacsek OE, Dalal AA. COPD affects worker productivity and health care costs. *Int J Chron Obstruct Pulmon Dis*. 2018;13:2301-2311. doi:10.2147/copd.S163795
114. Bureau of Labor Statistics. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. Accessed February 1, 2024, 2024. <https://www.bls.gov/news.release/empsit.t19.htm>
115. COPD Foundation. The COPD Caregiver. Accessed February 12, 2024. <https://www.copdfoundation.org/Learn-More/I-am-a-Caregiver/The-COPD-Caregiver.aspx#:~:text=Family%20caregivers%20provide%20an%20average,providing%20care%20around%20the%20clock.>
116. Rutten-van Mólken MP, Oostenbrink JB, Miravittles M, Monz BU. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. *Eur J Health Econ*. Jun 2007;8(2):123-35. doi:10.1007/s10198-007-0039-4
117. Institute for Clinical and Economic Review. 2020-2023 Value Assessment Framework. <https://icer.org/our-approach/methods-process/value-assessment-framework/>

118. Pearson SD. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value. *Value Health*. Mar 2018;21(3):258-265. doi:10.1016/j.jval.2017.12.017

Supplemental Materials

A. Background: Supplemental Information

A1. Definitions

Chronic Obstructive Lung Disease (COPD): A heterogeneous group of lung conditions caused by abnormalities of the airway and/or alveoli that cause persistent, often progressive, airflow obstruction. The presence of a post-bronchodilator FEV₁/FVC ratio of less than 0.7 on spirometry testing is required for the diagnosis of COPD. Subtypes include emphysema and chronic bronchitis. The most common symptoms include dyspnea, cough, and sputum production.⁶⁸

Long-acting muscarinic antagonists (LAMA): A bronchodilator treatment that works by blocking the bronchoconstriction effect of acetylcholine. This prevents the neurotransmitter from causing the muscles surrounding the lungs' airways to constrict, reducing symptoms of COPD.⁶⁹

Long-acting beta-adrenoceptor agonists (LABA): A bronchodilator treatment option that induces smooth muscle relaxation by stimulating beta-adrenergic receptors.⁶⁹

Inhaled corticosteroids (ICS): An anti-inflammatory therapeutic option for COPD that can be taken alone or in combination with LAMA and/or LABA treatment. Targeting lung inflammation with ICS can have clinical benefits on lung function, symptoms, and exacerbation risk, but it can also be associated with adverse effects including an increased risk of pneumonia.⁷⁰

Dual bronchodilator therapy (dual therapy): A combination of LAMA and LABA therapies. These can either be delivered separately or as a fixed dose combination and are usually offered to patients who have had COPD exacerbations (see guidelines in Section C).

Triple bronchodilator therapy (triple therapy): A combination of LAMA, LABA, and ICS therapies. These are delivered in various combinations: LAMA+LABA+ICS, LABA/ICS + LAMA, LAMA/LABA + ICS, or LAMA/LABA/ICS as a fixed dose combination. Triple therapy is usually offered to patients who have a history of one or more recent moderate or severe exacerbations or those who continue to have exacerbations on monotherapy and have eosinophils count ≥ 300 cells/ μ L.

Eosinophil count: A measure of the number of eosinophils per microliter of blood. High blood eosinophil count (≥ 300 cells/ μ L) serves as a biomarker for response to ICS in preventing acute exacerbations.⁷¹


Rescue medication: A medicine used to quickly relieve symptoms of COPD when experiencing a sudden worsening of symptoms.

Assessments of Symptoms and Severity in COPD

The modified Medical Research Council (mMRC) dyspnea scale: The mMRC scale is a self-assessment tool used to measure the level of impairment caused by breathlessness during daily activities in respiratory diseases, such as COPD. Ratings on the scale ranges from 0 to 4, with 0 representing no breathlessness except during strenuous exercise; and 4 being too breathless to leave the house, or breathless when dressing.⁷²

Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification: A measure of the severity of airflow obstruction, based on spirometry testing.⁶⁸ Patients have a spirometrically confirmed diagnosis (i.e., post-bronchodilator FEV₁/FVC <0.7). Next, patients have an assessment of airflow obstruction and are categorized into different GOLD categories (GOLD 1, 2, 3, and 4) based on their FEV₁ % predicted. Finally, patients are assessed for their symptoms and risk of exacerbations are classified into three groups: group A (those with 0 or 1 moderate exacerbation, mMRC of 0-1, and COPD Assessment Test [CAT] <10), group B (those with 0 or 1 moderate exacerbation, mMRC ≥2, and CAT ≥10), and group E (≥2 moderate exacerbation or ≥1 severe exacerbation leading to hospitalization). See Figure A1 for a visual description of the categories.

Figure A1. GOLD ABE assessment tool from Agusti et al (2023)⁶⁸



Lung Function Outcome Measures Definitions

Spirometry: A test used to measure the ability of a person to inhale and exhale air respective to time. Measurements from spirometry are used to help classify severity of disease (see GOLD classification above). Common measurements from spirometry include FEV₁, forced vital capacity (FVC), and forced expiratory volume (FEV₁).

Forced vital capacity (FVC): The maximal volume of air that can be expired following maximum inspiration.

Forced expiratory volume in 1 second (FEV₁): The volume of air (in liters) exhaled in the first second during forced exhalation after maximal inspiration.⁹

Patient-Important Outcomes Definitions

Minimal clinically important difference (MCID): The smallest change in an outcome that represents a meaningful change for the patient.

COPD exacerbations: Defined as worsening of COPD symptoms (two or more major symptoms or one major and one minor symptom).

- Moderate exacerbation: Worsening of COPD symptoms for >2 days requiring a minimum of 3 days of therapy with oral or systemic corticosteroids and/or antibiotics.
- Severe exacerbation: Worsening of COPD symptoms requiring inpatient hospitalization.⁹
Major symptoms: Dyspnea, sputum volume, sputum purulence (color)⁹
- Minor symptoms: Sore throat, colds (nasal discharge and/or nasal congestion), fever (oral temperature >37.5 °C) without other cause, increased cough, increased wheeze⁹

EuroQol-5-Domain Questionnaire (EQ-5D-5L): A self-reported, standardized instrument designed to measure health utility in terms of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The EQ-5D-5L scale ranges from 0-100, with higher scores representing better health. EQ-5D-5L utility index ranges from -0.59 to 1, with 1 being the best possible health state. The anchor-based minimal clinically important difference (MCID) for EQ-5D-5L utility index ranged from 0.037 to 0.063 in those with a COPD diagnosis.⁴³

Transitional Dyspnea Index (TDI): Interviewer-administered rating used to measure change in dyspnea in 3 categories (functional impairment, magnitude of task, and magnitude of effort). Scores range from -3 (major deterioration) to +3 (major improvement) for each domain. The sum of all domains yields the TDI focal score (-9 to +9). A negative score indicates more severity in dyspnea

whereas a positive score shows positive gains. A 1-unit change has been determined to be MCID for those with a COPD diagnosis.³⁹

Evaluating-Respiratory Symptoms (E-RS) Total Score: Patient-reported outcome that evaluates the effect of treatment on the severity of respiratory symptoms in stable COPD. This measure consists of 11 items which are specific to respiratory symptoms, including breathlessness, cough and sputum, and chest symptoms. Total score ranges from 0-40, MCID: ≥ 2.0 -point reduction³⁸, based on three subscales:

- Severity of breathlessness subscale (RS-breathlessness): Score range from 0-17, MCID: ≥ 1.0 -point reduction;
- Cough and sputum subscale (RS-cough and sputum): Score range 0-11, MCID: ≥ 0.7 -point reduction;
- Chest symptoms subscale (RS-Chest symptoms): Score range 0-12, MCID: ≥ 0.7 -point reduction.

In the ENHANCE trials, participants reported symptoms every evening and scores were calculated by taking the sum of the items for the total score. Higher values indicate more severe symptoms.³⁸

St. George's Respiratory Questionnaire (SGRQ): An instrument designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. The self-reported questionnaire consists of 50 items evaluating symptom components (frequency & severity) and impact components (social functioning, psychological disturbances resulting from airways disease).⁴² Scores range from 0 to 100, with higher scores indicating more health limitations. A mean change score of 4 units is associated with slightly efficacious treatment, 8 units for moderately efficacious change and 12 units for very efficacious treatment in COPD and asthma.⁴¹ However, a recent thesis reported that for those with moderate to very severe COPD, the MCID should be at least 7 points.⁴²

Health Care resource utilization: All unscheduled visits to a physician office, visits to urgent care, visits to emergency department, and hospitalizations for any cause and/or related to COPD and visits/contact due to COPD exacerbation.⁹

Daily average rescue medication: The mean number of self-reported rescue medication puffs/day over 7 a day period.⁹

Other Relevant Definitions

Absolute and Proportional Shortfalls: Absolute and proportional shortfalls are empirical measurements that capture different aspects of society's instincts for prioritization related to the severity or burden of an illness. The absolute shortfall is defined as the total absolute amount of future health patients with a condition are expected to lose without the treatment that is being

assessed.⁷³ The ethical consequences of using absolute shortfall to prioritize treatments is that conditions that cause early death or that have very serious lifelong effects on quality of life receive the greatest prioritization. Thus, certain kinds of treatments, such as treatments for rapidly fatal conditions of children, or for lifelong disabling conditions, score highest on the scale of absolute shortfall. The proportional shortfall is measured by calculating the proportion of the total health units of remaining life expectancy that would be lost due to untreated illness.^{74,75} The proportional shortfall reflects the ethical instinct to prioritize treatments for patients whose illness would rob them of a large percentage of their expected remaining lifetime. As with absolute shortfall, rapidly fatal conditions of childhood have high proportional shortfalls, but high numbers can also often arise from severe conditions among older adults who may have only a few years left of average life expectancy but would lose much of that to the illness without treatment. Details on how to calculate the absolute and proportional QALY and evLY shortfalls can be found in [ICER's reference case](#). Shortfalls will be highlighted when asking the independent appraisal committees to vote on unmet need despite current treatment options as part of characterizing a treatment's benefits beyond health and special ethical priorities ([Section 5](#)).

Health Improvement Distribution Index (HIDI): The HIDI identifies a subpopulation that has a higher prevalence of the disease of interest and therefore, creates an opportunity for proportionately more health gains within the subpopulation. This opportunity may be realized by achieving equal access both within and outside the identified subpopulation to an intervention that is known to improve health. The HIDI is defined as the disease prevalence in the subpopulation divided by the disease prevalence in the overall population. For example, if a disease has a prevalence of 10% among Black Americans whereas the disease prevalence among all Americans is 4%, then the Health Improvement Distribution Index is $10\%/4\% = 2.5$. In this example, a HIDI of 2.5 means that Black Americans as a subpopulation would benefit more on a relative basis (2.5 times more) from a new effective intervention compared with the overall population. HIDs above 1 suggest that more health may be gained on the relative scale in the subpopulation of interest when compared to the population as a whole. The HIDI may be helpful in characterizing a treatment's benefits beyond health and special ethical priorities ([Section 5](#)).

A2. Potential Cost-Saving Measures in COPD

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, see <https://icer.org/our-approach/methods-process/value-assessment-framework/>). These services are ones that would not be directly affected by therapies for COPD (e.g., hospitalizations for pneumonia from ICS therapy), as these services will be captured in the economic model. Rather, we are seeking services used in the current management of COPD beyond the potential offsets that arise from a new intervention. During stakeholder engagement and public comment periods, ICER encouraged all stakeholders to suggest

services (including treatments and mechanisms of care) currently used for patients with COPD that could be reduced, eliminated, or made more efficient. One clinical expert mentioned that routine repeat spirometry tests to monitor lung function after diagnosis are not necessary, as clinical practice guidelines recommend that therapy choices are driven by symptoms and exacerbations.

A3. Patient Input on Clinical Trial Design

We solicited this information from the manufacturer of ensifentrine and did not receive any feedback on this topic.

B. Patient Perspectives: Supplemental Information

B1. Methods

To gather stakeholder perspectives for this report, we engaged with people living with COPD, patient advocacy groups, including representatives from COPD advocacy organizations, clinical experts, and two payers to gather information to better understand the experience and treatment of COPD.

We spoke with six people in the US living with moderate to severe COPD, referred to us by COPD Foundation. We spoke with people who were diagnosed at a variety of ages, lived in geographically disparate areas, and who were and were not oxygen-dependent. We also spoke with two patient advocacy groups, both general respiratory health and COPD specific.

We interviewed nine clinical experts with expertise diagnosing, treating, and/or researching COPD. All were pulmonologists practicing in academic and Veteran's Affairs settings throughout the US. Clinical experts were referred to us by the manufacturer, patient organizations, and other clinical experts.

We spoke with two payers from different parts of the US, a commercial health plan based in the northeast US and a Medicaid plan based in the southern US.

C. Clinical Guidelines

American Thoracic Society (ATS) 2020 Clinical Practice Guideline for the Pharmacologic Management of COPD⁷⁶

ATS guidelines focus on therapy choices for specific clinical situations. For those with COPD who experience dyspnea or exercise intolerance, ATS recommends LABA + LAMA over monotherapy. If patients continue to experience symptoms despite LABA + LAMA therapy, ATS recommends use of the triple therapy (LABA + LABA + ICS) in those with a history of one or more exacerbations in the past year requiring antibiotics, oral steroids, or hospitalization. In those receiving triple therapy, ICS can be withdrawn if the patient has had no exacerbations in the past year. ATS notes that they do not recommend for or against ICS as an additive therapy to long-acting bronchodilators in those with COPD and eosinophilia, except if they have had a history of one or more exacerbations in the past year where they recommend ICS as an additive therapy. In patients with COPD and a history of severe and frequent exacerbations, ATS advises against maintenance oral corticosteroid therapy. For those with COPD who experience advanced refractory dyspnea, ATS suggests opioid-based therapy be considered in a personalized shared decision-making approach.⁷⁶

The National Institute for Health and Care Excellence (NICE) 2019⁷⁷

For those with a confirmed diagnosis of COPD, the fundamentals of care include: 1) treatment and support to stop smoking, 2) pneumococcal and influenza vaccinations; 3) pulmonary rehabilitation if indicated, co-developing a personalized self-management plan, and optimizing treatment for comorbidities. Inhaled therapies should be started if all the above interventions have been offered. If the patient is limited by symptoms or has exacerbations despite short-acting bronchodilators treatment, they should be offered long-acting bronchodilators. If the patient has no asthmatic features or features suggesting steroid responsiveness (e.g., any previous diagnosis of asthma or atopy, a higher blood eosinophil count, substantial variation in FEV₁ over time [at least 400 ml] or substantial diurnal variation in peak expiratory flow [at least 20%]), they should be offered LABA + LABA. If the patient has symptoms that impact quality of life or has one severe or two moderate exacerbations in one year, the clinician could consider triple therapy with awareness of risk of pneumonia in those who take ICS. If there is no improvement after 3 months of ICS use, then the patient should revert to LABA + LAMA. If the patient has asthmatic features or features suggesting steroid responsiveness, they should be offered LABA + ICS. If patients continue to have symptoms that impact quality of life or have one severe or two moderate exacerbations in a year, they should be offered triple therapy.⁷⁷

Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023⁵

The recommended pharmacological treatment for patients with COPD is based upon which group they would be best placed in. Patients with COPD group A should be offered a bronchodilator. Patients in group B should be offered LABA + LAMA, preferably as a single inhaler. Patients in group E should be offered LABA + LABA and consider offering triple therapy if eosinophils count is ≥ 300 cells/ μL . The guidelines note that LABA + ICS is no longer recommended, since LABA + LAMA + ICS has been shown to be superior to LABA + ICS if there is an indication for ICS.

For follow-up therapy, treatment should be based upon two traits: 1) dyspnea and 2) occurrence of exacerbations. For those with dyspnea on monotherapy (e.g., LABA or LAMA), they should be offered LABA + LAMA. If there is no improvement, clinicians should consider switching inhaler devices or treating other causes of dyspnea. Those with exacerbations on monotherapy should also receive LABA + LAMA, except those with eosinophils count is ≥ 300 cells/ μL , who should be offered LABA + LAMA + ICS. For patients on LABA + LAMA and persistent exacerbations, they should be offered LABA + LAMA + ICS if their eosinophil count is ≥ 100 cells/ μL . For patients who continue to have exacerbations on triple therapy, the addition of roflumilast or a macrolide antibiotic such as azithromycin may be considered. ICS should be used when: 1) there is a history of hospitalization for exacerbations of COPD; 2) ≥ 2 moderate exacerbations of COPD per year, 3) eosinophils ≥ 300 cells/ μL ; or 4) there is a history of asthma. ICS *could* be considered when: 1) there is 1 moderate exacerbation of COPD per year; or 2) eosinophil count is 100 to < 300 cells/ μL . However, ICS should not be used when: 1) there are repeated pneumonia events; 2) eosinophil count is < 100 cells/ μL ; or 3) there is a history of mycobacterial infection.⁵

D. Comparative Clinical Effectiveness: Supplemental Information

D1. Detailed Methods

PICOTS

Population

The population of focus for the review was adults with moderate to severe chronic obstructive pulmonary disease (COPD).

Data permitting, we evaluated the evidence for treatment effect modification by subpopulations defined by:

- Sociodemographic factors (e.g., sex, age [e.g., >75 years], socioeconomic status)
- Medical comorbidities (e.g., hypertension, osteoporosis, obesity, cardiovascular disease, diabetes, frailty)
- Eosinophil count (e.g., ≥ 300 cells/ μ l)
- People with frequent exacerbations (e.g., at least one exacerbation in the past year)
- Emphysema (i.e., destruction of alveoli causing difficulty with oxygen exchange) versus chronic bronchitis (i.e., airway inflammation that causes mucus production)
- Moderate versus severe COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] classification 2 versus 3)

Interventions

The intervention of interest for this review was:

- Ensifentrine (Verona Pharma)

Comparators

We examined ensifentrine as an add-on therapy to current COPD maintenance therapy versus no additional treatment.

- Current maintenance drug therapies may include:
 - Long-acting beta-agonists (LABAs)
 - LABA and inhaled corticosteroids (ICS)
 - Long-acting muscarinic antagonists (LAMAs)

- LAMA and ICS
- LABA and LAMA
- Triple therapy: LABA, LAMA, and ICS

Outcomes

The outcomes of interest are described in the list below.

- Patient-Important Outcomes
 - Changes in dyspnea (e.g., transitional dyspnea index [TDI], Modified Medical Research Council Dyspnea Scale [mMRC])
 - Changes in functional capacity (e.g., 6-minute walk distance)
 - COPD-related hospitalization or emergency room visit
 - Use of rescue medication
 - Requirement for long-term continuous or intermittent oxygen use
 - Health-related quality of life (e.g., St. George's Respiratory Questionnaire [SGRQ])
 - Number of exacerbations
- Changes in lung function (e.g., changes in average or peak forced expiratory volume [FEV₁])
- Adverse events (AEs) including but not limited to:
 - Serious AEs
 - Discontinuation due to AEs
 - Other AEs including but not limited to:
 - Mortality
 - Pneumonia
 - Cardiovascular outcomes (e.g., myocardial infarction, ischemic heart disease, stroke, hypertension)
 - Urinary tract risks, including urinary retention

Timing

Evidence on intervention effectiveness and harms was derived from studies of any duration.

Settings

All relevant settings were considered, with a focus on outpatient settings in the United States.

Table D1.1 PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item
TITLE		
Title	1	Identify the report as a systematic review.
ABSTRACT		
Abstract	2	See the PRISMA 2020 for Abstracts checklist.
INTRODUCTION		
Rationale	3	Describe the rationale for the review in the context of existing knowledge.
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.
METHODS		
Eligibility Criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.
Information Sources	6	Specify all databases, registers, websites, organizations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.
Search Strategy	7	Present the full search strategies for all databases, registers, and websites, including any filters and limits used.
Selection Process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.
Data Collection Process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.
Data Items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g., for all measures, time points, analyses), and if not, the methods used to decide which results to collect.
	10b	List and define all other variables for which data were sought (e.g., participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.
Study Risk of Bias Assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.
Effect Measures	12	Specify for each outcome the effect measure(s) (e.g., risk ratio, mean difference) used in the synthesis or presentation of results.

Section and Topic	Item #	Checklist item
Synthesis Methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g., tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g., subgroup analysis, meta-regression).
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.
Reporting Bias Assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).
Certainty Assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.
RESULTS		
Study Selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.
Study Characteristics	17	Cite each included study and present its characteristics.
Risk of Bias in Studies	18	Present assessments of risk of bias for each included study.
Results of Individual Studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g., confidence/credible interval), ideally using structured tables or plots.
Results of Syntheses	20a	For each synthesis, briefly summarize the characteristics and risk of bias among contributing studies.
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g., confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.
	20c	Present results of all investigations of possible causes of heterogeneity among study results.
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.
Reporting Biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.
Certainty of Evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.

Section and Topic	Item #	Checklist item
DISCUSSION		
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.
	23b	Discuss any limitations of the evidence included in the review.
	23c	Discuss any limitations of the review processes used.
	23d	Discuss implications of the results for practice, policy, and future research.
OTHER INFORMATION		
Registration and Protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.
	24c	Describe and explain any amendments to information provided at registration or in the protocol.
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.
Competing Interests	26	Declare any competing interests of review authors.
Availability of Data, Code, and Other Materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.

From: Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *PLoS Med.* 2021;18(3):e1003583.

Data Sources and Searches

Procedures for the systematic literature review assessing the evidence on ensifentrine for treatment of moderate to severe COPD followed established best research methods.^{78,79} We conducted the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.⁸⁰ The PRISMA guidelines include a checklist of 27 items (see Table D1.1).

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. We included abstracts from conference proceedings identified from the systematic literature search. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and Emtree terms in EMBASE), as well as free-text terms.

To supplement the database searches, we performed manual checks of the reference lists of included trials and systematic reviews and invited key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, see the [Policy on Inclusion of Grey Literature in Evidence Reviews](#)). Where feasible and deemed necessary, we also accepted data submitted by manufacturers “in-confidence,” in accordance with ICER’s [published guidelines](#) on acceptance and use of such data).


Table D1.2. Search Strategy of Medline 1996 to Present with Daily Update and Cochrane Central Register of Controlled Trials

1	exp chronic obstructive pulmonary disease/
2	('Chronic Obstructive Lung Disease*' or 'COAD' or 'COPD' or 'Chronic Obstructive Airway Disease' or 'Pulmonary Disease, Chronic Obstructive' or 'Airflow Obstruction, Chronic' or 'Airflow Obstructions, Chronic' or 'Chronic Airflow Obstruction*').ti,ab.
3	1 or 2
4	('ensifentrine' or 'RPL 554' or 'RPL554' or 'RPL-554').ti,ab.
5	3 and 4
6	(animals not (humans and animals)).sh.
7	5 NOT 6
8	(addresses OR autobiography OR bibliography OR biography OR comment OR congresses OR consensus development conference OR dictionary OR directory OR duplicate publication OR editorial OR encyclopedia OR guideline OR interactive tutorial).pt
9	7 NOT 8
10	limit 9 to English language
11	Remove duplicates from 10

Table D1.3. Search Strategy of EMBASE

1	'chronic obstructive pulmonary disease'/exp
2	'chronic airflow obstruction' OR 'chronic airway obstruction' OR 'chronic obstructive bronchopulmonary disease' OR 'chronic obstructive respiratory disease' OR 'copd' OR 'lung chronic obstructive disease' OR 'lung disease, chronic obstructive' OR 'obstructive chronic lung disease' OR 'obstructive chronic pulmonary disease' OR 'obstructive lung disease, chronic' OR 'pulmonary disease, chronic obstructive' OR 'pulmonary disorder, chronic obstructive' OR 'chronic obstructive lung dis*' OR 'chronic obstructive pulmonary dis*' OR 'chronic pulmonary obstructive dis*'
3	#1 or #2
4	'rpl 554' OR 'rpl554' OR 'vmx 554' OR 'vmx554' OR 'ensifentrine'.ti,ab
5	#3 and #4
6	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
7	#5 NOT #6
8	#7 AND [english]/lim
9	#8 AND ('chapter'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'short survey'/it)
10	#8 NOT #9

Figure D1.4. PRISMA flow Chart Showing Results of Literature Search for Ensifentrine for COPD



Study Selection

We performed screening at both the abstract and full-text level. Two investigators independently screened all titles and abstracts identified through electronic searches according to the inclusion and exclusion criteria described earlier using Nested Knowledge (Nested Knowledge, Inc, St. Paul, MN); a third reviewer worked with the initial two reviewers to resolve any issues of disagreement through consensus. We did not exclude any study at abstract-level screening due to insufficient information. For example, an abstract that did not report an outcome of interest would be accepted for further review in full text. We retrieved the citations that were accepted during abstract-level screening for full text appraisal. One investigator reviewed full papers and provided justification for exclusion of each excluded study.

Data Extraction

Data were extracted into Microsoft Word and Microsoft Excel. The basic design and elements of the extraction forms followed those used for other ICER reports. Elements included a description of patient populations, sample size, duration of follow-up, funding source, study design features, interventions (agent, dosage, frequency, schedules), concomitant therapy allowed and used (agent, dosage, frequency, schedules), outcome assessments, results, and risk of bias for each published study. The data extraction was performed in the following steps:

1. One reviewer extracted information from the full articles, and a second reviewer validated the extracted data.
2. Extracted data were reviewed for logic, and a random proportion of data were validated by a third investigator for additional quality assurance.

Risk of Bias Assessment

We examined the risk of bias for each randomized trial in this review using criteria published in the Cochrane Risk of Bias Assessment Tool Version 2.^{79,81} Risk of bias was assessed by study outcome for each of the following aspects of the trials: randomization process, deviation from the intended interventions, missing outcome data, measurement of the outcome, selection of the reported results, and overall risk of bias. Two reviewers independently assessed these domains. Any disagreements were resolved through discussion or by consulting a third reviewer. We did not assess the risk of bias in trials where we only had access to conference abstracts/presentations.

To assess the risk of bias in trials, we rated the categories as: “low risk of bias,” “some concerns,” or “high risk of bias.” Guidance for risk of bias ratings using these criteria is presented below:

Low risk of bias: *The study is judged to be at low risk of bias for all domains for this result.*

Some concerns: *The study is judged to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain.*

High risk of bias: *The study is judged to be at high risk of bias in at least one domain for this result or the study is judged to have some concerns for multiple domains in a way that substantially lowers confidence in the result.*

We examined the risk of bias for the following outcomes: annualized exacerbation event rate, lung function (average FEV₁, AUC 0-12h), and discontinuation due to adverse events. See Table D1.3.

Table D1.5. Risk of Bias Assessment: Annualized Exacerbation Event Rate

Studies (Author, Year)	Randomization process	Deviation from the intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Risk of Bias	Comment
Phase III							
ENHANCE-1	Low	Low	Low	Low	Low	Low	-
ENHANCE-2	Low	Low	Some Concerns	Low	Low	Some Concerns	Higher proportion of patients with severe COPD receiving placebo withdrew from treatment and trial.
Phase II							
Ferguson et al. 2021	NA	NA	NA	NA	NA	NA	-
Singh et al. 2020	NA	NA	NA	NA	NA	NA	-

Table D1.6. Risk of Bias Assessment: Lung Function (Average FEV₁, AUC 0-12h)

Studies (Author, Year)	Randomization process	Deviation from the intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Risk of Bias	Comme nt
Phase III							
ENHANCE-1	Low	Low	Low	Low	Low	Low	-
ENHANCE-2	Low	Low	Low	Low	Low	Low	-
Phase II							
Ferguson et al. 2021*	Low	Low	Low	Low	Low	Low	-
Singh et al. 2020*	Low	Low	Low	Low	Low	Low	-

* Peak FEV₁, not Average FEV₁, was the primary outcome in this study. Though, average FEV₁ was analyzed using the same approach as the primary outcome.

Table D1.7. Risk of Bias Assessment: Discontinuation due to Adverse Events

Studies (Author, Year)	Randomization process	Deviation from the intended interventions	Missing outcome data	Measurement of the outcome	Selection of the reported result	Overall Risk of Bias	Comment
Phase III							
ENHANCE-1	Low	Low	Low	Low	Low	Low	-
ENHANCE-2	Low	Low	Low	Low	Low	Low	-
Phase II							
Ferguson et al. 2021	Low	Low	Low	Low	Low	Low	-
Singh et al. 2020	Low	Low	Low	Low	Low	Low	-

Evaluation of Clinical Trial Diversity

We evaluated the demographic diversity of clinical trials using the ICER-developed Clinical trial Diversity Rating (CDR) Tool.⁸² The CDR tool was designed to evaluate the three demographic characteristics described in Table D1.8. Representation for each demographic category was evaluated by quantitatively comparing clinical trial participants with disease-specific prevalence estimates, using the metric “Participant to Disease-prevalence Representation Ratio” (PDRR).^{83,84} Next, a representation score between 0 to 3 was assigned based on the PDRR estimate (See Table D1.9 for the PDRR cut points that correspond to each representation score). Finally, based on the total score of the demographic characteristics (e.g., race and ethnicity), the categories “Good,” “Fair,” or “Poor” are used to communicate the overall level of diversity of a clinical trial. The description of the rating categories for each demographic characteristic is provided in Table D1.10.

Table D1.8. Demographic Characteristics and Categories

Demographic Characteristics	Categories
1. Race and Ethnicity*	Racial categories: <ul style="list-style-type: none"> • White • Black or African American • Asian • American Indian and Alaskan Native • Native Hawaiian and Other Pacific Islanders Ethnic Category: <ul style="list-style-type: none"> • Hispanic or Latino
2. Sex	<ul style="list-style-type: none"> • Female • Male
3. Age	<ul style="list-style-type: none"> • Older adults (≥65 years)

* Multinational trials: For multinational clinical trials, our approach is to evaluate only the subpopulation of patients enrolled from the US on racial and ethnic diversity

Table D1.9. Representation Score

PDRR	Score
0	0
>0 and Less Than 0.5	1
0.5 to 0.8	2
≥0.8	3

PDRR: Participant to Disease-prevalence Representation Ratio

Table D1.10. Rating Categories

Demographic Characteristics	Demographic Categories	Maximum Score	Rating Categories (Total Score)
Race and Ethnicity*	Asian, Black, or African American, White, and Hispanic or Latino	12	Good (11-12) Fair (7-10) Poor (≤ 6)
Sex	Male and Female	6	Good (6) Fair (5) Poor (≤ 4)
Age	Older adults (≥ 65 years)	3	Good (3) Fair (2) Poor (≤ 1)

* American Indian or Alaskan Native & Native Hawaiian or Other Pacific Islander are not factored into the overall racial and diversity rating. However, information on enrollment and PDRR estimates are reported when reliable prevalence estimates are available.

Results

Table D1.11. Diversity Ratings on Race and Ethnicity, Sex, and Age (Older Adults)

Trial	Race and Ethnicity	Sex	Age (Older adults)
ENHANCE-1	Fair	Fair	Fair
ENHANCE-2	Fair	Good	Fair

NE: Not Estimated, NR: Not Reported.

Table D1.11. presents the clinical trial diversity ratings on race and ethnicity, sex, and age (older adults) for ENHANCE-1 and -2. Given that ENHANCE-1 and -2 are multinational clinical trials, we requested information on the subpopulation of patients recruited in the US from the manufacturer for our evaluation of racial and ethnic diversity.

Race and Ethnicity: The manufacturer did not provide US-specific enrollment data; therefore, these trials were rated using the full sample. Both ENHANCE-1 and -2 trials, which we rated as “fair” on racial and ethnic diversity, had an adequate representation of White individuals compared to the disease prevalence; however, Black or African American individuals were underrepresented (3.8% of trial participants were Black or African American vs. 11.4% of patients with COPD⁸³). In addition, Asian individuals were underrepresented in ENHANCE-2 (0.25% of trial participants vs. 1.4% of patients with COPD⁸³), while Hispanic individuals were underrepresented in ENHANCE-1 (2.6% of trial participants vs. 9.6% of patients with COPD⁸³). See Table D1.12.

Sex: ENHANCE-2 adequately represented males and females. However, ENHANCE-1 underrepresented females and thus was rated as “fair”. See Table D1.13.

Age: Both trials underrepresented older adults (50% of trial participants vs. 80% of patients with COPD⁸⁴) and were rated as “fair” based on pre-defined cut points. See Table D1.13.

Table D1.12. Race and Ethnicity

	White	Black/ African American	Asian	Hispanic/ Latino	Total score	Diversity Rating	AIAN	NHPI
Prevalence⁸³	71.3%	11.40%	1.40%	9.60%	-	-	1.50%	0.10%
ENHANCE-1	89.8%	3.3%	3.3%	2.6%	-	-	0%	0%
PDRR	1.26	0.29	2.36	0.27	-	-	0	0
Score	3	1	3	1	8	Fair	NC	NC
ENHANCE-2	94.7%	4.3%	0.25%	5.0%	-	-	0.1%	0%
PDRR	1.33	0.38	0.18	0.52	-	-	0.07	0
Score	3	1	1	2	7	Fair	NC	NC

AIAN: American Indian or Alaskan Native, NR: Not Reported, NC: Not Calculated, NE: Not Estimated, NHPI: Native Hawaiian or Pacific Islander, PDRR: Participant to Disease-prevalence Representation Ratio

Table D1.13. Sex and Age

	Sex				Age		
	Male	Female	Score	Rating	Older Adults (≥65 years)	Score	Rating
Prevalence⁸⁴	46.90%	53.10%	-	-	79.70%	-	-
ENHANCE-1	58.2%	41.8%	-	-	53.6%	-	-
PDRR	1.24	0.79	-	-	0.66	-	-
Score	3	2	6	Fair	2	2	Fair
ENHANCE-2	48.2%	51.8%	-	-	56.2%	-	-
PDRR	1.03	0.98	-	-	0.69	-	-
Score	3	3	6	Good	2	2	Fair

NC: Not Calculated, PDRR: Participant to Disease-prevalence Representation Ratio

Assessment of Level of Certainty in Evidence

We used the [ICER Evidence Rating Matrix](#) to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus (see Appendix D).^{85,86}

Assessment of Bias

As part of our quality assessment, we evaluated the evidence base for the presence of potential publication bias. Given the emerging nature of the evidence base for these newer treatments, we scanned the ClinicalTrials.gov site to identify studies completed more than two years ago. Search terms include: ensifentrine, RPL554, VMX554, chronic obstructive pulmonary disease, and COPD. We selected studies which would have met our inclusion criteria, and for which no findings have been published. We will provide qualitative analysis of the objectives and methods of these studies

to ascertain whether there may be a biased representation of study results in the published literature.

Data Synthesis and Statistical Analyses

The studies were summarized in the text and in evidence tables of the Evidence Report. This summary is key to understanding the evidence base pertaining to the topic. Any key differences between the studies in terms of the study design, patient characteristics, interventions (including dosing and frequency), outcomes (including definitions and methods of assessments), and study quality was noted in the text of the report. For each outcome of interest, we evaluated the feasibility of conducting a quantitative synthesis by exploring the differences in study populations, study design, analytic methods, and outcome assessments.

If we had at least two studies comparing the same two interventions were sufficiently similar, we conducted pairwise meta-analyses. Two Phase III trials (ENHANCE-1 and -2) were included in a pairwise fixed-effects meta-analyses of primary and secondary endpoints (change from baseline in E-RS, TDI, SGRQ, and daily average rescue medication use at week 24, change in rate ratio in exacerbation rate at week 24, change in hazard ratio of time to first event at week 24, and change from baseline in lung function at week 12). Mean difference was chosen as the metric to analyze continuous outcomes (e.g., change in E-RS score). Risk or hazard ratios were chosen as the metric to analyze binary outcomes (e.g., annualized exacerbation event rate or time to first exacerbation). We used change from baseline, RR, or HR reported in the trials. We converted the 95% confidence intervals (CIs) to standard deviation to conduct the meta-analyses. As noted in the main report, the mean difference and 95% CIs estimated by our meta-analyses may be different to the estimates reported in the main trial publication. In our meta-analyses, because we were not able to obtain the exact number of participants who were included in each outcome, we included the total number of participants reported to have been included in the trial. The analyses in the manuscript may be based upon a smaller pool of participants and hence the difference in estimates. Model fit and heterogeneity were examined by reviewing AIC (Akaike Information Criterion), BIC (Bayesian Information Criterion), deviance, and I^2 (quantifies the degree of heterogeneity across studies). We also compared the fixed-effects model to a random-effects model to confirm model fit. (See Table D2.1.) The analyses were conducted in R using the metafor package. Results in terms of a point estimate and 95% confidence intervals were summarized graphically in forest plots in the main report or supplement.

Feasibility for indirect comparisons

We did not aim to compare ensifentrine to any other therapy than placebo.

Data Synthesis Limitations

There were two trials included in our meta-analysis. While the minimum number of trials for a fixed-effect meta-analysis is two,⁸⁷ more studies would have increased the precision in our estimates. While conducting our meta-analyses, we found one case of moderate heterogeneity - daily average rescue medication use. In this case, we examined the outcome measures and conducted random-effects analyses to compare model fit and determined that the fixed-effects models had the best fit to the data.

D2. Additional Clinical Evidence

Additional Methods

Evidence Base

Phase II Trials

We supplemented our evidence with two Phase II trials.^{31,32} These two Phase II trials were included as they reported data from 3 mg ensifentrine versus placebo with a duration of at least four weeks. We specifically focused on harms data from the ensifentrine 3 mg arm of these two trials. We did not include data that examined other administrations of ensifentrine (e.g., dry powder inhaler, metered dose inhaler), as the data from those arms for lung function were only available at one week.

Singh et al. (2020) was a Phase IIb randomized, double-blind trial that evaluated four doses of nebulized ensifentrine twice daily versus placebo for four weeks in patients with moderate to severe COPD.³² We only reviewed the 3 mg arm of ensifentrine. Participants were prohibited from using any maintenance COPD medication, e.g., steroids, antibiotics for lower respiratory tract infection, theophylline, and roflumilast, oral beta-blockers, LABAs, LAMAs, or oxygen therapy. The primary outcome was change in peak FEV₁ at week four. Participants were included if they were aged between 40-75 years of age, had a resting heart rate between 50-90 beats per minute (BPM), body mass index (BMI) between 18-35 mg/m², and established COPD for at least one year (i.e., score of ≥ 2 on the mMRC Dyspnea Scale and post-bronchodilator FEV₁/FVC < 0.70 [to confirm COPD] and FEV₁ $\geq 30\%$ and $\leq 70\%$ [to confirm moderate-severe COPD]). Exclusion criteria included: life-threatening COPD, hospitalization due to COPD in the past 6 months, or exacerbation due to COPD in the last 3 months, history of another respiratory disorder, or had a cardiovascular disorder.

Ferguson et al. (2021) was a Phase IIb randomized, double-blind trial that evaluated four doses of nebulized ensifentrine twice daily versus placebo for four weeks in patients with moderate to severe COPD.³¹ We only reviewed the 3 mg arm of ensifentrine. All participants also received open-label tiotropium (LAMA) once daily. The primary outcome was change in peak FEV₁ at week four.

Participants were included if they were aged between 40-80 years of age, had a resting heart rate between 45-90 BPM, BMI between 18-35 mg/m², and established COPD (following the same criteria as Singh et al. 2020). Exclusion criteria included: life-threatening COPD, hospitalization due to COPD or pneumonia, lung resection or reduction surgery in the last year, history of another respiratory disorders, or had long-term use of oxygen. Baseline characteristics and key outcome measures for both Phase II trials are reported in Supplement Table D3.3. Baseline characteristics were similar to Phase III trials, with participants being around 63 years of age, mostly White and non-Hispanic, and the majority had chronic bronchitis. The key differences compared to Phase III trials were that participants in Singh et al. were not on any background medication, compared to 62% in the ENHANCE-1 and -2 trials. But, in Ferguson et al., around 19% of participants were on dual therapy (LAMA+LABA) and 3% were on triple therapy (LAMA+LABA+ICS), compared to none in the ENHANCE-1 and -2 trials.

Additional Results

Meta-Analysis Results

We conducted fixed-effects meta-analyses which are reported in the main report. To compare and confirm model fit, we also conducted random-effects meta-analyses for all outcomes. Based upon the model fit data reported in Table D2.1., the fixed-effects model was a better fit to the data and thus we used these results.

Table D2.1. Model Fit for Fixed- and Random-Effects Meta-Analysis Models.

	Estimate (95% CI)	P-Value	I ²	AIC	BIC	Deviance
Fixed-effects meta-analysis						
Evaluating Respiratory Symptoms (E-RS)	-0.69 (-1.38, -0.01)	0.047	0%	3.17	1.86	0.16
Transition Dyspnea Index (TDI)	1.00 (0.58, 1.41)	<0.001	0%	1.08	-0.22	0.22
St. George's Respiratory Questionnaire (SGRQ)	-1.51 (-3.13, 0.12)	0.069	22%	7.62	6.31	1.28
Daily average rescue medication use	-0.28 (-0.52, -0.04)	0.02	39.30%	0.36	-0.94	1.65
Exacerbation rate	0.60 (0.41, 0.79)	<0.0001	0%	-2.11	-3.42	0.13
Time to first exacerbation	0.60 (0.41, 0.78)	<0.0001	0%	-2.26	-3.57	0.04
Average FEV₁ (ml)	92.29 (66.22, 118.36)	<0.0001	0%	17.77	16.46	0.05
Random-effects meta-analysis						
Evaluating Respiratory Symptoms (E-RS)	-0.69 (-1.38, -0.01)	0.047	0%	5.17	2.56	0.16
Transition Dyspnea Index (TDI)	0.99 (0.58, 1.42)	<0.0001	0%	3.08	0.47	0.22
St. George's Respiratory Questionnaire (SGRQ)	-1.47 (-3.32, 0.37)	0.12	21.70%	9.83	7.23	1.5
Daily average rescue medication use	-0.29 (-0.60, 0.03)	0.07	39.30%	2.73	0.11	2.01
Exacerbation rate	0.60 (0.41, 0.79)	<0.0001	0%	-0.11	-2.73	0.13
Time to first exacerbation	0.60 (0.41, 0.78)	<0.0001	0%	-0.26	-2.88	0.04
Average FEV₁ (ml)	92.29 (66.22, 118.36)	<0.0001	0%	19.77	17.15	0.05

AIC: Akaike Information Criterion, BIC: Bayesian Information Criterion, CI: confidence interval, FEV₁: forced expiratory volume in 1 second, I²: degree of heterogeneity across studies, ml: milliliters.

Subdomain Results

Evaluating Respiratory Symptoms (E-RS)

As noted in our main report, our pooled estimate for ensifentrine versus placebo on E-RS was statistically significant. Aligned with this, pooled data presented by the manufacturer reported greater improvements in those who received ensifentrine versus placebo in the chest symptoms and breathlessness subdomains at week 24.^{45,88}


St. George's Respiratory Questionnaire (SGRQ)

As noted in our main report, our pooled estimate for ensifentrine versus placebo on SGRQ was not statistically significant. Pooled data presented by the manufacturer provides data from two of the SGRQ subdomains: symptoms and activity. The data shows significantly greater improvements in those who received ensifentrine versus placebo on the SGRQ symptom subdomain, but the difference between ensifentrine and placebo did not appear to meet statistical significance for the activity subdomain.⁸⁸

Change in Raw Scores


Figures D2.1.-4 represent the change in scores for the patient-important outcomes from baseline to week 6, 12, and 24. The data is based upon raw scores presented in the manuscript and thus the follow-up time points likely do not include data from all participants.

Figure D2.1. Line Chart Representing Change in Raw Scores for E-RS.




Legend: X-Axis represents the time point at which the assessment was taken by the participant and the Y-Axis represents the score on the E-RS.

Figure D2.2. Line Chart Representing Change in Raw Scores for TDI.




Legend: X-Axis represents the time point at which the assessment was taken by the participant and the Y-Axis represents the score on the TDI.

Figure D2.3. Line Chart Representing Change in Raw Scores for SGRQ.



Legend: X-Axis represents the time point at which the assessment was taken by the participant and the Y-Axis represents the score on the SGRQ.

Figure D2.4. Line Chart Representing Change in Raw Means for Daily Average Rescue Medication Use.



Legend: X-Axis represents the time point at which the assessment was taken by the participant and the Y-Axis represents the daily average rescue medication use (based on 7 day average).

Lung Function

Both ENHANCE-1 and -2 trials reported a statistically significant improvement in peak and morning trough FEV₁ in the ensifentrine groups versus placebo groups at week 12.⁹ Data for evening trough FEV₁ were only available from a conference abstract for ENHANCE-1. The investigators reported that there was a statistically significant improvement in the ensifentrine versus placebo group at week 12.⁴⁵ See Supplement Table D3.4.

Health Care Resource Utilization

Data for health care resource utilization were only available from a conference abstract for ENHANCE-2. Participants in the ensifentrine group had fewer unplanned physician office visits and hospitalizations (11.8%), compared to those in the placebo group (15%).⁸⁹ Though, no statistical analyses were conducted or reported for these values.

Phase II Results


Efficacy data at week four for the two Phase II trials^{31,32} are reported in Supplement Tables D3.10-11. In brief, Singh et al. (2020)³² reported statistically significant improvements in lung function (average FEV₁, peak FEV₁, and morning trough) respiratory symptoms (E-RS and TDI) and use of rescue medication in the ensifentrine (3 mg) group versus placebo at week 4. However, there was no statistically significant difference in change in quality of life, as measured by SGRQ, between the groups at week 4. Ferguson et al. (2021)³¹ reported statistically significant improvements in lung function (average FEV₁ and peak FEV₁) in the ensifentrine (3 mg) group versus placebo at week 4, but not for morning trough FEV₁. Unlike Singh et al., there were no statistically significant differences in change in respiratory symptoms (i.e., E-RS and TDI) or use of rescue medication between the ensifentrine (3 mg) and placebo groups at week 4. However, there was a statistically significant difference in change in SGRQ, with ensifentrine associated with greater improvement in quality of life compared to placebo. Caution should be taken when interpreting these results as these trials were not powered to detect significant differences between the groups. In addition, while Ferguson et al. included participants on dual and triple therapy, which would have been interest to our review as dual and triple therapy are now considered standard of care according to GOLD guidelines, the investigators did not conduct subgroup analyses that examined potential differences between those who were on dual or triple therapy, compared to those who were not.^{5,31}

Additional Harms

Phase III Harms

As discussed in our main report, the pooled estimate for discontinuation rates due to TEAEs, excluding COVID-19 cases, was not statistically significant (RR: 0.92; 95% CI: 0.6, 1.41; P=0.7) (Figure D2.5) suggesting no difference in discontinuation between the two groups.

Figure D2.5. Forest Plot of Discontinuation due to Treatment-Emergent Adverse Events*



*Participants who received a COVID-19 diagnosis were removed

Phase II Harms

Two four-week Phase II trials were evaluated for harms.^{31,32} In Singh et al. 2020³², which evaluated ensifentrine in patients who received no background therapy, there was a low percentage of adverse events reported. Participants who received ensifentrine were more likely to experience hypertension (5% vs. 1%), headache (9% vs. 4%), and cough (5% vs. 1%). Total adverse events and discontinuation due to adverse events were comparable between the ensifentrine and placebo groups (see Supplement Table 3.18). In Ferguson et al. 2021³¹, which evaluated ensifentrine combined with tiotropium, total adverse events and discontinuation due to adverse events were comparable between the groups (see Supplement Table 3.18). The safety profile observed in these Phase II trials of ensifentrine aligns with results seen in the Phase III trials, ENHANCE-1 and -2.

D3. Evidence Tables

Table D3.1. Study Design of Key Trials^{9,31,32}

Trial/NCT	Study Design	Treatment Arms	Background Therapy	Inclusion/Exclusion Criteria	Primary Outcome [Timepoint]
Phase III trials					
ENHANCE-1 NCT04535986	Phase III randomized, double-blind, placebo-controlled Duration: 24 weeks (with a 48-week safety subset) N=760	Enfisentrine nebulized suspension; 3mg BID Placebo nebulized solution; BID	<p>Permitted</p> <ul style="list-style-type: none"> -Rescue medication of albuterol/salbutamol -Maintenance use of LAMA or LABA therapy if taken for at least 3 months prior to screening -Maintenance use of ICS if taken for at least 4 weeks prior to screening, taken with LAMA or LABA -Smoking cessation programs <p>Prohibited</p> <ul style="list-style-type: none"> -Oral, systemic or parenteral steroid therapies, antibiotics for lower respiratory tract infection, high doses of ICS, leukotriene inhibitors, theophylline and PDE4 inhibitor, terbutaline, ipratropium, beta2-agonists -Experimental drugs within 30 days or 5 half-lives of screening 	<p>Inclusion</p> <ul style="list-style-type: none"> -Age 40 to 80 years -Current or former cigarette smoker (≥10 pack years) -Established COPD diagnosis with score of ≥2 on the mMRC Dyspnea Scale -Pre- and Post-albuterol/salbutamol FEV₁/FVC ratio of <0.70, and post-albuterol/salbutamol FEV₁ ≥30% and ≤70% of predicted normal <p>Exclusion</p> <ul style="list-style-type: none"> -History of life-threatening COPD, hospitalization due to COPD, pneumonia, COVID-19 in last 12 weeks, or COPD exacerbation requiring steroids in the last 3 months -Previous lung resection or lung reduction surgery in the last year, or pulmonary rehabilitation -Lower respiratory tract infection in the last 6 weeks 	Least square mean change from baseline in average FEV ₁ AUC0-12h [12 weeks]

Trial/NCT	Study Design	Treatment Arms	Background Therapy	Inclusion/Exclusion Criteria	Primary Outcome [Timepoint]
Phase III trials					
ENHANCE-2 NCT04542057	Phase III randomized, double-blind, placebo-controlled Duration: 24 weeks N=789	Ensifentrine nebulized suspension; 3mg BID Placebo nebulized solution; BID	Same criteria as ENHANCE-1	Same criteria as ENHANCE-1	Least square mean change from baseline in average FEV ₁ AUC0-12h [12 weeks]
Phase II trials					
NCT03937479	Phase IIb, randomized, double-blind, placebo-controlled, 5-arm parallel group trial. Duration: 4 weeks N=166	Open-label tiotropium once daily plus blinded escalating doses of ensifentrine or placebo BID	Prohibited -Parenteral steroids, antibiotics for lower respiratory tract infection, oral steroids, theophylline, roflumilast, ICS therapy, or other antibiotics) -Experimental drugs within 30 days or five half-lives -Non-selective oral β -blockers -Use of oxygen therapy, even on an occasional basis	Inclusion -Age 40 and 80 years -Diagnosis of COPD as defined by the ATS/ERS guidelines -Post-bronchodilator spirometry at Screening demonstrating the following: FEV ₁ /FVC ratio of ≤ 0.70 , FEV ₁ $\geq 30\%$ and $\leq 70\%$ of predicted normal -Clinically stable COPD, score of ≥ 2 on mMRC dyspnea scale -Current and former smokers Exclusion -Life-threatening COPD including ICU admission and/or requiring intubation -A history of one or more hospitalizations for COPD or pneumonia -Pulmonary rehabilitation	Mean change from baseline in Peak FEV ₁ 0–3h [Week 4]

Trial/NCT	Study Design	Treatment Arms	Background Therapy	Inclusion/Exclusion Criteria	Primary Outcome [Timepoint]
NCT03443414	Phase IIb, randomized, double blind, placebo controlled, dose ranging study Duration: 4 weeks N=162	Nebulized formulation of ensifentrine 0.75mg, 1.5mg, 3mg, 6mg, or placebo	<p>Permitted</p> <ul style="list-style-type: none"> -ICS if the dose is stable for at least 4 weeks prior to visit 1 <p>Prohibited</p> <ul style="list-style-type: none"> -Oral, systemic or parenteral steroids, antibiotics for lower respiratory tract infection, theophylline, and roflumilast, oral beta-blockers, LABAs or LAMAs -Experimental drugs within 3 months or five half-lives, whichever is longer -Oxygen therapy 	<p>Inclusion</p> <ul style="list-style-type: none"> -Aged 40 to 75 years -COPD diagnosis with symptoms compatible with COPD for at least 1 year -Clinically stable COPD -FEV₁/FVC ratio of ≤0.70 and FEV₁ must be ≥40 % to ≤80% of predicted normal -Current and former smokers <p>Exclusion</p> <ul style="list-style-type: none"> -A history of life-threatening COPD -COPD exacerbation requiring oral steroids in the previous 3 months -One or more hospitalizations for COPD in the previous 6 months -Pulmonary rehabilitation 	Mean change from baseline in Peak FEV ₁ (over 3 hours) [Week 4]

0-3h: over three hours, 0-12h: over twelve hours, ATS: American Thoracic Society, AUC: area under the curve, BID: twice daily, COPD: chronic obstructive pulmonary disease, ERS: European Respiratory Society, FEV₁: forced expiratory volume in 1 second, FVC: Forced vital capacity, ICS: inhaled corticosteroids, ICU: Intensive Care Unit, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, mg: milligram, mMRC: the modified Medical Research Council, N: number, %: percent

Table D3.2. Phase III Baseline Characteristics⁹

Study		ENHANCE-1		ENHANCE-2		ENHANCE-1&2	
Arms		Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N		477	283	498	291	975	574
Age	Mean age, years (SD)	65.1 (7.1)	64.9 (7.7)	65 (7.4)	65.3 (7.3)	65	65
	≥65 years, n (%)	258 (54.1)	150 (53.0)	274 (55.0)	167 (57.4)	532 (54.6)	317 (55.2)
Sex, n (%)	Female	203 (42.6)	116 (41.0)	254 (51.0)	153 (52.6)	457 (47)	269 (47)
	Male	274 (57.4)	167 (59.0)	244 (49.0)	138 (47.4)	518 (53.1)	305 (53.1)
Race, n (%)	White	435 (91.2)	250 (88.3)	471 (94.6)	276 (94.8)	NR	NR
	Black or African American	16 (3.4)	9 (3.2)	24 (4.8)	11 (3.8)	NR	NR
	Asian	13 (2.7)	11 (3.9)	1 (0.2)	1 (0.3)	NR	NR
	American Indian or Alaska Native	0 (0)	0 (0)	1 (0.2)	0 (0)	NR	NR
	Other	0 (0)	1 (0.4)	1 (0.2)	3 (1.0)	NR	NR
	Not reported	13 (2.7)	12 (4.2)	0 (0)	0 (0)	NR	NR
Ethnicity, n (%)	Hispanic or Latino	15 (3.1)	6 (2.1)	26 (5.2)	14 (4.8)	NR	NR
	Not Hispanic or Latino	462 (96.9)	277 (97.9)	472 (94.8)	277 (95.2)	NR	NR
US participants, n (%)		87 (18.2)	58 (20.5)	281 (56.4)	174 (59.8)	NR	NR
mMRC score*, n (%)	Grade 2	333 (69.8)	197 (69.6)	275 (55.2)	162 (55.7)	NR	NR
	Grade 3	137 (28.7)	79 (27.9)	208 (41.8)	116 (39.9)	NR	NR
	Grade 4	7 (1.5)	7 (2.5)	15 (3.0)	13 (4.5)	NR	NR
Rescue medication puffs per day, mean (SD)		1.54 (2.40)	1.52 (2.23)	1.86 (2.35)	1.93 (2.43)	NR	NR
St. George's Respiratory Questionnaire (SGRQ), mean (SD)		48.1 (18.3)	46.9 (17.1)	50.6 (17.4)	51.2 (16.4)	NR	NR
Evaluating Respiratory Symptoms (E-RS), mean (SD)		14.1 (6.8)	13.3 (6.1)	13.3 (6.7)	13.3 (6.2)	NR	NR
Transition Dyspnea Index (TDI), mean (SD)		5.9 (1.1)	5.9 (1.1)	5.9 (1.3)	5.9 (1.2)	NR	NR
Mean baseline FEV ₁ , ml (SD)		1420 (487)	1403 (468)	1285 (451)	1279 (473)	NR	NR
Mean post-bronchodilator FEV ₁	L (SD)	1.53 (0.46)	1.51 (0.47)	1.43 (0.44)	1.42 (0.45)	NR	NR
	% predicted (SD)	52.9 (10.3)	51.7 (10.5)	50.8 (10.7)	50.4 (10.7)	51.8 (10.6)	51.0 (10.6)

Study		ENHANCE-1		ENHANCE-2		ENHANCE-1&2	
Arms		Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N		477	283	498	291	975	574
Severity of airflow obstruction (post-bronchodilator FEV ₁), n (%)	GOLD 1 (mild)	1 (0.2)	0 (0)	1 (0.2)	0 (0)	NR	NR
	GOLD 2 (moderate)	294 (61.6)	164 (58.0)	265 (53.2)	143 (49.1)	559 (57)	307 (54)
	GOLD 3 (severe)	179 (37.5)	119 (42.0)	231 (46.4)	148 (50.9)	410 (42)	267 (46)
		ENHANCE-1		ENHANCE-2		ENHANCE-1&2	
	GOLD 4 (very severe)	3 (0.6)	0 (0)	1 (0.2)	0 (0)	NR	NR
Eosinophil count, n (%)	≤150 cells/μL	NR	NR	NR	NR	408 (42)	245 (43)
	>150 cells/μL	NR	NR	NR	NR	565 (57.9)	329 (57.3)
Concomitant maintenance COPD therapy use, n (%)	None used	146 (30.6)	91 (32.2)	223 (44.8)	131 (45.0)	369 (37.8)	222 (38.7)
	Maintenance therapy used	331 (69.4)	192 (67.8)	275 (55.2)	160 (55.0)	NR	NR
	LAMA†	151 (31.7)	76 (26.9)	168 (33.7)	90 (30.9)	319 (33)	166 (29)
	LAMA + ICS	4 (0.8)	5 (1.8)	1 (0.2)	0 (0)	5 (0.5)	5 (1)
	LABA†	89 (18.7)	45 (15.9)	34 (6.8)	23 (7.9)	123 (13)	68 (12)
	LABA + ICS	87 (18.2)	66 (23.3)	72 (14.5)	47 (16.2)	159 (16)	113 (20)
	ICS	NR	NR	NR	NR	164 (16.8)	118 (20.6)
Smoking history	Current smoker, n (%)	268 (56.2)	163 (57.6)	276 (55.4)	160 (55.0)	544 (56)	323 (56)
	Former smoker, n (%)	209 (43.8)	120 (42.4)	222 (44.6)	131 (45.0)	431 (44.2)	251 (43.7)
	Mean pack-years (SD)	41.1 (20.7)	41.8 (20.6)	42.7 (22.9)	41.9 (20.9)	NR	NR
	Mean years of smoking (SD)	39.3 (11.3)	39.0 (11.5)	38.9 (10.4)	39.9 (10.8)	NR	NR
COPD history	Chronic bronchitis‡, n (%)	385 (80.7)	215 (76.0)	322 (64.7)	190 (65.3)	707 (73)	404 (70)
	Emphysema, n (%)	195 (40.9)	146 (51.6)	303 (60.8)	179 (61.5)	NR	NR
	COPD exacerbations, ≤15 months prior to screening, n (%)	120 (25.2)	75 (26.5)	102 (20.5)	62 (21.3)	220 (23)	136 (24)

Cells/μL: cells per microliter, FEV₁: forced expiratory volume in 1 second, GOLD: Global Initiative for Chronic Obstructive Lung Disease, ICS: inhaled corticosteroids, L: volume, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, ml: milliliter, mMRC: the modified Medical Research Council, n: number, NR: not reported, SD: standard deviation, US: United States, %: percent

* mMRC scored from 0 (least out of breath) to 4 (most out of breath)

† The total number of patients receiving LAMAs excludes LAMA+ICS. The total number of patients receiving LABAs excludes LABA+ICS

‡ Defined as regular production of sputum for >3 months in two consecutive years (in the absence of other conditions that may explain it)

Table D3.3. Phase II Baseline Characteristics^{31,32}

Study		Ferguson et al. 2021		Singh et al. 2020	
		NCT03937479		NCT03443414	
Arms		Ensifentrine	Placebo	Ensifentrine	Placebo
N		82	84	82	80
Age	Mean age, years (SD)	64.5 (7.92)	63.6 (8.41)	62.5 (6.51)	63.5 (6.44)
	≥65 years, n (%)	41 (50.0)	37 (44.0)	NR	NR
Sex, n (%)	Female	45 (54.9)	44 (52.4)	37 (45)	30 (38)
	Male	37 (45.1)	40 (47.6)	45 (55)	50 (63)
Race, n (%)	White	76 (92.7)	75 (89.3)	82 (100)	80 (100)
	Black or African American	6 (7.3)	9 (10.7)	0 (0)	0 (0)
Ethnicity, n (%)	Hispanic or Latino	2 (2.4)	3 (3.6)	0 (0)	0 (0)
	Not Hispanic or Latino	80 (97.6)	81 (96.4)	82 (100)	80 (100)
mMRC score, n (%)	<Grade 2	NR	NR	6 (7)	4 (5)
	≥Grade 2	NR	NR	76 (93)	76 (95)
Rescue medication puffs per day, mean (SD)		2.1 (0-10.6)*†	2.7 (0-13.6)*†	1.9 (2.14)	1.5 (1.88)
St. George's Respiratory Questionnaire (SGRQ), mean (SD)		52.9 (8.1-91.4)*	58.3 (21.2-99.5)*	42.1 (18.78)	42.3 (17.07)
Evaluating Respiratory Symptoms (E-RS), mean (SD)		12.2 (0-24.2)*‡	14.2 (1.2-30.3)*	12.0 (6.03)	11.5 (6.23)
Transition Dyspnea Index (TDI), mean (SD)		6.0 (1-12)*§	5.6 (0-9)*§	6.4 (1.43)	6.4 (1.38)
Concomitant maintenance COPD therapy use, n (%)	LAMA#	32 (39.0)	43 (51.2)	NA	NA
	LAMA + ICS	NR	NR	NA	NA
	LABA#	0 (0)	2 (2.4)	NA	NA
	LABA + ICS	5 (6.1)	13 (15.5)	NA	NA
	LABA + LAMA	16 (19.5)	16 (19.0)	NA	NA
	LAMA + LABA + ICS	3 (3.7)	2 (2.4)	NA	NA
	ICS	0 (0)	2 (2.4)	29 (35)	28 (35)
Smoking History	Current smoker, n (%)	43 (52.4)	53 (63.1)	47 (57)	43 (54)
	Former smoker, n (%)	39 (47.6)	31 (36.9)	35 (43)	37 (46)
	Mean pack-years (SD)	51.0 (20.56)	52.5 (27.37)	41.8 (19.05)	43.3 (20.21)
Chronic bronchitis‡, n (%)		42 (51.2)	47 (56.0)	56 (68)	46 (58)

COPD: chronic obstructive pulmonary disease, ICS: inhaled corticosteroids, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, mMRC: the modified Medical Research Council, n: number, NA: not applicable, NR: not reported, SD: standard deviation, %: percent

* range

† N= Ensifentrine: 71, Placebo: 76

‡ N= Ensifentrine: 74, Placebo: 77

§ N= Ensifentrine: 78, Placebo: 80

The total number of patients receiving LAMAs excludes LAMA+ICS. The total number of patients receiving LABAs excludes LABA+ICS

⌘ Defined as regular production of sputum for >3 months in two consecutive years (in the absence of other conditions that may explain it)

Table D3.4. Phase III Changes in Lung Function^{9,45,47,90}

Trial		Timepoint	ENHANCE-1		ENHANCE-2	
Study Arms			Ensifentrine	Placebo	Ensifentrine	Placebo
N			477	283	498	291
Average FEV ₁ , AUC 0-12h	LS mean change from baseline, ml (95% CI)	Week 12	61 (25, 97)	-26 (-64, 13)	48 (30, 66)	-46 (-70, -22)
	Vs. placebo (95% CI); P value		87 (55, 119); P<0.001		94 (65, 124); P<0.001	
Peak FEV ₁	LS mean change from baseline, ml (95% CI)	Week 12	204 (165, 244)	57 (15, 100)	195 (175, 214)	48 (22, 75)
	Vs. placebo (95% CI); P value		147 (111, 183); P<0.001		146 (113, 179); P<0.001	
	LS mean change from baseline, ml (95% CI)		162 (21.2)*	46 (23.4)*	196 (11)*	43 (14.8)*
Morning trough FEV ₁	LS mean change from baseline, ml (95% CI)	Week 12	8 (-30, 45)	-27 (-67, 13)	6 (-13, 24)	-44 (-68, -19)
	Vs. placebo (95% CI); P value		35 (1, 68); P=0.041		49 (19, 80); P=0.002	
	LS mean change from baseline, ml (95% CI)	Week 24	-24 (20.5)*	-37 (21.9)*	-7 (10.1)*	-32 (13.2)*
Evening trough FEV ₁	Vs. placebo (95% CI); P value	Week 12	58 (24, 92); P<0.001		NR	

0-12h: over 12 hours, AUC: area under the curve, CI: confidence interval, FEV₁: forced expiratory volume in 1 second, N: number, NR: not reported, LS: least square, %: percent

* Standard error

† Average FEV₁, AUC 0-12h: FEV₁ is performed at various timepoints across a 12-hour period (pre dose and 30min and 1, 2, 4, 6, 8, and 12 hours post-dose). The FEV₁ assessments are divided by 12 hours to provide an average measure of lung function over the 12-hour time period.⁹

‡ Peak FEV₁: Highest FEV₁ recorded across the post-dose assessments.⁹

§ Morning trough FEV₁: Morning, pre-dose FEV₁ assessment.⁹

Evening trough FEV₁: Evening FEV₁ assessment.⁹

Table D3.5. Phase III Changes in Respiratory Symptoms^{9,46,47,88,90-92}

Trial		Timepoint	ENHANCE-1		ENHANCE-2		ENHANCE-1&2 Pooled	
Study Arms			Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N			477	283	498	291	975	574
Evaluating Respiratory Symptoms (E-RS)	LS mean change from baseline, ml (95% CI)	Week 6	-1.94 (0.4) [†]	-1.16 (0.4) [†]	-1.9 (0.2) [†]	-0.61 (0.3) [†]	NR	NR
	Vs. placebo (95% CI); P value		-0.79 (-1.42, -0.16); P=0.015		-1.3 (-2.0, -0.7); P<0.001		NR	
	LS mean change from baseline, ml (95% CI)	Week 12	-2.5 (0.4) [†]	-1.1 (0.4) [†]	-2.1 (0.2) [†]	-1.2 (0.3) [†]	NR	NR
	Vs. placebo (95% CI); P value		-1.37 (-2.06, -0.68); P<0.001		-0.9 (-1.6, -0.2); P=0.016		NR	
	LS mean change from baseline, ml (95% CI)	Week 24	-2.2 (-3.1, -1.4)	-1.3 (-2.2, -0.4)	-2.1 (-2.6, -1.6)	-1.5 (-2.2, -0.9)	NR	NR
	Vs. placebo (95% CI); P value		-1.0 (-1.7, -0.2); P=0.011		-0.6 (-1.4, 0.2); P=0.134		NR	
E-RS Responders*	Odds ratio (95% CI); P value	Week 12	2.17 (1.55, 3.04); P<0.001		NR		NR	
	Odds ratio (95% CI); P value	Week 24	1.41 (1.01, 1.97); P=0.042		NR		NR	
E-RS symptom subdomain score [†]	Mean change vs. placebo (95% CI); P value	Week 6	-4.58 (-6.96, -2.21); P<0.001		NR		NR	
		Week 12	-6.84 (-9.29, -4.40); P<0.001		NR		NR	
		Week 24	-4.63 (-7.33, -1.93); P<0.001		NR		NR	
E-RS breathlessness subdomain score	LS mean change from baseline, ml (95% CI)	Week 24	NR	NR	NR	NR	-0.9 (-1.3, -0.5)	-0.6 (-1.0, -0.2)
Transition Dyspnea Index (TDI)	LS mean change from baseline, ml (95% CI)	Week 6	1.3 (0.2) [‡]	0.6 (0.2) [†]	1.6 (0.1) [‡]	0.9 (0.2) [‡]	NR	NR
	Vs. placebo (95% CI); P value		NR		0.7 (0.3, 1.1); P<0.001		NR	

	LS mean change from baseline, ml (95% CI)	Week 12	1.6 (0.2)‡	0.4 (0.2) [†]	1.8 (0.1)‡	1.2 (0.2)‡	NR	NR
	Vs. placebo (95% CI); P value		NR		0.6 (0.1, 1.0); P=0.010		NR	
	LS mean change from baseline, ml (95% CI)	Week 24	1.9 (1.4, 2.3)	0.8 (0.3, 1.4)	2.2 (1.9, 2.5)	1.3 (0.9, 1.7)	2.0 (1.5, 2.4)	0.9 (0.4, 1.4)
	Vs. placebo (95% CI); P value		1.0 (0.6, 1.5); P<0.001		0.9 (0.4, 1.4); P<0.001		P<0.05	
TDI Responders§	Percent of participants	Week 24	NR	NR	NR	NR	65%	45%
	Placebo-corrected odds ratio (95% CI); P value		NR	NR	NR	NR	1.9 (1.5, 2.7); P<0.05	

CI: confidence interval, LS: least square, MCID: Minimal Clinically Important Difference, N: number, %: percent

* Defined as those having a MCID (≥ 2 -unit improvement) on the E-RS

[†] Included: breathlessness, cough and sputum, chest symptoms

‡ Standard error

§ Defined as those having a MCID (≥ 1 -unit improvement) on the TDI

Table D3.6. Phase III Changes in Quality of Life^{9,47,90-92}

Trial		Timepoint	ENHANCE-1		ENHANCE-2		ENHANCE-1&2 Pooled	
Study Arms			Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N			477	283	498	291	975	574
St. George's Respiratory Questionnaire (SGRQ)	LS mean change from baseline, ml (SE)	Week 6	-6.18 (1.0)	-3.97 (1.1)	-3.60 (0.59)	-1.89 (0.77)	NR	NR
	LS mean change from baseline, ml (SE)	Week 12	-5.7 (1.0)	-2.7 (1.1)	-4 (0.6)	-2.9 (0.8)	NR	NR
	LS mean change from baseline, ml (95% CI)	Week 24	-6.2 (-8.4, -3.9)	-3.9 (-6.3, -1.5)	-4.5 (-5.9, -3.2)	-4.1 (-5.8, -2.3)	NR	NR
	Vs. placebo (95% CI); P value		-2.3 (-4.3, -0.3); P=0.025		-0.5 (-2.7, 1.7); P=0.669		NR	
SGRQ responders*	Odds ratio (95% CI); P value	Week 6	-4.58 (-6.96, -2.21); P<0.001		NR		NR	
	Odds ratio (95% CI); P value	Week 12	-6.84 (-9.29, -4.40); P<0.001		NR		NR	
	Odds ratio (95% CI); P value	Week 24	-4.63 (-7.33, -1.93); P<0.001		NR		NR	
SGRQ symptom subdomain	LS mean change from baseline, ml (95% CI)	Week 24	NR		NR		-8.0 (-11.1, -5.0) [†]	-4.9 (-8.1, -1.6)
SGRQ activity subdomain	LS mean change from baseline, ml (95% CI)	Week 24	NR		NR		-5.9 (-8.5, -3.3)	-4.5 (-7.3, -1.7)
EuroQol-5-Domain Questionnaire (EQ-5D-5L)	Vs. placebo (95% CI); P value	Week 12	NR		0.027 (0.004, 0.050); P=0.019		NR	
EQ-5D-5L VAS	Vs. placebo (95% CI); P value	Week 12	NR		0.8 (1.5, 3.0); P>0.05		NR	

CI: confidence interval, LS: least square, MCID: Minimal Clinically Important Difference, N: number, NR: not reported, SE: standard error, VAS: visual analogue scale, %: percent

* Defined as those having a MCID (≥4-unit improvement) in the SGRQ

† Reported as significant p<0.05

Table D3.7. Phase III Use of Rescue Medication^{9,47,90,92}

Trial		Timepoint	ENHANCE-1		ENHANCE-2	
Study Arms			Ensifentrine	Placebo	Ensifentrine	Placebo
N			477	283	498	291
Average daily rescue med use over 7 days	LS mean change from baseline, ml (SE)	Week 6	-0.44 (0.11)	-0.31 (0.11)	-0.53 (0.09)	-0.19 (0.12)
	Vs. placebo (95% CI); P value		NR		-0.34 (-0.62, -0.06); P=0.017	
	LS mean change from baseline, ml (SE)	Week 12	-0.47 (0.1)	-0.18 (0.1)	-0.57 (0.07)	-0.29 (0.1)
	Vs. placebo (95% CI); P value		NR		-0.28 (-0.53, -0.04); P=0.021	
	LS mean change from baseline, ml (95% CI)	Week 24	-0.51 (-0.79, -0.22)	-0.05 (-0.36, 0.25)	-0.49 (-0.66, -0.31)	-0.35 (-0.57, -0.12)
	Vs. placebo (95% CI); P value		-0.45 (-0.70, -0.20); P<0.001		-0.14 (-0.41, 0.14); P=0.32	

CI: confidence interval, med: medication, LS: least square, N: number, NR: not reported, SE: standard error, %: percent

* Standard error

Table D3.8. Phase III Moderate or Severe COPD Exacerbations and COPD-related Hospitalization or Emergency Room Visits^{9,44,48,89}

Trial		Timepoint	ENHANCE-1		ENHANCE-2		ENHANCE-1&2	
Study Arms			Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N			477	283	498	291	975	574
Annualized exacerbation event rate	LS mean (95% CI)	Week 24	0.26 (0.17, 0.40)	0.41 (0.27, 0.63)	0.24 (0.18, 0.32)	0.42 (0.30, 0.57)	0.27 (0.19, 0.39)	0.45 (0.31, 0.65)
	Rate ratio (95% CI); P value		0.64 (0.40, 1.00); P=0.05		0.57 (0.38, 0.87); P=0.009		0.59 (0.43, 0.80); P<0.001	
	LS mean (95% CI)	Week 48	0.25 (0.13, 0.48)	0.44 (0.22, 0.87)	NR	NR	NR	NR
	Rate ratio (95% CI); P value		0.56 (0.32, 1.00); P=0.052		NR		NR	
Time to first event	Log-rank test vs. placebo	Week 24	P=0.041		P=0.011		NR	
	Hazard ratio (95% CI); P value		0.62 (0.39, 0.97); P=0.038		0.58 (0.38, 0.87); P=0.009		0.59 (0.44, 0.81); P<0.001	
	Log-rank test vs. placebo	Week 48	P=0.014		NR		NR	
	Hazard ratio (95% CI); P value		0.48 (0.28, 0.82); P=0.007		NR		NR	
Transition to GOLD Group E from Group B	Hazard ratio (95% CI); P value	Week 24	NR	NR	NR	NR	0.64 (0.41, 1.01); P=0.058	
COPD-related hospitalization or emergency room visit, n (%)		Week 24	NR	NR	59 (11.8)	44 (15.1)	NR	NR

CI: confidence interval, LS: least square, N: number, NR: not reported, %: percent

* Group B (0 or 1 moderate exacerbations in the prior year) to GOLD Group E (2 or more moderate or 1 serious exacerbation in the prior year)

Table D3.9. Phase II Changes in Lung Function^{31,32}

Study		Timepoint	Ferguson et al. 2021		Singh et al. 2020	
			NCT03937479		NCT03443414	
Arms			Ensifentrine	Placebo	Ensifentrine	Placebo
N			82	84	82	79
Average FEV ₁ , AUC 0-12h	LS mean change from baseline, ml (95% CI)	Week 4	97 (49, 145)	10 (-38, 57)	NR	NR
	Vs. placebo (95% CI); P value		87 (20, 155); P=0.011		111 (51, 170)*; P<0.01	
Peak FEV ₁	LS mean change from baseline, ml (95% CI)	Week 4	243 (191, 295)	119 (68, 170)	NR	NR
	Vs. placebo (95% CI); P value		124 (52, 197); P=0.001		199 (130, 270)*; P<0.001	
Morning trough FEV ₁	LS mean change from baseline, ml (95% CI)	Week 4	5 (-40, 51)	-22 (-66, 23)	NR	NR
	Vs. placebo (95% CI); P value		27 (-36, 91); P=0.400		68 (4, 131)*; P<0.05	

0-12h: over 12 hours, AUC: area under the curve, CI: confidence interval, FEV₁: forced expiratory volume in 1 second, LS: least square, N: number, NR: not reported, %: percent

* Data has been digitized

Table D3.10. Phase II Changes in Respiratory Symptoms^{31,32}

Study		Timepoint	Ferguson et al. 2021		Singh et al. 2020	
			NCT03937479		NCT03443414	
Arms			Ensifentrine	Placebo	Ensifentrine	Placebo
N			82	84	82	79
Evaluating Respiratory Symptoms (E-RS)	LS mean change from baseline, ml (95% CI)	Week 4	-1.1 (-1.93, -0.21)	-0.2 (-1.08, 0.62)	NR	NR
	Vs. placebo (95% CI); P value		-0.8 (-2.05, 0.37); P=0.171		-2 (-0.7, -3.3)*; P<0.01	
Transition Dyspnea Index (TDI)	LS mean change from baseline, ml (95% CI)	Week 4	2.1 (1.39, 2.74)	1.8 (1.1, 2.43)	1.55 (3.44)	0.37 (3.22)
	Vs. placebo (95% CI); P value		0.3 (-0.65, 1.25); P=0.538		1.19 (0.25, 2.14); P=0.014	

CI: confidence interval, LS: least square, N: number, NR: not reported, %: percent

* Data has been digitized

Table D3.11. Phase II Changes in Quality of Life^{31,32}

Trial		Timepoint	Ferguson et al. 2021		Singh et al. 2020	
			NCT03937479		NCT03443414	
Study Arms			Ensifentrine	Placebo	Ensifentrine	Placebo
N			82	84	82	79
St. George's Respiratory Questionnaire (SGRQ)	LS mean change from baseline, ml (95% CI)	Week 4	-4.2 (-6.81, -1.51)	-0.1 (-2.71, 2.48)	40.1 (15.93)*	43.5 (16.99)*
	Vs. placebo (95% CI); P value		-4.1 (-7.76, -0.33); P=0.033		-2.29 (-5.96, 1.37); P=0.220	
SGRQ responders	Odds ratio (95% CI); P value	Week 4	NR		1.11 (0.53, 2.31); 0.791	
	Percentage of responders	Week 4	20.5	9.8	42	26

CI: confidence interval, VAS: visual analogue scale, LS: least square, N: number, %: percent

* St. George's Respiratory Questionnaire for COPD patients (SGRQ-C) is a shorter version of the SGRQ, derived from the original version following detailed analysis of data from large studies in COPD.

Table D3.12. Phase II Use of Rescue Medication^{31,32}

Trial		Timepoint	Ferguson et al. 2021		Singh et al. 2020	
			NCT03937479		NCT03443414	
Study Arms			Ensifentrine	Placebo	Ensifentrine	Placebo
N			71	76	82	81
Average daily rescue med use over 7 days	LS mean change from baseline, ml (95% CI)	Week 4	-0.5 (-0.86, -0.16)	-0.7 (-1.01, -0.33)	NR	NR
	Vs. placebo (95% CI); P value		0.2 (-0.33, 0.65); P=0.508		-0.49 (-0.91, -0.07); P=0.022	

CI:-confidence interval, LS: least square, N: number, NR: not reported, %: percent

Table D3.13. Phase III Treatment-Emergent Adverse Events⁹

Trial Timepoint Study Arms N	ENHANCE-1		ENHANCE-1		ENHANCE-2	
	Week 24		Week 48		Week 24	
	Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
Any TEAE, n (%)	183 (38.4)	103 (36.4)	58 (25.4)	19 (27.1)	176 (35.3)	103 (35.4)
Serious TEAE, n (%)	32 (6.7)	19 (6.7)	11 (4.8)	5 (7.1)	28 (5.6)	17 (5.8)
Severe TEAE, n (%)	27 (5.7)	15 (5.3)	5 (2.2)	3 (4.3)	22 (4.4)	12 (4.1)
Leading to death, n (%)	2 (0.4)	4 (1.4)	2 (0.9)	1 (1.4)	4 (0.8)	1 (0.3)
TEAE causally related to treatment, n (%)	24 (5.0)	11 (3.9)	2 (0.9)	0	20 (4.0)	12 (4.1)
TEAE leading to discontinuation, n (%)	29 (6.1)	18 (6.4)	5 (2.2)	2 (2.9)	45 (9.0)	29 (10.0)
TEAE leading to discontinuation (minus COVID-19 cases), n (%) [*]	21 (4.4)	13 (4.6)	3 (1.3)	2 (2.9)	29 (5.8)	19 (6.5)
TEAE leading to withdrawal, n (%)	19 (4.0)	10 (3.5)	4 (1.8)	1 (1.4)	35 (7.0)	20 (6.9)
TEAE leading to withdrawal of trial (with COVID-19 diagnosis), n (%)	8 (1.7)	5 (1.8)	2 (0.9)	0	16 (3.2)	10 (3.4)
TEAE leading to withdrawal of trial (no COVID-19 diagnosis), n (%)	11 (2.3)	5 (1.8)	2 (0.9)	1 (1.4)	19 (3.8)	10 (3.4)

TEAE: treatment-emergent adverse event, N: number, %: percent

^{*} Values for this outcome were estimated

Table D3.14. Phase III Select TEAEs^{9,34,47,90,93}

Trial Timepoint	ENHANCE-1		ENHANCE-1		ENHANCE-2	
	Week 24		Week 48		Week 24	
Study Arms	Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N	477	283	228	70	498	291
Nasopharyngitis, n (%)	13 (2.7)	16 (5.7)	6 (2.6)	0	9 (1.8)	3 (1.0)
Gastrointestinal, n (%)	NR	NR	NR	NR	26 (5.2)	15 (5.2)
Back pain, n (%)	10 (2.1)	1 (0.4)	NR	NR	8 (1.6)	5 (1.7)
COPD, n (%)	7 (1.5)	6 (2.1)	NR	NR	11 (2.2)	5 (1.7)
Toothache, n (%)	6 (1.3)	2 (0.7)	NR	NR	0	1 (0.3)
Pneumonia, n (%)	6 (1.3)	2 (0.7)	NR	NR	4 (0.8)	5 (1.7)
Urinary tract infection, n (%)	5 (1.0)	1 (0.4)	NR	NR	8 (1.6)	5 (1.7)
Diarrhea, n (%)	2 (0.4)	2 (0.7)	NR	NR	8 (1.6)	2 (0.7)
Sinusitis, n (%)	1 (0.2)	1 (0.4)	NR	NR	6 (1.2)	0
Upper respiratory tract infection, n (%)	6 (1.3)	5 (1.8)	4 (1.8)	0	NR	NR
Headache, n (%)	16 (3.4)	12 (4.2)	4 (1.8)	2 (2.9)	10 (2.0)	7 (2.4)

TEAE: treatment-emergent adverse event, N: number, NR: not reported, %: percent

Table D3.15. Phase III Cardiovascular Outcomes^{9,47,90,93}

Trial		ENHANCE-1		ENHANCE-1		ENHANCE-2	
Timepoint		Week 24		Week 48		Week 24	
Study Arms		Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N		477	283	228	70	498	291
Cardiovascular outcomes, n (%)	TEAEs	NR	NR	NR	NR	11 (2.2)	13 (4.5)
	TEAEs causally related to treatment	NR	NR	NR	NR	1 (0.2)	1 (0.3)
	Serious TEAEs	NR	NR	NR	NR	1 (0.2)	2 (0.7)
	Myocardial Infarction	0	0	1 (0.44)	0	NR	NR
Hypertension, n (%)		12 (2.5)	4 (1.4)	NR	NR	5 (1.0)	1 (0.3)

TEAE: treatment-emergent adverse event, N: number, NR: not reported, %: percent

Table D3.16. Phase III COVID-19^{9,47,90,94}

Trial		ENHANCE-1		ENHANCE-1		ENHANCE-2	
Timepoint		Week 24		Week 48		Week 24	
Study Arms		Ensifentrine	Placebo	Ensifentrine	Placebo	Ensifentrine	Placebo
N		477	283	228	70	498	291
COVID-19 detected, n (%)		16 (3.4)	9 (3.2)	2 (0.9)	2 (2.9)	16 (3.2)	10 (3.4)
COVID-19 leading to study withdrawal (before week 12), n (%)				NR	NR		
Those with COVID-19 included in analysis, n (%)				NR	NR		
COVID-19 leading to study withdrawal (total duration), n (%)		8	6	NR	NR	16	11

N: number, NR: not reported, %: percent

Table D3.17. Phase III Trial Withdrawal from Trial⁹

Trial	ENHANCE-1		ENHANCE-2	
	Week 48*		Week 24	
Timepoint				
Study Arms	Ensifentrine	Placebo	Ensifentrine	Placebo
N	477	283	498	291
All cause, n (%)	77 (16.1)	38 (13.4)	105 (21.1)	73 (25.1)
Withdrew consent, n (%)	30 (39)	13 (34)	51 (49)	30 (41)
Positive COVID-19, n (%)	8 (10)	6 (16)	16 (15)	11 (15)
Adverse event, n (%)	10 (13)	1 (3)	15 (14)	6 (8)
Lost to follow-up, n (%)	5 (7)	3 (8)	8 (8)	11 (15)
COPD exacerbation withdrawal criteria, n (%)	7 (9)	5 (13)	5 (5)	6 (8)
Death, n (%)	4 (5)	5 (13)	3 (3)	1 (1)
Lack of efficacy, n (%)	3 (4)	2 (5)	2 (2)	5 (7)
Investigator discretion, n (%)	3 (4)	0	2 (2)	1 (1)
Other, n (%)	7 (9)	3 (8)	2 (2)	2 (3)
Sponsor discretion, n (%)	0	0	1 (1)	0

N: number, NR: not reported, %: percent

* Trial withdrawal data only available at week 48 of the ENHANCE-1 trial

Table D3.18. Phase II Treatment-Emergent Adverse Events^{31,32}

Trial	Ferguson et al. 2021		Singh et al. 2020	
	NCT03937479		NCT03443414	
Timepoint	Week 4		Week 4	
Study Arms	Ensifentrine	Placebo	Ensifentrine	Placebo
N	83	84	82	79
Any TEAE, n (%)	18 (21.7)	17 (20.2)	12 (15)	10 (13)
Serious TEAE, n (%)	2 (2.4)	0 (0)	0	0
Severe TEAE, n (%)	NR	NR	2 (2)*	2 (3)*
Leading to death, n (%)	0	0	0	0
TEAE causally related to treatment, n (%)	2 (2.4)	4 (4.8)	NR	NR
TEAE Leading to discontinuation, n (%)	0 (0)	1 (1.2)	4 (5)*	2 (3)*

AE: adverse event, TEAE: treatment-emergent adverse event, N: number, %: percent

* AE not TEAE

Table D3.19. Phase II Select TEAEs^{9,31,32}

Trial	Ferguson et al. 2021		Singh et al. 2020	
	NCT03937479		NCT03443414	
Timepoint	Week 4		Week 4	
Study Arms	Ensifentrine	Placebo	Ensifentrine	Placebo
N	83	84	82	79
Nasopharyngitis, n (%)	1 (1.2)	2 (2.4)	NR	NR
Hypertension, n (%)	NR	NR	4 (5)*	1 (1)*
COPD, n (%)	3 (3.6)	0 (0)	NR	NR
Diarrhea, n (%)	1 (1.2)	0 (0)	NR	NR
Cough, n (%)	NR	NR	4 (5)	1 (1)
Headache, n (%)	2 (2.4)	1 (1.2)	7 (9)*	3 (4)*

TEAE: treatment-emergent adverse event, N: number, %: percent

*Adverse event not TEAE

Table D3.20. Phase II Trial Withdrawal from Trial^{31,32}

Trial	Ferguson et al. 2021		Singh et al. 2020	
	NCT03937479		NCT03443414	
Timepoint	Week 4		Week 4	
Study Arms	Ensifentrine	Placebo	Ensifentrine	Placebo
N	83	84	82	79
All cause, n (%)	6 (7.3)	5 (6)	6 (7.3)	4 (5)
Withdrew consent, n (%)	2 (2.4)	1 (1.19)	2 (2.53)	1 (1.2)
Adverse event, n (%)	0	1 (1.19)	4 (4.87)	3 (3.79)
Lost to follow-up, n (%)	1 (1.2)	0	0	0
Investigator discretion, n (%)	0	1 (1.19)	0	0
Protocol deviation, n (%)	3 (3.61)	2 (2.38)	0	0

N: number, NR: not reported, %: percent

Table D3.21. Phase III Background Medication Subgroup Data: Changes in Lung Function^{51-54,95,96}

Trial	Subgroup	Arms	N	Average FEV ₁ , AUC 0-12h	Peak FEV ₁ over 4h	Morning trough FEV ₁																																																																																
				LS mean change from baseline vs. placebo (95% CI); P value	LS mean change from baseline vs. placebo (95% CI); P value	LS mean change from baseline vs. placebo (95% CI); P value																																																																																
				Week 12	Week 12	Week 12																																																																																
ENHANCE-1	Any background medication	Ensifentrine	331	101.7 (66.2, 137.2); P<0.001	NR	NR																																																																																
		Placebo	192				ENHANCE-2	Ensifentrine	275	76 (39, 114); P<0.0001	NR	NR	Placebo	160	Pooled	Ensifentrine	606	NR	NR	NR	Placebo	352	ENHANCE-1	LABA/LABA+ICS	Ensifentrine	176	97 (50, 143)	154 (104, 204)	50 (5, 96)	Placebo	111	ENHANCE-2	Ensifentrine	106	75 (24, 126)	149 (93, 206)	66 (11, 121)	Placebo	70	Pooled	Ensifentrine	282	88 (53, 122); P<0.001	P<0.05	P<0.05	Placebo	181	Pooled	LABA/ICS	Ensifentrine	159	74; P<0.05	141; P<0.05	59; P<0.05	Placebo	113	ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155	112 (57, 166)	155 (90, 220)	57 (-7, 121)	Placebo	81	ENHANCE-2	Ensifentrine	169	79 (27, 131)	122 (64, 180)	37 (-17, 90)	Placebo	90	Pooled	Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05
ENHANCE-2		Ensifentrine	275	76 (39, 114); P<0.0001	NR	NR																																																																																
		Placebo	160				Pooled	Ensifentrine	606	NR	NR	NR	Placebo	352	ENHANCE-1	LABA/LABA+ICS	Ensifentrine	176	97 (50, 143)	154 (104, 204)	50 (5, 96)	Placebo	111		ENHANCE-2	Ensifentrine	106	75 (24, 126)	149 (93, 206)	66 (11, 121)	Placebo	70	Pooled	Ensifentrine	282	88 (53, 122); P<0.001	P<0.05	P<0.05	Placebo	181	Pooled	LABA/ICS	Ensifentrine	159	74; P<0.05	141; P<0.05	59; P<0.05	Placebo	113	ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155	112 (57, 166)	155 (90, 220)	57 (-7, 121)	Placebo		81	ENHANCE-2	Ensifentrine	169	79 (27, 131)	122 (64, 180)	37 (-17, 90)	Placebo	90	Pooled	Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166		
Pooled		Ensifentrine	606	NR	NR	NR																																																																																
		Placebo	352				ENHANCE-1	LABA/LABA+ICS	Ensifentrine	176	97 (50, 143)	154 (104, 204)	50 (5, 96)	Placebo	111		ENHANCE-2	Ensifentrine	106	75 (24, 126)	149 (93, 206)	66 (11, 121)	Placebo		70	Pooled	Ensifentrine	282	88 (53, 122); P<0.001	P<0.05	P<0.05	Placebo	181	Pooled	LABA/ICS	Ensifentrine	159	74; P<0.05	141; P<0.05	59; P<0.05	Placebo	113	ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155	112 (57, 166)	155 (90, 220)	57 (-7, 121)	Placebo		81	ENHANCE-2	Ensifentrine	169	79 (27, 131)	122 (64, 180)		37 (-17, 90)	Placebo	90	Pooled	Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166								
ENHANCE-1		LABA/LABA+ICS	Ensifentrine	176	97 (50, 143)	154 (104, 204)			50 (5, 96)																																																																													
			Placebo	111			ENHANCE-2			Ensifentrine	106	75 (24, 126)	149 (93, 206)	66 (11, 121)	Placebo		70	Pooled	Ensifentrine	282	88 (53, 122); P<0.001	P<0.05	P<0.05	Placebo	181	Pooled	LABA/ICS	Ensifentrine	159	74; P<0.05	141; P<0.05	59; P<0.05	Placebo	113	ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155	112 (57, 166)	155 (90, 220)	57 (-7, 121)	Placebo	81		ENHANCE-2	Ensifentrine	169	79 (27, 131)	122 (64, 180)	37 (-17, 90)		Placebo	90	Pooled	Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166																
ENHANCE-2			Ensifentrine	106	75 (24, 126)	149 (93, 206)			66 (11, 121)																																																																													
	Placebo		70	Pooled			Ensifentrine			282	88 (53, 122); P<0.001	P<0.05	P<0.05	Placebo	181	Pooled	LABA/ICS	Ensifentrine	159	74; P<0.05	141; P<0.05	59; P<0.05	Placebo	113	ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155	112 (57, 166)	155 (90, 220)	57 (-7, 121)	Placebo	81	ENHANCE-2	Ensifentrine		169	79 (27, 131)	122 (64, 180)	37 (-17, 90)	Placebo	90	Pooled		Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166																										
Pooled	Ensifentrine		282		88 (53, 122); P<0.001	P<0.05	P<0.05																																																																															
	Placebo		181	Pooled				LABA/ICS	Ensifentrine	159	74; P<0.05	141; P<0.05	59; P<0.05	Placebo	113	ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155	112 (57, 166)	155 (90, 220)	57 (-7, 121)	Placebo	81	ENHANCE-2		Ensifentrine	169	79 (27, 131)	122 (64, 180)	37 (-17, 90)	Placebo	90	Pooled	Ensifentrine		324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166																																			
Pooled	LABA/ICS	Ensifentrine	159		74; P<0.05	141; P<0.05	59; P<0.05																																																																															
		Placebo	113	ENHANCE-1				LAMA/LAMA+ICS	Ensifentrine	155	112 (57, 166)	155 (90, 220)	57 (-7, 121)	Placebo	81	ENHANCE-2		Ensifentrine	169	79 (27, 131)	122 (64, 180)	37 (-17, 90)	Placebo	90	Pooled		Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166																																												
ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155		112 (57, 166)	155 (90, 220)	57 (-7, 121)																																																																															
		Placebo	81	ENHANCE-2					Ensifentrine	169	79 (27, 131)	122 (64, 180)	37 (-17, 90)	Placebo	90	Pooled		Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166																																																					
ENHANCE-2		Ensifentrine	169		79 (27, 131)	122 (64, 180)	37 (-17, 90)																																																																															
		Placebo	90	Pooled					Ensifentrine	324	93 (55, 131); P<0.001	NR	NR	Placebo	171	Pooled	LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166																																																														
Pooled		Ensifentrine	324		93 (55, 131); P<0.001	NR	NR																																																																															
		Placebo	171	Pooled				LAMA	Ensifentrine	319	92; P<0.05	135; P<0.05	44; P<0.05	Placebo	166																																																																							
Pooled	LAMA	Ensifentrine	319		92; P<0.05	135; P<0.05	44; P<0.05																																																																															
		Placebo	166																																																																																			

Trial	Subgroup	Arms	N	Average FEV ₁ , AUC 0-12h	Peak FEV ₁ over 4h	Morning trough FEV ₁												
				LS mean change from baseline vs. placebo (95% CI); P value	LS mean change from baseline vs. placebo (95% CI); P value	LS mean change from baseline vs. placebo (95% CI); P value												
				Week 12	Week 12	Week 12												
ENHANCE-1	No background medication	Ensifentrine	146	60 (-3, 123); P=0.061	144 (72, 216)	6 (-60, 71)												
		Placebo	91				ENHANCE-2	Ensifentrine	223	115 (69, 161); P<0.001	161 (110, 212)	49 (0.9, 98)	Placebo	131	Pooled	Ensifentrine	369	NR
ENHANCE-2		Ensifentrine	223	115 (69, 161); P<0.001	161 (110, 212)	49 (0.9, 98)												
		Placebo	131				Pooled	Ensifentrine	369	NR	NR	NR	Placebo	222				
Pooled		Ensifentrine	369	NR	NR	NR												
		Placebo	222															

CI: confidence interval, FEV₁: forced expiratory volume in 1 second, ICS: inhaled corticosteroids, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, N: number, NR: not reported, %: percent

Table D3.22. Phase III Background Medication Subgroup Data: Moderate or Severe COPD Exacerbations^{51,54,95,96}

Trial	Subgroup	Arms	N	Annualized exacerbation rate	Time to first event	
				Rate ratio (95% CI); P value	Hazard ratio (95% CI); P value	
				Week 24	Week 24	
ENHANCE-1	Any background medication	Ensifentrine	331	NR	NR	
		Placebo	192			
ENHANCE-2		Ensifentrine	275	0.55 (0.32, 0.96); P=0.035	0.51 (0.29, 0.89); P=0.017	
		Placebo	160			
Pooled		Ensifentrine	606	0.60 (0.41, 0.88)	0.55 (0.38, 0.81)	
		Placebo	352			
ENHANCE-1		LABA/LABA+ICS	Ensifentrine	176	0.66 (0.34, 1.30)	0.59 (0.29, 1.17)
			Placebo	111		
ENHANCE-2			Ensifentrine	106	0.71 (0.31, 1.63)	0.58 (0.26, 1.32)
			Placebo	70		
Pooled	Ensifentrine		282	0.69 (0.41, 1.16)	0.58 (0.34, 0.99)	
	Placebo		181			
Pooled	LABA+ICS		Ensifentrine	159	0.49 (0.24, 0.99); P<0.05	0.47 (0.23, 0.96); P<0.05
			Placebo	113		
ENHANCE-1	LAMA/LAMA+ICS	Ensifentrine	155	0.67 (0.29, 1.53)	0.61 (0.26, 1.43)	
		Placebo	81			
ENHANCE-2		Ensifentrine	169	0.47 (0.23, 0.98)	0.47 (0.22, 0.98)	
		Placebo	90			
Pooled		Ensifentrine	324	NR	NR	
		Placebo	171			
Pooled	LAMA	Ensifentrine	319	0.54 (0.31, 0.94); P<0.05	0.51 (0.29, 0.90); p<0.05	
		Placebo	166			
ENHANCE-1	No background medication	Ensifentrine	146	0.57 (0.22, 1.47)	0.66 (0.27, 1.62)	
		Placebo	91			
ENHANCE-2		Ensifentrine	223	0.6 (0.32, 1.14); P=0.117)	0.69 (0.37, 1.29); P=0.244	
		Placebo	131			
Pooled		Ensifentrine	369	0.60 (0.35, 1.01)	0.68 (0.41, 1.14)	
		Placebo	222			

CI: confidence interval, ICS: inhaled corticosteroids, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, N: number, NR: not reported, %: percent

Table D3.23. Phase III Background Medication Subgroup Data: Changes in Respiratory Symptoms^{9,51,55,56,95}

Trial	Subgroup	Arms	N	Evaluating Respiratory Symptoms (E-RS)	Transition Dyspnea Index (TDI)	TDI Responders*
				LS mean change from baseline vs. placebo (95% CI)	LS mean change from baseline vs. placebo (95% CI)	Placebo-corrected odds ratio (95% CI); P value
				Week 24	Week 24	Week 24
ENHANCE-1	Any background medication	Ensifentrine	331	NR	NR	NR
		Placebo	192			
ENHANCE-2		Ensifentrine	275	NR	NR	NR
		Placebo	160			
Pooled		Ensifentrine	606	NR	NR	NR
		Placebo	352			
ENHANCE-1	LABA/LABA +ICS	Ensifentrine	176	-0.8 (-1.9, 0.3)	0.8 (0.2, 1.5)	NR
		Placebo	111			
ENHANCE-2		Ensifentrine	106	-0.7 (-2.3, 0.9)	0.7 (-0.3, 1.7)	NR
		Placebo	70			
Pooled		Ensifentrine	282	-0.8 (-1.7, 0.1)	NR	NR
		Placebo	181			
Pooled	LABA+ICS	Ensifentrine	159	NR	1.4 (0.5, 2.3) [†]	1.6 (0.9, 2.8)
		Placebo	113		0.6 (-0.3, 1.6) [†]	
ENHANCE-1	LAMA/LAMA +ICS	Ensifentrine	155	-1.4 (-2.7, -0.1)	1.0 (0.1, 1.8)	NR
		Placebo	81			
ENHANCE-2		Ensifentrine	169	-0.5 (-1.9, 0.8)	1.4 (0.7, 2.2)	NR
		Placebo	90			
Pooled		Ensifentrine	324	-0.9 (-1.9, 0.0)	NR	NR
		Placebo	171			
Pooled	LAMA	Ensifentrine	319	NR	2.4 (1.8, 3.0) [†]	2.4 (1.6, 3.8); P<0.05
		Placebo	166		1.2 (0.6, 1.9) [†]	

Trial	Subgroup	Arms	N	Evaluating Respiratory Symptoms (E-RS)	Transition Dyspnea Index (TDI)	TDI Responders*
				LS mean change from baseline vs. placebo (95% CI)	LS mean change from baseline vs. placebo (95% CI)	Placebo-corrected odds ratio (95% CI); P value
				Week 24	Week 24	Week 24
ENHANCE-1	No background medication	Ensifentrine	146	-0.7 (-2.2, 0.7)	1.2 (0.4, 1.9)	NR
		Placebo	91			
ENHANCE-2		Ensifentrine	223	-0.6 (-1.9, 0.6)	0.7 (-0.1, 1.4)	NR
		Placebo	131			
Pooled		Ensifentrine	369	NR	NR	NR
		Placebo	222			

CI: confidence interval, ICS: inhaled corticosteroids, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, N: number, NR: not reported, %: percent

* Defined as those having a MCID (≥ 1 -unit improvement) on the TDI

† Least-squares mean change from baseline

Table D3.24. Phase III Background Medication Subgroup Data: Changes in Quality of Life and Rescue Medication use^{9,51,55,56,95}

Trial	Subgroup	Arms	N	St. George's Respiratory Questionnaire (SGRQ)	Average daily rescue medication use over 7 days	
				LS mean change from baseline vs. placebo (95% CI)	LS mean change from baseline vs. placebo (95% CI)	
				Week 24	Week 24	
ENHANCE-1	Any background medication	Ensifentrine	331	NR	NR	
		Placebo	192			
ENHANCE-2		Ensifentrine	275	NR	NR	
		Placebo	160			
Pooled		Ensifentrine	606	NR	NR	
		Placebo	352			
ENHANCE-1		LABA/LABA+ICS	Ensifentrine	176	-1.6 (-4.7, 1.5)	-0.17 (-0.61, 0.26)
			Placebo	111		
ENHANCE-2			Ensifentrine	106	-0.7 (-5.5, 4.1)	0.01 (-0.55, 0.57)
	Placebo		70			
Pooled	Ensifentrine		282	-1.2 (-3.9, 1.4)	NR	
	Placebo		181			
Pooled	LABA+ICS		Ensifentrine	159	-2.8 (-7.2, 1.6)*	NR
			Placebo	113	-1.2 (-5.7, 3.3)*	
ENHANCE-1	LAMA/LAMA+ICS		Ensifentrine	155	-2.4 (-6.1, 1.4)	-0.42 (-0.78, -0.05)
		Placebo	81			
ENHANCE-2		Ensifentrine	169	-2.2 (-5.9, 1.5)	0.00 (-0.36, 0.36)	
		Placebo	90			
Pooled		Ensifentrine	324	-2.3 (-4.9, 0.3)	NR	
		Placebo	171			
Pooled		LAMA	Ensifentrine	319	-8.0 (-10.8, -5.3)*	NR
			Placebo	166	-5.6 (-8.7, -2.5)*	

Trial	Subgroup	Arms	N	St. George's Respiratory Questionnaire (SGRQ)	Average daily rescue medication use over 7 days
				LS mean change from baseline vs. placebo (95% CI)	LS mean change from baseline vs. placebo (95% CI)
				Week 24	Week 24
ENHANCE-1	No background medication	Ensifentrine	146	-2.9 (-6.6, 0.8)	-0.74 (-1.16, -0.32)
		Placebo	91		
ENHANCE-2		Ensifentrine	223	0.9 (-2.4, 4.1)	-0.32 (-0.80, 0.15)
		Placebo	131		
Pooled		Ensifentrine	369	NR	NR
		Placebo	222		

CI: confidence interval, ICS: inhaled corticosteroids, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, N: number, NR: not reported, %: percent

* Least-squares mean change from baseline

Table D3.25. Phase III Other Subgroup Data^{52,53,95,97}

Trial	Subgroup	Arms	N	Changes in lung function	Moderate or severe COPD exacerbations																																																															
				Average FEV ₁ , AUC 0-12h	Annualized exacerbation rate	Time to first event																																																														
				LS mean change from baseline vs. placebo (95% CI); P value	Rate ratio (95% CI); P value	Hazard ratio (95% CI); P value																																																														
				Week 12	Week 24	Week 24																																																														
ENHANCE-1	Female	Ensifentrine	203	90.6 (50.8, 130.4); P<0.001	NR	NR																																																														
		Placebo	116				ENHANCE-2	Ensifentrine	254	75 (39, 112); P<0.001	NR	NR	Placebo	153	Pooled	Ensifentrine	457	NR	0.58 (0.38, 0.89)	0.56 (0.36, 0.86)	Placebo	269	ENHANCE-1	Male	Ensifentrine	274	85 (39.2, 130.8) P<0.001	NR	NR	Placebo	167	ENHANCE-2	Ensifentrine	244	114 (68, 161); P<0.001	NR	NR	Placebo	138	Pooled	Ensifentrine	518	NR	0.64 (0.41, 0.98)	0.63 (0.41, 0.97)	Placebo	305	ENHANCE-1	<65 years	Ensifentrine	219	70 (14.9, 125.1); P=0.013	NR	NR	Placebo	113	ENHANCE-2	Ensifentrine	224	87 (39, 135); P<0.001	NR	NR	Placebo	124	Pooled	Ensifentrine	443	NR
ENHANCE-2		Ensifentrine	254	75 (39, 112); P<0.001	NR	NR																																																														
		Placebo	153				Pooled	Ensifentrine	457	NR	0.58 (0.38, 0.89)	0.56 (0.36, 0.86)	Placebo	269	ENHANCE-1	Male	Ensifentrine	274	85 (39.2, 130.8) P<0.001	NR	NR	Placebo	167		ENHANCE-2	Ensifentrine	244	114 (68, 161); P<0.001	NR	NR	Placebo	138	Pooled	Ensifentrine	518	NR	0.64 (0.41, 0.98)	0.63 (0.41, 0.97)	Placebo	305	ENHANCE-1	<65 years	Ensifentrine	219	70 (14.9, 125.1); P=0.013	NR	NR	Placebo		113	ENHANCE-2	Ensifentrine	224	87 (39, 135); P<0.001	NR	NR	Placebo	124	Pooled	Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)	Placebo	257		
Pooled		Ensifentrine	457	NR	0.58 (0.38, 0.89)	0.56 (0.36, 0.86)																																																														
		Placebo	269				ENHANCE-1	Male	Ensifentrine	274	85 (39.2, 130.8) P<0.001	NR	NR	Placebo	167		ENHANCE-2	Ensifentrine	244	114 (68, 161); P<0.001	NR	NR	Placebo		138	Pooled	Ensifentrine	518	NR	0.64 (0.41, 0.98)	0.63 (0.41, 0.97)	Placebo	305	ENHANCE-1	<65 years	Ensifentrine	219	70 (14.9, 125.1); P=0.013	NR	NR	Placebo		113	ENHANCE-2	Ensifentrine	224	87 (39, 135); P<0.001	NR		NR	Placebo	124	Pooled	Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)	Placebo	257								
ENHANCE-1	Male	Ensifentrine	274	85 (39.2, 130.8) P<0.001	NR	NR																																																														
		Placebo	167				ENHANCE-2		Ensifentrine	244	114 (68, 161); P<0.001	NR	NR	Placebo	138		Pooled	Ensifentrine	518	NR	0.64 (0.41, 0.98)	0.63 (0.41, 0.97)	Placebo	305	ENHANCE-1	<65 years	Ensifentrine	219	70 (14.9, 125.1); P=0.013	NR	NR	Placebo	113	ENHANCE-2		Ensifentrine	224	87 (39, 135); P<0.001	NR	NR	Placebo		124	Pooled	Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)	Placebo	257																	
ENHANCE-2		Ensifentrine	244	114 (68, 161); P<0.001	NR	NR																																																														
		Placebo	138				Pooled		Ensifentrine	518	NR	0.64 (0.41, 0.98)	0.63 (0.41, 0.97)	Placebo	305	ENHANCE-1	<65 years	Ensifentrine	219	70 (14.9, 125.1); P=0.013	NR	NR	Placebo	113	ENHANCE-2		Ensifentrine	224	87 (39, 135); P<0.001	NR	NR	Placebo	124	Pooled		Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)	Placebo	257																										
Pooled		Ensifentrine	518	NR	0.64 (0.41, 0.98)	0.63 (0.41, 0.97)																																																														
		Placebo	305				ENHANCE-1	<65 years	Ensifentrine	219	70 (14.9, 125.1); P=0.013	NR	NR	Placebo	113	ENHANCE-2		Ensifentrine	224	87 (39, 135); P<0.001	NR	NR	Placebo	124	Pooled		Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)	Placebo	257																																			
ENHANCE-1	<65 years	Ensifentrine	219	70 (14.9, 125.1); P=0.013	NR	NR																																																														
		Placebo	113				ENHANCE-2		Ensifentrine	224	87 (39, 135); P<0.001	NR	NR	Placebo	124	Pooled		Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)	Placebo	257																																												
ENHANCE-2		Ensifentrine	224	87 (39, 135); P<0.001	NR	NR																																																														
		Placebo	124				Pooled		Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)	Placebo	257																																																					
Pooled		Ensifentrine	443	NR	0.63 (0.39, 1.01)	0.59 (0.37, 0.93)																																																														
		Placebo	257																																																																	

Trial	Subgroup	Arms	N	Changes in lung function	Moderate or severe COPD exacerbations																																																																																								
				Average FEV ₁ , AUC 0-12h	Annualized exacerbation rate	Time to first event																																																																																							
				LS mean change from baseline vs. placebo (95% CI); P value	Rate ratio (95% CI); P value	Hazard ratio (95% CI); P value																																																																																							
				Week 12	Week 24	Week 24																																																																																							
ENHANCE-1	≥65 years	Ensifentrine	258	102.3 (67.1, 137.6); P<0.001	NR	NR																																																																																							
		Placebo	150				ENHANCE-2	Ensifentrine	274	100 (63, 136); P<0.001	NR	NR	Placebo	167	Pooled	Ensifentrine	532	NR	0.57 (0.38, 0.85)	0.60 (0.40, 0.90)	Placebo	317	ENHANCE-1	Current smoker	Ensifentrine	268	94.4 (50, 138.7); P<0.001	NR	NR	Placebo	163	ENHANCE-2	Ensifentrine	276	83 (42, 124); P<0.001	NR	NR	Placebo	160	Pooled	Ensifentrine	544	NR	0.57 (0.37, 0.87)	0.58 (0.38, 0.89)	Placebo	323	ENHANCE-1	Former smoker	Ensifentrine	209	75.8 (31.9, 119.7); P<0.001	NR	NR	Placebo	120	ENHANCE-2	Ensifentrine	222	107 (66, 149); P<0.001	NR	NR	Placebo	131	Pooled	Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR	Placebo	212	ENHANCE-2	Ensifentrine	73	92 (28, 156); P=0.005	NR	NR	Placebo	47	Pooled	Ensifentrine	164	NR
ENHANCE-2		Ensifentrine	274	100 (63, 136); P<0.001	NR	NR																																																																																							
			Placebo				167	Pooled	Ensifentrine	532	NR	0.57 (0.38, 0.85)	0.60 (0.40, 0.90)	Placebo	317	ENHANCE-1	Current smoker	Ensifentrine	268	94.4 (50, 138.7); P<0.001	NR	NR	Placebo		163	ENHANCE-2	Ensifentrine	276	83 (42, 124); P<0.001	NR	NR	Placebo	160	Pooled	Ensifentrine	544	NR	0.57 (0.37, 0.87)	0.58 (0.38, 0.89)	Placebo	323	ENHANCE-1	Former smoker	Ensifentrine	209	75.8 (31.9, 119.7); P<0.001	NR	NR		Placebo	120	ENHANCE-2	Ensifentrine	222	107 (66, 149); P<0.001	NR	NR	Placebo	131	Pooled	Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR		NR	Placebo	212	ENHANCE-2	Ensifentrine	73	92 (28, 156); P=0.005	NR	NR	Placebo	47	Pooled	Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118
Pooled		Ensifentrine	532	NR	0.57 (0.38, 0.85)	0.60 (0.40, 0.90)																																																																																							
			Placebo				317	ENHANCE-1	Current smoker	Ensifentrine	268	94.4 (50, 138.7); P<0.001	NR	NR	Placebo	163		ENHANCE-2	Ensifentrine	276	83 (42, 124); P<0.001	NR	NR		Placebo	160	Pooled	Ensifentrine	544	NR	0.57 (0.37, 0.87)	0.58 (0.38, 0.89)	Placebo	323	ENHANCE-1	Former smoker	Ensifentrine	209	75.8 (31.9, 119.7); P<0.001	NR	NR	Placebo		120	ENHANCE-2	Ensifentrine	222	107 (66, 149); P<0.001		NR	NR	Placebo	131	Pooled	Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR		Placebo	212	ENHANCE-2	Ensifentrine		73	92 (28, 156); P=0.005	NR	NR	Placebo	47	Pooled	Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118					
ENHANCE-1	Current smoker	Ensifentrine	268	94.4 (50, 138.7); P<0.001	NR	NR																																																																																							
		Placebo	163				ENHANCE-2	Ensifentrine		276	83 (42, 124); P<0.001	NR	NR	Placebo	160	Pooled		Ensifentrine	544	NR	0.57 (0.37, 0.87)	0.58 (0.38, 0.89)	Placebo	323	ENHANCE-1	Former smoker	Ensifentrine	209	75.8 (31.9, 119.7); P<0.001	NR	NR	Placebo	120	ENHANCE-2	Ensifentrine		222	107 (66, 149); P<0.001	NR	NR	Placebo	131		Pooled	Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR	Placebo	212	ENHANCE-2	Ensifentrine		73	92 (28, 156); P=0.005	NR	NR	Placebo		47	Pooled	Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118															
ENHANCE-2		Ensifentrine	276	83 (42, 124); P<0.001	NR	NR																																																																																							
			Placebo				160	Pooled		Ensifentrine	544	NR	0.57 (0.37, 0.87)	0.58 (0.38, 0.89)	Placebo	323	ENHANCE-1	Former smoker	Ensifentrine	209	75.8 (31.9, 119.7); P<0.001	NR	NR	Placebo	120		ENHANCE-2	Ensifentrine	222	107 (66, 149); P<0.001	NR	NR	Placebo	131	Pooled		Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR	Placebo	212		ENHANCE-2	Ensifentrine	73	92 (28, 156); P=0.005	NR	NR	Placebo	47	Pooled		Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118																							
Pooled		Ensifentrine	544	NR	0.57 (0.37, 0.87)	0.58 (0.38, 0.89)																																																																																							
			Placebo				323	ENHANCE-1	Former smoker	Ensifentrine	209	75.8 (31.9, 119.7); P<0.001	NR	NR	Placebo	120	ENHANCE-2		Ensifentrine	222	107 (66, 149); P<0.001	NR	NR	Placebo	131		Pooled	Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR	Placebo	212	ENHANCE-2		Ensifentrine	73	92 (28, 156); P=0.005	NR	NR	Placebo	47		Pooled	Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118																																
ENHANCE-1	Former smoker	Ensifentrine	209	75.8 (31.9, 119.7); P<0.001	NR	NR																																																																																							
		Placebo	120				ENHANCE-2	Ensifentrine		222	107 (66, 149); P<0.001	NR	NR	Placebo	131	Pooled	Ensifentrine		431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR	Placebo	212	ENHANCE-2	Ensifentrine		73	92 (28, 156); P=0.005	NR	NR	Placebo	47	Pooled	Ensifentrine		164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118																																										
ENHANCE-2		Ensifentrine	222	107 (66, 149); P<0.001	NR	NR																																																																																							
			Placebo				131	Pooled		Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)	Placebo	251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR	Placebo	212		ENHANCE-2	Ensifentrine	73	92 (28, 156); P=0.005	NR	NR	Placebo	47	Pooled		Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118																																																		
Pooled		Ensifentrine	431	NR	0.64 (0.41, 1.00)	0.62 (0.40, 0.96)																																																																																							
			Placebo				251	ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR	Placebo	212	ENHANCE-2		Ensifentrine	73	92 (28, 156); P=0.005	NR	NR	Placebo	47		Pooled	Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118																																																											
ENHANCE-1	ICS use	Ensifentrine	386	64.4 (-0.5, 129.2); P=0.052	NR	NR																																																																																							
		Placebo	212				ENHANCE-2	Ensifentrine		73	92 (28, 156); P=0.005	NR	NR	Placebo	47	Pooled	Ensifentrine		164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118																																																																					
ENHANCE-2		Ensifentrine	73	92 (28, 156); P=0.005	NR	NR																																																																																							
			Placebo				47	Pooled		Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)	Placebo	118																																																																													
Pooled		Ensifentrine	164	NR	0.57 (0.29, 1.12)	0.49 (0.25, 0.97)																																																																																							
			Placebo				118																																																																																						

Trial	Subgroup	Arms	N	Changes in lung function	Moderate or severe COPD exacerbations																																																																																								
				Average FEV ₁ , AUC 0-12h	Annualized exacerbation rate	Time to first event																																																																																							
				LS mean change from baseline vs. placebo (95% CI); P value	Rate ratio (95% CI); P value	Hazard ratio (95% CI); P value																																																																																							
				Week 12	Week 24	Week 24																																																																																							
ENHANCE-1	No ICS use	Ensifentrine	386	95.3 (559.4, 131.3); P<0.001	NR	NR																																																																																							
		Placebo	212				ENHANCE-2	Ensifentrine	425	94 (62, 127); P<0.001	NR	NR	Placebo	244	Pooled	Ensifentrine	811	NR	0.62 (0.44, 0.88)	0.63 (0.45, 0.89)	Placebo	456	ENHANCE-1	Chronic bronchitis	Ensifentrine	385	75.5 (39.8, 111.2); P<0.001	NR	NR	Placebo	215	ENHANCE-2	Ensifentrine	322	78 (42, 114); P<0.001	NR	NR	Placebo	190	Pooled	Ensifentrine	707	NR	0.63 (0.44, 0.92)	0.65 (0.45, 0.94)	Placebo	405	ENHANCE-1	Not known chronic bronchitis	Ensifentrine	92	122.1 (53.4, 190.8); P<0.001	NR	NR	Placebo	68	ENHANCE-2	Ensifentrine	176	121 (73, 170); P<0.001	NR	NR	Placebo	101	Pooled	Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-2	Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled	Ensifentrine	408	NR
ENHANCE-2		Ensifentrine	425	94 (62, 127); P<0.001	NR	NR																																																																																							
		Placebo	244				Pooled	Ensifentrine	811	NR	0.62 (0.44, 0.88)	0.63 (0.45, 0.89)	Placebo	456	ENHANCE-1	Chronic bronchitis	Ensifentrine	385	75.5 (39.8, 111.2); P<0.001	NR	NR	Placebo	215		ENHANCE-2	Ensifentrine	322	78 (42, 114); P<0.001	NR	NR	Placebo	190	Pooled	Ensifentrine	707	NR	0.63 (0.44, 0.92)	0.65 (0.45, 0.94)	Placebo	405	ENHANCE-1	Not known chronic bronchitis	Ensifentrine	92	122.1 (53.4, 190.8); P<0.001	NR	NR	Placebo		68	ENHANCE-2	Ensifentrine	176	121 (73, 170); P<0.001	NR	NR	Placebo	101	Pooled	Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR		Placebo	NR	ENHANCE-2	Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled	Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245	
Pooled		Ensifentrine	811	NR	0.62 (0.44, 0.88)	0.63 (0.45, 0.89)																																																																																							
		Placebo	456				ENHANCE-1	Chronic bronchitis	Ensifentrine	385	75.5 (39.8, 111.2); P<0.001	NR	NR	Placebo	215		ENHANCE-2	Ensifentrine	322	78 (42, 114); P<0.001	NR	NR	Placebo		190	Pooled	Ensifentrine	707	NR	0.63 (0.44, 0.92)	0.65 (0.45, 0.94)	Placebo	405	ENHANCE-1	Not known chronic bronchitis	Ensifentrine	92	122.1 (53.4, 190.8); P<0.001	NR	NR	Placebo		68	ENHANCE-2	Ensifentrine	176	121 (73, 170); P<0.001	NR		NR	Placebo	101	Pooled	Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR		Placebo	NR	ENHANCE-2	Ensifentrine	NR		NR	NR	NR	Placebo	NR	Pooled	Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245						
ENHANCE-1	Chronic bronchitis	Ensifentrine	385	75.5 (39.8, 111.2); P<0.001	NR	NR																																																																																							
		Placebo	215				ENHANCE-2		Ensifentrine	322	78 (42, 114); P<0.001	NR	NR	Placebo	190		Pooled	Ensifentrine	707	NR	0.63 (0.44, 0.92)	0.65 (0.45, 0.94)	Placebo	405	ENHANCE-1	Not known chronic bronchitis	Ensifentrine	92	122.1 (53.4, 190.8); P<0.001	NR	NR	Placebo	68	ENHANCE-2		Ensifentrine	176	121 (73, 170); P<0.001	NR	NR	Placebo		101	Pooled	Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-2		Ensifentrine	NR	NR	NR	NR		Placebo	NR	Pooled	Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245															
ENHANCE-2		Ensifentrine	322	78 (42, 114); P<0.001	NR	NR																																																																																							
		Placebo	190				Pooled		Ensifentrine	707	NR	0.63 (0.44, 0.92)	0.65 (0.45, 0.94)	Placebo	405	ENHANCE-1	Not known chronic bronchitis	Ensifentrine	92	122.1 (53.4, 190.8); P<0.001	NR	NR	Placebo	68	ENHANCE-2		Ensifentrine	176	121 (73, 170); P<0.001	NR	NR	Placebo	101	Pooled		Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-2		Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245																								
Pooled		Ensifentrine	707	NR	0.63 (0.44, 0.92)	0.65 (0.45, 0.94)																																																																																							
		Placebo	405				ENHANCE-1	Not known chronic bronchitis	Ensifentrine	92	122.1 (53.4, 190.8); P<0.001	NR	NR	Placebo	68	ENHANCE-2		Ensifentrine	176	121 (73, 170); P<0.001	NR	NR	Placebo	101	Pooled		Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-2		Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245																																	
ENHANCE-1	Not known chronic bronchitis	Ensifentrine	92	122.1 (53.4, 190.8); P<0.001	NR	NR																																																																																							
		Placebo	68				ENHANCE-2		Ensifentrine	176	121 (73, 170); P<0.001	NR	NR	Placebo	101	Pooled		Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-2		Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245																																										
ENHANCE-2		Ensifentrine	176	121 (73, 170); P<0.001	NR	NR																																																																																							
		Placebo	101				Pooled		Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)	Placebo	169	ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-2		Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245																																																			
Pooled		Ensifentrine	268	NR	0.56 (0.32, 0.96)	0.51 (0.30, 0.88)																																																																																							
		Placebo	169				ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-2		Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245																																																												
ENHANCE-1	Baseline eosinophils ≤150 cells/μL	Ensifentrine	NR	NR	NR	NR																																																																																							
		Placebo	NR				ENHANCE-2		Ensifentrine	NR	NR	NR	NR	Placebo	NR	Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245																																																																					
ENHANCE-2		Ensifentrine	NR	NR	NR	NR																																																																																							
		Placebo	NR				Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)	Placebo	245																																																																														
Pooled		Ensifentrine	408	NR	0.69 (0.42, 1.13)	0.69 (0.43, 1.13)																																																																																							
		Placebo	245																																																																																										

Trial	Subgroup	Arms	N	Changes in lung function	Moderate or severe COPD exacerbations	
				Average FEV ₁ , AUC 0-12h	Annualized exacerbation rate	Time to first event
				LS mean change from baseline vs. placebo (95% CI); P value	Rate ratio (95% CI); P value	Hazard ratio (95% CI); P value
				Week 12	Week 24	Week 24
ENHANCE-1	Baseline eosinophils >150 cells/μL	Ensifentrine	NR	NR	NR	NR
		Placebo	NR			
ENHANCE-2		Ensifentrine	NR	NR	NR	NR
		Placebo	NR			
Pooled		Ensifentrine	565	NR	0.55 (0.37, 0.81)	0.54 (0.36, 0.80)
		Placebo	329			
Pooled	Baseline eosinophils <100 cells/μL	Ensifentrine	182	69; P<0.05	0.59 (0.24, 1.43)	0.56 (0.23, 1.35)
		Placebo	107			
Pooled	Baseline eosinophils ≥100 cells/μL	Ensifentrine	791	94; P<0.05	0.61 (0.44, 0.84); P<0.05	0.60 (0.43, 0.83); P<0.05
		Placebo	467			
ENHANCE-1	Previous exacerbation (15 months)	Ensifentrine	NR	NR	NR	NR
		Placebo	NR			
ENHANCE-2		Ensifentrine	NR	NR	NR	NR
		Placebo	NR			
Pooled		Ensifentrine	220	NR	0.70 (0.43, 1.17)	0.69 (0.41, 1.18)
		Placebo	136			
ENHANCE-1	No previous exacerbation (15 months)	Ensifentrine	NR	NR	NR	NR
		Placebo	NR			
ENHANCE-2		Ensifentrine	NR	NR	NR	NR
		Placebo	NR			
Pooled		Ensifentrine	755	NR	0.57 (0.39, 0.84)	0.57 (0.39, 0.83)
		Placebo	438			

Trial	Subgroup	Arms	N	Changes in lung function	Moderate or severe COPD exacerbations																																						
				Average FEV ₁ , AUC 0-12h	Annualized exacerbation rate	Time to first event																																					
				LS mean change from baseline vs. placebo (95% CI); P value	Rate ratio (95% CI); P value	Hazard ratio (95% CI); P value																																					
				Week 12	Week 24	Week 24																																					
ENHANCE-1	Moderate COPD	Ensifentrine	294	88.3 (46.2, 130.3); P<0.001	NR	NR																																					
		Placebo	164				ENHANCE-2	Ensifentrine	265	140 (98, 181); P<0.001	NR	NR	Placebo	143	Pooled	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-1	Severe COPD	Ensifentrine	179	84.4 (36.7, 132); P<0.001	NR	NR	Placebo	119	ENHANCE-2	Ensifentrine	231	45 (4, 87); P=0.034	NR	NR	Placebo	148	Pooled	Ensifentrine	NR	NR
ENHANCE-2		Ensifentrine	265	140 (98, 181); P<0.001	NR	NR																																					
		Placebo	143				Pooled	Ensifentrine	NR	NR	NR	NR	Placebo	NR	ENHANCE-1	Severe COPD	Ensifentrine	179	84.4 (36.7, 132); P<0.001	NR	NR	Placebo	119		ENHANCE-2	Ensifentrine	231	45 (4, 87); P=0.034	NR	NR	Placebo	148	Pooled	Ensifentrine	NR	NR	NR	NR	Placebo	NR			
Pooled		Ensifentrine	NR	NR	NR	NR																																					
		Placebo	NR				ENHANCE-1	Severe COPD	Ensifentrine	179	84.4 (36.7, 132); P<0.001	NR	NR	Placebo	119		ENHANCE-2	Ensifentrine	231	45 (4, 87); P=0.034	NR	NR	Placebo		148	Pooled	Ensifentrine	NR	NR	NR	NR	Placebo	NR										
ENHANCE-1	Severe COPD	Ensifentrine	179	84.4 (36.7, 132); P<0.001	NR	NR																																					
		Placebo	119				ENHANCE-2		Ensifentrine	231	45 (4, 87); P=0.034	NR	NR	Placebo	148		Pooled	Ensifentrine	NR	NR	NR	NR	Placebo	NR																			
ENHANCE-2		Ensifentrine	231	45 (4, 87); P=0.034	NR	NR																																					
		Placebo	148				Pooled		Ensifentrine	NR	NR	NR	NR	Placebo	NR																												
Pooled		Ensifentrine	NR	NR	NR	NR																																					
		Placebo	NR																																								

Cells/ μ L: cells per microliter, CI: confidence interval, FEV₁: forced expiratory volume in 1 second, ICS: inhaled corticosteroids, LABA: long-acting b2-agonist, LAMA: long-acting muscarinic antagonist, N: number, NR: not reported, %: percent

D4. Ongoing Studies

Table D4.1. Ongoing Studies

Trial/ NCT	Study Design	Treatment Arms	Background Therapy	Inclusion/Exclusion Criteria	Key Primary Outcomes [Timepoints]
ENHANCE-CHINA NCT05743075	Phase III, randomized, double-blind, placebo-controlled, parallel-group Duration: 24 weeks N= 488 (estimated)	Ensifentrine 3 mg BID or placebo BID will be administered by aerosol inhalation	<p>Permitted</p> <ul style="list-style-type: none"> -Maintenance use of LAMA or LABA therapy <p>Prohibited</p> <ul style="list-style-type: none"> -Long term of oxygen use -Pulmonary rehabilitation -Use of an experimental drug within 30 days or 5 half-lives prior to screening, -Use of traditional Chinese medicine with antispasmodic and anti-asthmatic effects that would interfere with the study within 2 weeks prior to first dose 	<p>Inclusion</p> <ul style="list-style-type: none"> -40 to 80 years -Current or former cigarette smokers with a history of cigarette smoking ≥ 10 pack-years -Patients with moderately to severe COPD -Pre- and Post- salbutamol FEV₁/FVC ratio < 0.70; and Post-salbutamol FEV₁ $\geq 30\%$ and $\leq 70\%$ of predicted -Score of ≥ 2 on the mMRC Dyspnea Scale <p>Exclusion</p> <ul style="list-style-type: none"> -History of life-threatening COPD -Hospitalizations for COPD, pneumonia, or COVID-19 in the 12 weeks prior to Screening and/or COPD exacerbation, -Patients with lower respiratory tract infection occurred and not resolved within 6 weeks prior to screening 	Change from baseline in average FEV ₁ AUC 0-12h [Week 12]

0-12h: over twelve hours, AUC: area under the curve, BID: twice daily, COPD: chronic obstructive pulmonary disease, FEV₁: forced expiratory volume in 1 second, FVC: Forced vital capacity, LABA: long-acting b₂-agonist, LAMA: long-acting muscarinic antagonist, mMRC: the modified Medical Research Council

Source: www.ClinicalTrials.gov

D5. Previous Systematic Reviews and Technology Assessments

We identified several previously conducted systematic literature reviews and report summaries of two in this supplement: one with a network meta-analysis and one with a meta-analysis. No health technology assessments were found. The reviews are briefly summarized below.

Axson EL, Lewis A, Potts J, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. *BMJ Open*. 2020.⁹⁸

This systematic review and network meta-analysis (NMA) aimed to investigate the effectiveness of inhaled therapies for COPD using data from RCTs and observational studies. The primary focus was to compare different inhaled therapy strategies, particularly triple bronchodilator therapy (LAMA+LABA+ICS) versus dual bronchodilator therapy (LAMA+LABA), to reduce exacerbation risk, improve lung function, enhance health-related quality of life, and minimize adverse events. Three databases were searched for RCTs, cohort studies, and case-control studies comparing interventions with each other or placebo for individuals with COPD. The primary outcome was the number of moderate-to-severe exacerbations in the short-term (<20 weeks of treatment) and long-term (≥20 weeks of treatment). The researchers included 231 studies (212 RCTs and 19 observational studies). Network meta-analyses were conducted for exacerbations, lung function (FEV₁), health-related quality of life (SGRQ), mortality, adverse events, and pneumonia. Observational studies were narratively summarized. The NMA found that triple therapy was more effective than dual therapy in reducing moderate-to-severe exacerbations, both in the short-term and long-term. There was no significant difference between triple and dual therapy in improving peak or trough FEV₁ nor health-related quality of life improvement, as measured by SGRQ. Triple therapy was associated with a significant reduction in all-cause mortality, but increased risk of pneumonia compared to dual therapy. Observational studies generally supported the findings from RCTs, favoring triple therapy in reducing exacerbations and improving health-related quality of life. Overall, triple therapy proved most effective in reducing moderate-to-severe exacerbations but has the potential of increasing pneumonia risk in individuals with COPD. The study acknowledges limitations, such as heterogeneity in patient characteristics and outcome reporting across studies and emphasizes the need for more studies to identify patient subgroups that may benefit more from specific therapies.

Koarai A, Sugiura H, Yamada M, et al. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. *BMC Pulm Med*. 2020.⁹⁹

This systematic review and meta-analysis aimed to compare the efficacy and safety of LAMA and LABA in the treatment of stable COPD using studies evaluated outcomes of interest for at least 12 weeks. Key outcomes of interest were exacerbations, SGRQ score, TDI score, trough FEV₁, and adverse events. Of 1023 search results, a total of 19 RCTs with over 19,000 participants were

included after screening. The meta-analysis found that LAMA treatment resulted in a significantly lower incidence of exacerbations and total adverse events compared to LABA. Additionally, LAMA led to a slightly higher trough FEV₁. No significant differences in SGRQ and TDI scores between the two treatments were reported. Overall, LAMA treatment appears to be more beneficial than LABA for patients with stable COPD due to its lower incidence of exacerbations and adverse events. Subgroup findings from two studies suggest that LAMA treatment is significantly superior to LABA in patients with COPD with a history of exacerbations, but further studies in patients with an exacerbation history are needed to confirm this result. The study highlights the importance of considering both efficacy and safety outcomes when selecting bronchodilators for COPD management. However, the authors acknowledged that there was an insufficient number of trials for certain drugs which prevented subgroup analyses from being conducted.

E. Long-Term Cost-Effectiveness: Supplemental Information

E1. Detailed Methods

Table E1.1. Impact Inventory

Sector	Type of Impact (Add additional domains, as relevant)	Included in This Analysis from [...] Perspective?		Notes on Sources (if quantified), Likely Magnitude & Impact (if not)
		Health Care Sector	Societal	
Formal Health Care Sector				
Health Outcomes	Longevity effects	X	X	
	Health-related quality of life effects	X	X	
	Adverse events	X	X	
Medical Costs	Paid by third-party payers	X	X	
	Paid by patients out-of-pocket	X	X	
	Future related medical costs	X	X	
	Future unrelated medical costs	X	X	
Informal Health Care Sector				
Health-Related Costs	Patient time costs	NA	X	
	Unpaid caregiver-time costs	NA	X	
	Transportation costs	NA	<input type="checkbox"/>	
Non-Health Care Sector				
Productivity	Labor market earnings lost	NA	X	
	Cost of unpaid lost productivity due to illness	NA	X	
	Cost of uncompensated household production	NA	<input type="checkbox"/>	
Consumption	Future consumption unrelated to health	NA	<input type="checkbox"/>	
Social Services	Cost of social services as part of intervention	NA	<input type="checkbox"/>	
Legal/Criminal Justice	Number of crimes related to intervention	NA	<input type="checkbox"/>	
	Cost of crimes related to intervention	NA	<input type="checkbox"/>	
Education	Impact of intervention on educational achievement of population	NA	<input type="checkbox"/>	
Housing	Cost of home improvements, remediation	NA	<input type="checkbox"/>	
Environment	Production of toxic waste pollution by intervention	NA	<input type="checkbox"/>	
Other	Other impacts (if relevant)	NA	<input type="checkbox"/>	

NA: not applicable

* Adapted from Sanders et al¹⁰⁰

Description of evLY Calculations

The equal value life year (evLY) considers any extension of life at the same “weight” no matter what treatment is being evaluated or what population is being modeled. Below are the stepwise calculations used to calculate the evLY.

1. First, we attribute a utility of 0.851, the age- and sex-adjusted utility of the general population in the US that are considered healthy.¹⁰¹
2. We calculate the evLY for each model cycle.
3. Within a model cycle, if using the intervention results in additional life years versus the primary comparator, we multiply the general population utility of 0.851 with the additional life years gained (Δ LY gained) within the cycle.
4. The life years shared between the intervention and the comparator use the conventional utility estimate for those life years within the cycle.
5. The total evLY for a cycle is calculated by summing steps 3 and 4.
6. The evLY for the comparator arm is equivalent to the QALY for each model cycle.
7. The total evLYs are then calculated as the sum of evLYs across all model cycles over the time horizon.

Finally, the evLYs gained is the incremental difference in evLYs between the intervention and the comparator arm.

Target Population

The population for the economic evaluation included adults with moderate to severe COPD at baseline. Table E1.2 reports the baseline population characteristics that defined the cohort at the start of the model.

Table E1.2. Base-Case Model Cohort Characteristics

	Value	Source
Mean Age, years	67	Pace et al., 2022 ¹⁰²
Female, %	56.4%	Pace et al., 2022 ¹⁰²
Moderate COPD* at Baseline, %	78.1%	Mannino et al., 2022 ⁶²
Severe COPD† at Baseline, %	21.9%	Mannino et al., 2022 ⁶²
Current Smokers, %	41.2%	Pace et al., 2022 ¹⁰²

COPD: Chronic Obstructive Pulmonary Disease

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

Treatment Strategies

The list of interventions was developed with input from patient organizations, clinicians, manufacturers, and payers on which treatments to include. The intervention of interest for this review is ensifentrine (Verona Pharma). Ensifentrine was modeled as an add-on therapy to current COPD maintenance therapy versus current maintenance therapy alone.

E2. Model Inputs and Assumptions

Model Inputs

Clinical Inputs

The clinical inputs for this model included inputs specific to COPD disease progression, exacerbations, mortality, discontinuation, adverse events, and smoking cessation.

Disease Progression

COPD disease progression was modeled by way of transitioning to more severe health states in the economic model. Table E2.1 reports the transition probabilities between each of the alive health states. These transition probabilities are conditioned on a member of the modeled cohort not dying within the cycle. Transition probabilities were not age-adjusted but were dependent on smoking status and disease severity.

Table E2.1. Health State Transition Probabilities

Smoking Status	Moderate COPD* to Severe COPD†	Severe COPD† to Very Severe COPD‡	Source	Notes
Past Smoker	7.0%	6.1%	Atsou et al., 2011 ¹⁰³	Average of the transition probabilities between ages 67 and 100 to align with the ages of the modeled population
Current Smoker	11.2%	9.4%		

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

‡ Defined as an FEV₁ of less than 30%, GOLD 4

Exacerbations

Within each of the alive health states, the frequency and severity of exacerbations was tracked as events. Exacerbations were defined using an event-based definition based on the health care utilization required.⁵⁹ A moderate exacerbation was defined as an exacerbation that led to a prescription of a corticosteroid and/or an antibiotic but did not result in a hospitalization, and a severe exacerbation was defined as an exacerbation that led to a hospitalization for COPD.⁵⁹ Subsequent sections of this report describe how exacerbations impact mortality, quality of life, and costs.

Table E2.2 reports the exacerbation parameters that were used in the economic model for current maintenance therapy alone, including the total number of exacerbations per model cycle and the severity distribution of the exacerbations, stratified by health state.

Table E2.2. Exacerbation Parameters, Current Maintenance Therapy Alone

Health State	Exacerbations [§] per Year	Severe Exacerbations per Year [#]	Moderate Exacerbations per Year [⌘]	Source	Notes
Moderate COPD [*]	1.17 (0.93, 1.44)	0.16	1.01	Hoogendoorn et al., 2011	13.7% of the total exacerbations are severe, 86.3% of the total exacerbations are moderate
Severe COPD [†]	1.61 (1.49, 1.74)	0.22	1.39		
Very Severe COPD [‡]	2.10 (1.46, 2.86)	0.29	1.81		

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

‡ Defined as an FEV₁ of less than 30%, GOLD 4

§ Either a moderate or severe exacerbation.

A severe exacerbation is defined as an exacerbation leading to a hospitalization for COPD.

⌘ A moderate exacerbation is defined as an exacerbation leading to a prescription of systemic corticosteroids and/or antibiotics.

Table E2.3 reports the effectiveness of ensifentrine on reducing exacerbations. The ensifentrine rate ratio was applied to the total exacerbations per year as reported in Table E2.2. The relative percentage of total exacerbations that are severe versus moderate did not differ between the intervention and comparator arm.

Table E2.3. Ensifentrine Treatment Effect

Treatment	Exacerbation Rate Ratio (95% Confidence Interval)	Source	Notes
Ensifentrine	0.60 (0.41, 0.79)	ENHANCE-1 & ENHANCE-2	From ICER's meta-analysis of trial data at week 24

Mortality

All patients can transition to the death health state due to all-cause mortality, COPD-attributable mortality not due to an exacerbation, and exacerbation-related mortality. All-cause mortality was sourced from age- and sex-adjusted actuarial life tables.¹⁰⁴

Standardized mortality ratios for COPD patients not due to exacerbations were applied to the all-cause mortality estimates. Table E2.4 reports these standardized mortality ratios stratified by health state.

Table E2.4. COPD Standardized Mortality Ratios

Health State	Standardized Mortality Ratio	Source	Notes
Moderate COPD*	1.6	Atsou et al., 2011 ¹⁰³	Applied to age- and sex-adjusted all-cause mortality
Severe COPD [†]	1.9		
Very Severe COPD [‡]	1.9		

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

‡ Defined as an FEV₁ of less than 30%, GOLD 4

Severe exacerbations were associated with an additional risk of mortality. The case-fatality rate per severe exacerbation was modeled as 15.6% (10.2%-21.9%).⁵⁹

Discontinuation

Members of the modeled cohort could discontinue ensifentrine due to adverse events. Table E2.5 reports the adverse event-related discontinuation rate that was used in the economic model. Individuals that discontinued ensifentrine due to adverse events discontinued at week 12. No subsequent discontinuation or treatment stopping was modeled. Discontinuation impacted the model by reducing the percent of the cohort in the ensifentrine arm of the model who received the cost of ensifentrine. The ensifentrine effect size was not adjusted for discontinuation due to the intent to treat nature of the evidence source for the ensifentrine effect. Members of the modeled cohort who discontinued due to adverse events only received the cost of ensifentrine for the first 12 weeks of the model.

Table E2.5. Discontinuation Parameters

Discontinuation Reason	Ensifentrine	Source	Notes
Adverse Event, Excluding COVID	5.1%	ENHANCE-1 & ENHANCE-2 ⁹	ICER combined trial data at 24 weeks

Adverse Events

Adverse events associated with ensifentrine only impacted discontinuation. No costs or consequences were assigned to any specific adverse event because adverse events in the trial were comparable between the ensifentrine arm and the placebo arm.

Smoking Cessation

Because the transition probabilities for disease progression are dependent on smoking status, smoking status was tracked in the model. The percentage of the cohort that are current smokers at baseline is described in Table E1.2. During each model cycle, a current smoker had a 4.5% probability of smoking cessation.¹⁰⁵ Successful smoking cessation was defined as more than 6 months without smoking a cigarette. Literature suggests that 22% of individuals that had stopped smoking for 182 days will resume smoking.¹⁰⁶ Therefore, we modeled that 3.51% (4.5% * (100%-22%)) of the cohort would permanently stop smoking each model cycle.

Utility Inputs

Health state utility estimates are reported in Table E2.6 and were from a source that elicited utility estimates using the EQ-5D from patients with COPD. Differences in health state utility values between the intervention and comparator arm were modeled in a scenario analysis.

Table E2.6. Health State Utility Values

Health State	Utility	Source/Notes	Notes
Moderate COPD*	0.787 (0.77, 0.80)	Fenwick et al., 2021 ¹⁰⁷	Elicited using the EQ-5D from patients with COPD
Severe COPD [†]	0.750 (0.73, 0.77)		
Very Severe COPD [‡]	0.647 (0.60, 0.70)		

COPD: Chronic Obstructive Pulmonary Disease

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

‡ Defined as an FEV₁ of less than 30%, GOLD 4

Exacerbations resulted in an additional disutility. The disutilities per exacerbation are presented in Table E2.7. Exacerbations are modeled as an event, rather than as health states, and thus these disutilities are applied per event.

Table E2.7. Disutility Values, Per Exacerbation

Health State	Moderate Exacerbation [§]	Severe Exacerbation [#]	Source/Notes	Notes
Moderate COPD*	-0.0131	-0.0379	Hoogendoorn et al., 2011 ⁵⁹	The annual disutility was 1.66% and 4.82% of the health state utility value for a moderate or severe exacerbation, respectively.
Severe COPD [†]	-0.0125	-0.0362		
Very Severe COPD [‡]	-0.0107	-0.0312		

COPD: chronic obstructive pulmonary disease

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

‡ Defined as an FEV₁ of less than 30%, GOLD 4

§ A moderate exacerbation was defined as an exacerbation leading to a prescription of systemic corticosteroids and antibiotics.

A severe exacerbation was defined as an exacerbation leading to a hospitalization for COPD.

Economic Inputs

All costs used in the model were updated to 2023 US dollars.

Drug Utilization

Table E2.8 reports the treatment regimen for ensifentrine.

Table E2.8. Ensifentrine Treatment Regimen

Treatment Regimen Parameter	Ensifentrine
Dose per Administration	3 mg
Frequency of Administration	Twice daily
Route of Administration	Nebulized

mg: milligram

For the purposes of estimating treatment costs, Table E2.9 details the current maintenance therapy basket that defined the comparator as well as what ensifentrine was added on to. The specific treatments within each maintenance therapy regimen included those with generic equivalents. If no generic equivalents existed for a maintenance therapy regimen, an average across all of the branded drugs within that maintenance therapy regimen was included in the cost estimation. If multiple generic equivalents existed for a maintenance therapy regimen, an average across all of the generic equivalents within that maintenance therapy regimen was included in the cost estimation.

Table E2.9. Current Maintenance Therapy Basket

Maintenance Therapy Regimens	Percent	Treatments in Regimen	Source
LAMA only	34%	Tiotropium bromide (100%)	Calculated the values in the percent column based on the number of patients in the GOLD 2, GOLD 3, and GOLD 4 groups on each maintenance therapy regimen as reported in Wallace et al., 2019. ⁶⁶ Included maintenance therapy regimens that at least 10% of the population reported being on.
LABA + ICS	51%	Budesonide/formoterol fumarate (33.3%), Fluticasone propionate/salmeterol xinafoate (33.3%), Vilanterol trifrenatate/fluticasone furoate (33.3%)	
LABA + LAMA + ICS	15%	Budesonide/glycopyrrolate/formoterol fumarate (50%), Fluticasone furoate/umeclidinium/vilanterol (50%)	

ICS: inhaled corticosteroid, LABA: long-active beta-agonist, LAMA: long-acting muscarinic antagonist

Drug Acquisition Costs

A price is not yet known for ensifentrine and thus a placeholder price was used in the economic model. IPD Analytics estimates an annual price of approximately \$18,000 per year for ensifentrine.⁶³ Therefore, we used an annual price of \$18,000 per year as a placeholder price in our economic model. This placeholder price can be adjusted if the manufacturer provides guidance on a more appropriate price or if a price becomes available for ensifentrine.

For drugs within the current maintenance therapy basket that had a generic equivalent available, the lowest cost wholesale acquisition cost (WAC) was used. For drugs within the current maintenance therapy basket that did not have a generic equivalent available (e.g., Budesonide/glycopyrrolate/formoterol fumarate, Fluticasone furoate/umeclidinium/vilanterol), we obtained net pricing estimates from SSR Health, LLC, which combines data on unit sales with publicly-disclosed US sales figures that are net of discounts, rebates, patient assistance programs, and concessions to wholesalers and distributors, to derive a net price. We estimated net prices by comparing the four-quarter averages of both net prices and WAC per unit to arrive at a mean discount from WAC for the drug. Finally, we applied this average discount to the WAC from Redbook (accessed January 31, 2024) to arrive at an estimated net price per unit.

Table E2.10 reports the drug cost parameters for the drugs within current maintenance therapy.

Table E2.10. Current Maintenance Therapy Drug Costs

Treatment	Package Size	Strength	WAC per Package	Mean Discount from WAC*	Net Price per Package	Net Price per Year
Tiotropium bromide (LAMA only)	60 puffs/30 days	18 mcg	\$460.82	N/A	\$460.82	\$5,607
Budesonide/formoterol fumarate (LABA+ICS)	120 puffs/30 days	80-160 mcg/4.5 mcg	\$218.77	N/A	\$218.77	\$2,662
Fluticasone propionate/salmeterol xinafoate (LABA+ICS)	60 puffs/30 days	250 mcg/50 mcg	\$116.44	N/A	\$116.44	\$1,417
Vilanterol trifenatate/fluticasone furoate (LABA+ICS)	60 blisters/30 days	100-200 mcg/25 mcg	\$249.50	N/A	\$249.50	\$3,036
Budesonide/glycopyrrolate/formoterol fumarate (LABA + LAMA + ICS)	120 puffs/30 days	160 mcg/9 mcg/4.8 mcg	\$645.14	71%	\$187.74	\$2,284
Fluticasone furoate/umeclidinium/vilanterol (LABA + LAMA + ICS)	30 blisters/30 days	100 mcg/62.5 mcg/25 mcg	\$657.60	72%	\$181.50	\$2,208

ICS: inhaled corticosteroid, LABA: long-active beta-agonist, LAMA: long-acting muscarinic antagonist, WAC: wholesale acquisition cost

* Calculated using net price data from SSR Health

Table E2.11 reports the drug costs used in the model, including the placeholder ensifentrine cost and the current maintenance therapy annual cost calculated by weighting the percentages in Table E2.9 by the costs in Table E2.10.

Table E2.11. Treatment Costs

Drug	Annual Cost	Source	Notes
Ensifentrine	\$18,000	IPD Analytics ⁶³	Placeholder price
Current Maintenance Therapy	\$3,453	Redbook, SSR Health	Calculated by weighting the percentages in Table E2.9 by the costs in Table E2.10

Administration Costs

Administration costs for ensifentrine included the purchase of a nebulizer at an assumed price of \$125 per nebulizer.¹⁰⁸ The lifespan of the nebulizer was assumed to be five years, and thus a new nebulizer was purchased every five years for those individuals receiving ensifentrine.¹⁰⁹

Additionally, the tubing and mouthpiece was replaced every six months.¹¹⁰ The purchase of new tubing and a mouthpiece was \$14.95 every six months.¹¹¹

Health Care Utilization Costs

Table E2.12 reports the health state costs that were used in the economic model. These costs include COPD-related health care utilization costs excluding emergency department, inpatient, and pharmacy costs as those costs were included elsewhere in the model but include office visits and other outpatient costs which includes oxygen therapy. The pharmacy costs are included in the drug costs detailed in the section above and the emergency department and inpatient costs are assumed to be included in the exacerbation-related costs detailed in the section below. The COPD-specific health state costs in Table E2.12 will be added on to the non-COPD health care costs experienced by patients with COPD which are \$22,113 per year.¹¹²

Table E2.12. Health State Costs

Health State	Annual Cost	Source	Notes
Moderate COPD*	\$1,509	Wallace et al., 2019 ⁶⁶	Inflated from 2015 US dollars to 2023 US dollars
Severe COPD [†]	\$2,683		
Very Severe COPD [‡]	\$3,432		

* Defined as an FEV₁ of 50%-79%, GOLD 2

† Defined as an FEV₁ of 30% to 49%, GOLD 3

‡ Defined as an FEV₁ of less than 30%, GOLD 4

Exacerbation Costs

Table E2.13 reports the costs associated with a moderate and a severe exacerbation.

Table E2.13. Exacerbation Costs

Exacerbation Severity	Cost per Event	Source	Notes
Moderate Exacerbation*	\$2,415	Bogart et al., 2020 ⁶⁴	Inflated from 2017 US dollars to 2023 US dollars
Severe Exacerbation [†]	\$26,047		

* A moderate exacerbation was defined as an exacerbation leading to a prescription of systemic corticosteroids and antibiotics.

† A severe exacerbation was defined as an exacerbation leading to a hospitalization for COPD.

Productivity Costs

We modeled a loss in productivity associated with each exacerbation. Each exacerbation was associated with 106 hours of lost productivity.¹¹³ Lost productivity time was monetized using an average hourly wage of \$34.27 as reported by the Bureau of Labor Statistics.¹¹⁴

Caregiver Costs

On average, caregivers of patients with COPD provide 20 hours of care per week.¹¹⁵ This estimate was equally applied to all members of the modeled cohort residing in any of the alive health states due to the lack of evidence available to suggest a differential in caregiver time based on exacerbation status. Caregiver time was monetized using an average hourly wage of \$34.27 as reported by the Bureau of Labor Statistics.¹¹⁴

E3. Results

Table E3.1. Results for the Base-Case for Ensifentrine Added on to Current Maintenance Therapy as Compared to Current Maintenance Therapy Alone

Treatment	Intervention Cost*	Maintenance Therapy Costs	Administration Costs	Health State Costs	Exacerbation-Related Costs	Unrelated Health Care Costs
Ensifentrine + Current Maintenance Therapy	\$144,300	\$29,100	\$500	\$19,000	\$45,400	\$186,500
Current Maintenance Therapy Alone	\$0	\$26,600	\$0	\$17,200	\$69,300	\$170,500

* Based on placeholder price of \$18,000 per year

E4. Sensitivity Analyses

Table E4.1. Tornado Diagram Inputs and Results

Input	Lower Input CE Ratio (\$/QALY)	Upper Input CE Ratio (\$/QALY)	Lower Input	Upper Input
Enfentrine exacerbation rate ratio	\$167,000	\$472,000	0.41	0.79
Percent of exacerbations that are moderate	\$172,000	\$440,000	77%	94%
Case-fatality rate per severe exacerbation	\$326,000	\$202,000	10%	22%
Total exacerbations per year, moderate COPD	\$273,000	\$226,000	0.93	1.44
Total exacerbations per year, very severe COPD	\$257,000	\$240,000	1.46	2.86
Annual maintenance therapy cost	\$244,000	\$260,000	\$87	\$12,738
Total exacerbations per year, severe COPD	\$254,000	\$242,000	1.49	1.74
Cost per severe exacerbation	\$253,000	\$242,000	\$21,193	\$31,394
Utility of very severe COPD	\$253,000	\$243,000	0.60	0.70
Cost per moderate exacerbation	\$251,000	\$245,000	\$1,965	\$2,911

CE: cost-effectiveness

Table E4.2. Results of Probabilistic Sensitivity Analysis

	Intervention Arm	Comparator Arm
Costs	\$426,000	\$285,000
QALYs	6.27 (5.5, 6.8)	5.71 (4.7, 6.5)
evLYs	6.35 (5.6, 6.9)	5.71 (4.7, 6.5)
Incremental CE Ratio (\$/QALY)	\$252,000	
Incremental CE Ratio (\$/evLY)	\$219,000	

CE: cost-effectiveness, evLY: equal-value life year, QALY: quality-adjusted life year

E5. Scenario Analyses

Scenario Analysis 1: Modified Societal Perspective

In a scenario analysis, we expanded the perspective to the modified societal perspective. In this perspective, we included productivity losses attached to exacerbations and caregiver time spent caregiving. Table E5.1 reports the model outcomes for this scenario analysis and Table E5.2 reports the incremental cost-effectiveness ratios.

Table E5.1. Model Outcomes for the Modified Societal Perspective Scenario Analysis

Treatment	Total Cost*	QALYs	evLYs	Life Years
Ensifentrine + Current Maintenance Therapy	\$755,000	6.25	6.34	8.43
Current Maintenance Therapy Alone	\$603,000	5.68	5.68	7.71

evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Table E5.2. Incremental Cost-Effectiveness Ratios for the Modified Societal Perspective Scenario Analysis

Treatment	Comparator	Cost per QALY Gained*	Cost per evLY Gained*	Cost per Life Year Gained*
Ensifentrine + Current Maintenance Therapy	Current Maintenance Therapy Alone	\$266,000	\$230,000	\$209,000

evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Scenario Analysis 2: Unrelated Health Care Costs Excluded

In a scenario analysis, we excluded unrelated health care costs. Table E5.3 reports the model outcomes for this scenario analysis and Table E5.4 reports the incremental cost-effectiveness ratios.

Table E5.3. Model Outcomes for the Scenario Analysis Excluding Unrelated Health Care Costs

Treatment	Total Cost*	QALYs	evLYs	Life Years
Ensifentrine + Current Maintenance Therapy	\$238,000	6.25	6.34	8.43
Current Maintenance Therapy Alone	\$113,000	5.68	5.68	7.71

evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Table E5.4. Incremental Cost-Effectiveness Ratios for the Scenario Analysis Excluding Unrelated Health Care Costs

Treatment	Comparator	Cost per QALY Gained*	Cost per evLY Gained*	Cost per Life Year Gained*
Ensifentrine + Current Maintenance Therapy	Current Maintenance Therapy Alone	\$220,000	\$190,000	\$173,000

evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Scenario Analysis 3: Ensifentrine Effect on Quality of Life

In a scenario analysis, we assumed that ensifentrine would result in higher utility estimates for moderate COPD, severe COPD, and very severe COPD due to the slower decline in lung function. We assumed that health state utility estimates would be 0.019 higher in ensifentrine-treated patients in this scenario analysis. To arrive at this estimate, we calibrated the first cycle difference in utility between the ensifentrine arm and comparator arm to be equivalent to the difference in EQ-5D-5L between the ensifentrine arm and the placebo arm reported in Rheault et al., 2023.⁹² Table E5.5 reports the model outcomes for this scenario analysis and Table E5.6 reports the incremental cost-effectiveness ratios.

Table E5.5. Model Outcomes for the Scenario Analysis Assuming an Ensifentrine Effect on Health State Quality of Life

Treatment	Total Cost*	QALYs	evLYs	Life Years
Ensifentrine + Current Maintenance Therapy	\$425,000	6.41	6.48	8.43
Current Maintenance Therapy Alone	\$284,000	5.68	5.68	7.71

evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

Table E5.2. Incremental Cost-Effectiveness Ratios for the Scenario Analysis Assuming an Ensifentrine Effect on Health State Quality of Life

Treatment	Comparator	Cost per QALY Gained*	Cost per evLY Gained*	Cost per Life Year Gained*
Ensifentrine + Current Maintenance Therapy	Current Maintenance Therapy Alone	\$193,000	\$175,000	\$195,000

evLYs: equal value of life years gained, QALY: quality-adjusted life year

* Based on placeholder price of \$18,000 per year

E6. Model Validation

Model validation followed standard practices in the field. First, we provided the preliminary model structure, methods and assumptions to manufacturers, patient groups, and clinical experts. Based on feedback from these groups, we refined data inputs used in the model, as needed. We tested all mathematical functions in the model to ensure they were consistent with the report (and supplemental materials). We also conducted sensitivity analyses with null input values to ensure the model was producing findings consistent with expectations. As part of ICER's efforts in acknowledging modeling transparency, we also offer to share the model with the manufacturer for external verification shortly after publishing this draft report. Model validation was also conducted

in terms of comparisons to other model findings. We searched the literature to identify models that were similar to our analysis, with comparable populations, settings, perspective, and treatments.

Prior Economic Models

This is the first cost-effectiveness analysis of ensifentrine that we are aware of; however, there have been numerous cost-effectiveness analyses within COPD.^{57,60,103,107 58,59,61} Additionally, this model closely follows existing models and uses key learnings from a cross-model comparison exercise.⁵⁸ Based on the cross-model comparison exercise conducted previously by Hoogendoorn and colleagues,⁵⁸ there has been between model variability in the disease progression framework and subgroup specifications and in the mortality framework and subgroup specifications. For the disease progression framework, our model used transition probabilities adapted from Atsou et al.¹⁰³ with transition rates specified by COPD disease severity and smoking status. This approach is most closely similar to the approach taken by Hansen and colleagues.⁶⁰ Exacerbations were modeled as events rather than health states, which is similar to the approach taken by Wacker and colleagues.⁵⁷ For the mortality framework and subgroup specifications, our model programmed mortality as a function of all-cause mortality from life tables, exacerbation-related mortality, and COPD-attributable mortality excluding exacerbation-related mortality specified by age and disease severity. This is most closely similar to the approach taken by Hoogendoorn and colleagues and by Wacker and colleagues.^{57,59}

To validate the model, we updated our model inputs to the inputs used in the standard reference scenario from the published cross-model comparison exercise and updated the treatment inputs specific to the hypothetical intervention two in the published cross-model comparison exercise.⁵⁸ After doing this, our model outcomes were nearly identical to the ones reported by Wacker in the cross-model comparison exercise.^{57,58} Our model produced an incremental €860 and 0.077 incremental QALYs when using these standard reference inputs. Wacker reported an incremental €844 and 0.075 incremental QALYs when using these standard reference inputs. It is not surprising that our findings most closely mirrored the findings reported by Wacker due to the similar way exacerbations and mortality were modeled. We then removed exacerbation-specific mortality, and our estimates were nearly identical to those reported by Rutten-van Mölken¹¹⁶ in the cross-model replication exercise that did not include any increased risk of mortality associated with an exacerbation.

F. Potential Budget Impact: Supplemental Information

Methods

We used results from the same model employed for the cost-effectiveness analyses to estimate total potential budget impact. Potential budget impact was defined as the total differential cost of using each new therapy rather than relevant existing therapy for the treated population, calculated as differential health care costs (including drug costs) minus any offsets in these costs from averted health care events. All costs were undiscounted and estimated over one- and five-year time horizons. The five-year timeframe was of primary interest, given the potential for cost offsets to accrue over time and to allow a more realistic impact on the number of patients treated with ensifentrine.

The potential budget impact analysis includes the estimated number of individuals in the US who would be eligible for treatment. To estimate the size of the potential candidate populations for treatment, we used inputs for the size of the adult U.S. population 271,616,592 (average over 2024-2028), the prevalence of COPD in adults (5.6%),⁶⁷ and the percentage of adult patients with moderate-to-severe COPD (63.3%).⁶² Applying these sources results in estimates of 9,628,265 eligible patients in the US. For the purposes of this analysis, we assume that 20% of these patients would initiate treatment in each of the five years, or 1,925,653 patients per year.

ICER's methods for estimating potential budget impact are described in detail elsewhere and have recently been updated.^{117,118} The intent of our revised approach to budgetary impact is to document the percentage of patients that could be treated at selected prices without crossing a budget impact threshold that is aligned with overall growth in the US economy.

Once estimates of budget impact were calculated, we compared our estimates to an updated budget impact threshold that represents a potential trigger for policy mechanisms to improve affordability, such as changes to pricing, payment, or patient eligibility. As described in [ICER's methods presentation](#) (Value Assessment Framework), this threshold is based on an underlying assumption that health care costs should not grow much faster than growth in the overall national economy. From this foundational assumption, our potential budget impact threshold is derived using an estimate of growth in US gross domestic product (GDP) +1%, the average number of new drug approvals by the FDA over the most recent two-year period, and the contribution of spending on retail and facility-based drugs to total health care spending.

For 2023-2024, therefore, the five-year annualized potential budget impact threshold that should trigger policy actions to manage access and affordability is calculated to total approximately \$735 million per year for new drugs.